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Abstract
An automated microscale bioprocessing platform for membrane filtration processes was
established to identify key process issues early and aid the rapid design of robust and
scaleable filtration processes. To demonstrate the utility of this platform, it was used to
investigate the impact of upstream operations on microfiltration performance. The
primary recovery of humanised antibody Fab’ fragments from Escherichia coli
(supplied courtesy of UCB Celltech) were used as a case study to evaluate the
microfiltration methodologies and devices created in this work.
Initially, the methodology associated with the microscale dead-end filtration device
previously created and investigated by Jackson et al. (2006) has been improved by
reducing the required volume by 50% (~500 L). This improved method demonstrated
reproducibility and sensitivity to changes in feed preparation. The method was then
applied in the study of the influence of various cell disruption operations on subsequent
solid-liquid separation and hence, Fab’ product recovery. Results showed that the heat
extracted cells showed better dead-end microfiltration performance in terms of
permeate flux and specific cake resistance. In contrast, the cell suspensions prepared by
homogenisation and sonication showed more efficient product release but with lower
product purity and poorer microfiltration performance. Having established the various
microscale methods, the linked sequence was automated on the deck of the Tecan™
robotic platform and used to illustrate how different conditions during thermo-chemical
extraction impacted on the optimal performance of the linked unit operations of product
release by extraction and subsequent recovery by microfiltration.
The microscale approach was then extended for crossflow operations. A microscale
crossflow filtration device was designed to enable integration also within the Tecan™
platform for automated processing. The device has an effective membrane area of
0.001 m2, which is a hundred-fold smaller than the larger scale Pellicon-2™ membrane
module used for scale translation studies, and has two independent membrane channels
for parallel analysis. The device was first characterised by determining the normalised
water permeability (NWP) of a Poly(vinylidene fluoride) membrane and compared this
with the NWP of the membrane by dead-end filtration. NWP is an inherent membrane
property and as expected, the NWP values derived from crossflow filtration
experiments match the values derived from dead-end filtration to within 90%. For scale
translation studies, two types of feeds were used: a model feed, which is resuspended
active dry yeast and Bovine Serum Albumen in phosphate buffer, and the antibody
fragment expressing E. coli strain. Results showed, that at matched optimal shear rates
and transmembrane pressure, the percentage differences between microscale and large
scale values were up to ± 25% for the permeate flux, ± 10% for Fab’ and total protein
yields. These scale-up predictions were achieved with a ten-fold reduction in feed
material requirement for crossflow operation.
Overall, the results illustrate the power of microscale techniques to identify and enable
the understanding of key process performance attributes in a bioprocess sequence. The
broader implications derived from using these microscale membrane devices, further
applications and recommendations for future research are also discussed.
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1. Introduction
1.1 Background and motivation of the project
The need for more efficient approaches to speed up the discovery and development of
manufacturing routes to new drug substances as well as to market such products is
widely recognized. This has prompted the review of development routes and strategies
in recent years (Lye et al., 2002; Dimasi et al., 2004). Traditionally, the focus of most
development efforts were on drug discovery which aims to obtain knowledge on
clinical efficacy and the parameters that may affect this. In recent years, efforts were
directed towards early stage bioprocess development and drug manufacturing
activities. This has emerged in line with strict regulatory requirements set by the United
States of America’s Food and Drug Administration (FDA). The FDA is the leading
regulatory body for pharmaceuticals with the USA being one of the largest target
markets. The significance of careful planning and experimentation during bioprocess
development is well recognised. The information obtained will provide the basis for the
creation of a scaleable process that meets the marketing and clinical needs of a
biotherapeutic product. The unavailability of critical information causes delays in the
actual plant start-up to manufacture such products (Goochee, 2002). These delays do
not help the patients who would have otherwise benefited from the manufacture of
these therapies. Furthermore, the delays translate to the rapid accumulation of millions
of dollars of lost future revenue and diminished competitive advantage of the drug
product.
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Due to the increased number of new drug candidates, the need to acquire a critical mass
of information for bioprocess development consequently becomes more acute. To avoid
process development bottlenecks, the use of automated microscale bioprocessing
techniques has been promoted to bring manufacturing process development in line with
drug discovery operations (Lye et al., 2003). Product processing studies, may be
accelerated and will benefit from the availability of microscale devices which allow
processing of small quantities of feed as well as multiple or parallel analysis of different
process conditions. Microscale bioprocessing provides a platform to explore a variety
of process conditions using minimal amounts of material so that essential bioprocess
information can be collected early in the process development stage, and therefore
process scaleability may be improved (Micheletti and Lye, 2006).
A recent review highlighted the increasing awareness in the resource effectiveness of
high throughput bioprocess development to obtain both bioprocess and product
understanding (Bhambure et al., 2011). With this awareness is the acknolwedgement
that it could potentially enable the application of Quality by Design (QbD) principles
for the commercial development of biopharmaceuticals. Under the QbD approach,
pharmaceutical quality is assured by the understanding and control of manufacturing
and formulation variables (Yu, 2007). A shift in development objectives is now
expected to focus on the understanding of the fundamentals of the unit operations since
the positive impact of QbD will be realised more rapidly and broadly through the
expansion of the knowledge space for manufacturing processes as a result of these
investments in a better understanding of the current platform (Kelley, 2009).
Figure 1.1 is a schematic representation of bioprocess development for a new
biopharmaceutical drug substance. Bioprocess development is depicted as a two-
dimensional process where in one dimension there is the process flowsheet involving
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the development of each unit operation and in the second dimension is the level or stage
of development, usually corresponding to a certain scale, of these unit operations.
The development of primary recovery and purification processes during the early phase
of development is difficult because the amount of material obtained from laboratory
scale cell culture is not sufficient for screening downstream process conditions. As
shown by Betts and Baganz (2006), most of the earlier microscale studies have mainly
focused on upstream operations which reflects the traditional focus in the early
development phase. In order to maximise the potential of the microscale bioprocessing
approach, however, Jackson et al. (2006) underlined the need to establish more
microscale downstream processing operations (shaded region in Figure 1.1) so that
evaluation could be made early in the development phase.
An important aspect of the microscale bioprocessing approach promoted in this thesis is
the link with laboratory robotics. This is central to the creation of high throughput
process development platforms (Bhambure et al., 2011). Thus, it is important to create
microscale or miniaturised unit operations for bioprocessing that mimics larger scale
modules and which are compatible with standard laboratory automation platforms (Lye
et al., 2003). The platforms allow modularisation of component unit operations
enabling the study of linked process sequences. Automated whole bioprocess analysis is
thus the ultimate aim of this philosophy whereby the development of each unit
operation in the bioprocess sequence is analysed with respect to its impact on the entire
bioprocess. This whole bioprocess approach will now enable the evaluation of different
process and economic trade-offs in order achieve the required final product yield and
quality in an optimised manner.
Figure 1.1
is the bioprocess flowsheet and on the ordinate is the development of each unit
operation (scale
indicates the opportu
With the application of laboratory robotics this could enable automated whole
bioprocess analysis.
Two-dimensional representation of bioprocess development: on the abscissa
-down and scale
nities for establishment of microscale bioprocessing techniques.
~
-up) within the process flowsheet. Shaded region
25 ~
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Figure 1.2 illustrates the interconnection between the three concepts of microscale
bioprocessing, high throughput process development and the whole bioprocess analysis
approach. It shows that the creation of the different devices and tools for microscale
unit operations will permit the growth of high throughput bioprocess development and
is necessary to underpin microscale investigation of a whole bioprocess sequence.
Against this backdrop, the overall aim of this thesis is to establish microscale
bioprocessing methods for the evaluation of membrane filtration processes. A review of
literature on membrane filtration (Section 1.5) has revealed that no other work has been
done on automated microscale membrane filtration since the initial work of Jackson et
al. (2006). In order to appreciate the requirement for microscale processing for
membrane filtration of biopharmaceuticals an overview is first given in Sections 1.2
and 1.3. The discuss the areas for growth and opportunities for expanding process
development and manufacturing of emerging therapies. It also provides the basis for the
selection of antibody Fab’ fragments production as a case study in the application of
membrane filtration as the key primary recovery unit operation. Section 1.4 provides a
brief review of membrane filtration concepts in order to understand the opportunities
available for development and optimisation of membrane filtration processes as applied
to the primary recovery of biopharmaceuticals. Section 1.5 then outlines current
knowledge on scale-down and microscale membrane filtration. Finally, the overall aim
of this thesis and the specific objectives are stated in Section 1.6.
Figure 1.2
high throughput bioprocess development, and ultimately whole bioprocess analysis.
Relationship between the different concepts of microscale bioprocessing,
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1.2 Overview of biopharmaceutical product development
1.2.1 Biopharmaceuticals and the drug development process
Biopharmaceuticals are biologically based therapeutic products, typically recombinant
macromolecules (Ho and Gibaldi, 2003). These biologics are not easily characterised
and therefore refinement to achieve high purity is a difficult process. Therapeutic
monoclonal antibodies (Mabs) are the fastest growing class of biologics and have the
largest market share of approved biopharmaceuticals (Strohl, 2009). Currently, 30
Mabs and related proteins are on the market with additionally 150 Mabs either in pre-
clinical, clinical trials or awaiting FDA approval (Shukla and Thömmes, 2010; Rao et
al., 2011). Advances in antibody engineering technologies enabled the fast generation
of high-affinity antibodies of defined specificity facilitating the development of a wide
range of antibody-based molecules for use in indications such as oncology,
inflammations and infectious diseases (Brekke and Løset 2003; Bowering, 2004). It is
projected that the number of antibodies in the market will increase to about 50 by 2012
even if only 50% of Phase III candidates are successful (Strohl, 2009). Table 1.1 shows
a list of marketed Mabs and related proteins.
It is acknowledged that the rate at which therapeutic Mabs and other related proteins are
identified and developed is so advanced that the impediment in launching these to
market rests on the constraints of human effort and resources required to demonstrate
the clinical efficacy and safety of these drug candidates (Ho and Gibaldi, 2003). The
task of evaluating the information on the new drug candidate is performed by the FDA.
Figure 1.3 shows the schematic diagram of the drug development process which aims
to demonstrate the effectiveness and safety of drug candidates before reaching the
market.
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Table 1.1 Marketed monoclonal antibodies and related proteins*
Year
approved
U.S. Trade name®
(Type, Protein
Format)
Company
(US$ Million Sales**)
Indication
1986 Orthoclone OKT3
(Murine, IgG)
Ortho Biotech/ now
J&J( >$80)
Acute kidney transplant
rejection
1994 ReoPro
(Chimeric, Fab
fragment)
Centocor/now J&J
($300)
Prevention of blood clot
1995 Panorex
(Murine, IgG)
GlaxoSmithKleine
(n.d.)
Colorectal cancer
1997 Rituxan
(Chimeric, IgG)
Biogen-Idec/
Genentech ($ 3800)
Non-Hodgkin’s lymphoma,
rheumatoid arthritis
Zenapax
(Humanised, IgG)
PDL/ Roche
( >$80M)
Acute kidney transplant
rejection
1998 Synagis
(Chimeric, IgG)
MedImmune
(n.d.)
Respiratory synctial virus
(infant)
Remicade
(Chimeric, IgG)
Centocor/now J&J
($ 3800)
Rheumatoid arthritis
Herceptin
(Humanised, IgG)
Genentech
($ 3000)
Breast cancer
Enbrel
(FC fusion protein)
Immunex/now
Amgen
($ 4400)
Rheumatoid arthritis, psoriasis,
ankylosing spondylitis
Simulect
(Chimeric, IgG)
Novartis
(>$ 80)
Prophylaxis of acute organ
transplant rejection
2000 Mylotarg
(Humanised, IgG)
Wyeth
($115)
Leukemia
2001 Campath-1H
(Humanised, IgG)
ILEX-Millenium/now
Takeda (>$ 80)
Leukemia
2002 Zevalin
(Murine, IgG)
Biogen-Idec
(>$ 80)
Non-Hodgkin’s lymphoma
Humira
(Human, IgG)
CAT/Abbott
($ 2000)
Rheumatoid arthritis, Crohn’s
disease
2003 Amivive
(FC fusion protein)
Biogen
(>$ 80)
Psoriasis
Xolair
(Humanised, IgG)
Genentech
($500)
Asthma
Bexxar
(Murine IgG)
Corixa/ now GSK
(>$ 80)
Non-Hodgkin lymphoma
* Adapted from Strohl (2009) and Shukla and Thömmes (2010)
** in 2006, rounded up to nearest hundreds
n.d. – no data
Table cont’d overleaf
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Table 1.1 Continued
Year
approved
U.S. Trade name®
(Type, Protein Format)
Company
(US$ Million Sales**)
Indication
2004 Erbitux
(Chimeric, IgG)
ImClone/Bristol-Myers
Squibb (Eli Lilly)
($ 1100)
Colorectal cancer
Avastin
(Humanised, IgG)
Genentech
($ 2400)
Colorectal cancer
Tysabri
(Humanised, IgG)
Biogen(-Idec)/Elan
(> $ 80)
Multiple sclerosis
2005 Orencia
(FC fusion protein)
Bristol-Myers Squibb
($ 100)
Rheumatoid athritis
2006 Lucentis
(Humanised, Fab
fragment)
Genentiech/Novartis
$ 380
Age-related macular
degeneration
Vectibix
(Humanised, IgG)
Amgen
(> $80)
Colorectal cancer
2007 Soliris
(Humanised, IgG)
Alexion Pharma Paroxysmal nocturnal
hemoglobinuria
Arcalyst
(Fc fusion protein)
Regeneron Cryopyrin Associated
Periodic Syndrome
2008 Cimzia
(Humanised, Fab’
fragment)
UCB/ Shwartz Rheumatoid athritis
Nplate
(FC fusion protein)
Amgen Thrombocytopenia
Stelara
(Human, IgG)
Centocor/ now J&J Psoriasis
Simponi
(Human, IgG)
Centocor/ now J&J Rheumatoid arthritis
Actemra
(Humanised, IgG)
Roche Rheumatoid arthritis
* Adapted from Strohl (2009) and Shukla and Thömmes (2010)
** in 2006, rounded up to nearest hundreds
n.d. – no data
Figure 1.3
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~
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Drug development activities, shown in Figure 1.3, are typically accomplished between
12-15 years with the clinical phase usually starting between the 6th-8th year (Ho and
Gibaldi, 2003). Given this long development phase, the ability to develop and create
the right process to manufacture the drug at the required scale is clearly in the critical
path of the launch of the new drug. The advantage of being first to launch to market
can be seen from the sales figures of 23 of the marketed antibodies shown in Table 1.1
which had accumulated sales of US$23 Billion in the year 2006 (Strohl, 2009) and
about $30 B in 2007(Liddell, 2009). Interestingly, 65% of these sales are from
antibodies which have reached the market first. This has formed the basis for the drive
to shorten the development timeline and enhance the drug development process.
Development activities related to manufacturing, highlighted with an asterisk (*) in
Figure 1.3, are usually performed later in drug development which add to the criticality
of process development activities. It is within this context of biopharmaceutical drug
development process where the concept of accelerated bioprocess development, as
illustrated by Figure 1.2, is expected to have a great impact.
1.2.2 Biopharmaceutical manufacturing process
The need to deliver new biopharmaceutical drugs to market in a tight timeline and
consistently to high quality and reproducibility has resulted in a consensus
manufacturing process, particularly for monoclonal antibodies (Kelley, 2009; Shukla
and Thömmes, 2010). In both upstream cell culture and downstream primary recovery
and purification, platform processes have become widely established. Figure 1.4 shows
a typical process flowsheet for manufacturing Mabs. Slight variations may be adapted
by different companies but close similarities remain (Farid, 2006). The figure shows the
typical unit operations (I) for each step of the process (II).
Figure 1.4
(I) are the unit operations that seek to accomplish the functional steps in (II). Shaded
elements are the unit operations which are the focus of this work (Shown in detail in
Figure 1.
Shukla and Thömmes (2010).
Typical process flowsheet for manufacturing monoclonal antibodies where
5). Adapted and modified from
~
Birch and Racher (2006), Kelley (2009), and
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The expression system that is commonly used in commercial Mab processes are
mammalian cells which produce the complex and large Mabs molecules with the
correct glycan chain structure (Shukla et al., 2009). It is now widely known that the
glycosylated structure is essential in maintaining the biological activity of these
monoclonal antibodies (Jefferis, 2005).
“Primary Recovery” is highlighted in Figure 1.4 since this is the main subject of this
thesis. This step involves the removal of cells and cellular debris and the clarification of
the broth suspension. Primary clarification is usually achieved by centrifugation while
depth filtration is employed for further particulate removal as well as the removal of
other undesired soluble components (Yigzaw et al., 2006; Birch and Racher, 2006).
This primary recovery strategy is typical for Mabs production at production scale
greater than 2000 L (Figure 1.5). Other common cell removal techniques are crossflow
microfiltration and depth filtration. However, these are commonly used at scales less
than 2000 L, with depth filtration only being used at scales of up to several hundred
litres (about 400L) (Shukla and Kandula 2009; Kelley et al., 2009).
The rest of the process steps in Figure 1.4 are aimed at purifying the recovered solution
from the recovery steps. Affinity chromatography (Protein A) is the usual primary
product capture step, with almost two-thirds of monoclonal antibodies captured by
Protein A (Curling, 2009). Polishing steps follow such as bind-and-elute cation-
exchange (CEX) chromatography and a flow-through mode anion-exchange (AEX).
These ion exchange chromatography (IEX) steps are used to reduce host cell protein
(HCP) levels, DNA and aggregates and to remove leached Protein A and endotoxins. A
crossflow ultrafiltration/diafiltration (UF/DF) step may be employed to concentrate or
exchange buffer as required by each chromatographic step to increase selectivity and
binding of the desired protein.
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As a result of the maturity and robustness of the technology, the use of the typical
process flowsheet in Figure 1.4 is common at many commercial scales of production.
The adoption of this generic platform may result in cost savings in time and material
resources when developing processes for several other Mabs for different indications.
This can be achieved by, among others, streamlining process development efforts of
cross-functional groups within a company, leveraging negotiations for reduced raw
material costs, and by facilitating the application of modular approaches in process
validation (Shukla et al., 2007). However, fine tuning of process flowsheets and
process development strategies are still important undertakings as Mabs molecules and
cell culture composition may widely vary in their biochemical identities which could
affect the ease of which they could be processed and purified (Kelley, 2009).
1.3 Opportunities in biopharmaceutical manufacturing
1.3.1 Monoclonal antibody therapies
As the Mabs sector matures, quality and flexibility of development efforts are gaining
attention as factors which could provide competitive advantage in addition to the
traditional focus of speed to market (Farid, 2009). Issues regarding capacity utilisation
have come into focus with increasing product titre. Titres of up to 5 g/L have left
bioreactors under-utilised as fermentation volumes of about 4000 L can now achieve
the same output which formerly required 20 000 L (Anicetti, 2009). A further increase
to double digit titres may lead to production scales less than 2000 L. If this becomes a
norm, crossflow microfiltration as a harvest step will become increasingly relevant (see
Figure 1.5) as this is the current unit operation used for primary recovery at the
intermediate scale.
Figure 1.5
monoclonal antibodies. Adapted and modified from Shukla and Kandula (2009).
Typical primary recovery strategy
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for the large-scale production of
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Kelley (2009) has shown that there is excess production capacity in the foreseeable
future and that efforts to reduce the cost of goods (COGs) are only highly applicable to
Mab products intended for large therapeutic markets and not for all products in the
pipeline. It was further explained that platform technologies will continue and new
purification technologies may not provide the advantage these are expected to make in
terms of reducing manufacturing costs. However, to keep manufacturing off the critical
path, continuous improvement is important, particularly on product quality and process
consistency which may greatly improve overall economics (Farid, 2009).
Understanding the process fundamentals of the current platform will help achieve this
especially when developing processes that are not based on mammalian cell culture.
Recent advances in antibody engineering resulted in the production of full length IgGs
in Escherichia coli and Pichia pastoris (Mazor et al., 2007; Potgieter et al., 2009). The
production process using E. coli and P. pastoris may or may not require modifications
of the current platform process. Certainly, development efforts are necessary to
understand and scope the unique process requirements of these new Mabs expression
systems.
1.3.2 Emerging therapies: antibody fragments
There are different antibody fragment formats which can be used for therapeutic use
aside from the full length IgG. Currently, three of these antibody fragments are in the
market (Table 1.1), at least eight antibody fragment products are in development and at
least two of these are Fab’ fragments (Liddell, 2009). When the effector functions of
the Fc portion are expendable, requiring only the antigen-binding site, and when better
tissue penetration to the specific target and rapid clearing from the body are just two of
the specific instances when antibody fragments may have particular advantage over
intact antibodies (Rowe et al., 2004). The latter is possible due to the characteristic
short serum half-life of the antibody fragment. To improve the pharmacokinetic
properties of the antibody fragments, protein engineering or chemical coupling of
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antibody fragments with polyethyleneglycol (PEG) have been explored (Dennis et al.,
2002; Humphreys, 2003). Both methods were shown to increase serum half-life to
approach that of native IgG. Another key advantage of using Fab’ fragments is that
these fragments hold the antibody property that stimulates a therapeutic response. Fab’
fragments can therefore be used as therapuetic entity building blocks, making the
design of therapeutic antibodies more flexible than using standard IgG (Bowering,
2004).
In the context of manufacturing, antibody fragments can be produced in microbial,
usually E. coli, and eukaryotic systems (Andersen and Reilly, 2004). However, E. coli
remains the main production system of choice for antibody fragments due to shorter,
thus faster, drug development process, lower cost of goods, short fermentation time,
large global fermentation capacity, as well as significant regulatory experience for
therapeutic protein production which may be absent in novel expression systems
(Humphreys, 2003; Liddell, 2009).
The biopharmaceutical industry is known to make conservative changes when it comes
to the use of manufacturing equipment and operation largely due to the regulatory
implication of process changes. This is understandable given the regulatory
requirements a product has to go through before it is launched to market. However, for
antibody fragment production, a defined process has yet to become widely established
(Shukla and Thömmes, 2010). Antibody fragment production in E. coli has its own
intricacies very different from intact Mab production. This is brought about by the
nature of the expression system such that antibody fragments in E. coli are produced
either as inclusion bodies in the cytoplasm or as soluble protein in the periplasm.
Therefore, the production of antibody fragments presents an opportunity to develop
process flowsheets that are different from the platform Mab process shown in Figure
1.4.
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Figure 1.6 shows the process sequence for antibody fragment production in E. coli. As
illustrated, there are different process options for antibody fragments production
depending on their location in the cells and whether PEGylation is required or not. It is
clear in Figure 1.6 that the primary recovery of antibody fragments is more complex
and now involves more unit operations than Mabs (Figure 1.5). This makes it ever
more important to consider the strategies for process route selection since an increased
number of process steps will result in a drop in the overall downstream processing yield
(Farid, 2009).
In the production of antibody fragments, the solid-liquid separation and clarification
steps are now two unit operations after fermentation (instead of just one) which means
these steps are affected not only by the characteristics of the broth coming from
fermentation but also by the impact of the product release methods. Product release is a
relatively new step in biopharmaceutical manufacture. As discussed in Section 1.2.2,
full length IgGs are secreted from the cell into the culture broth thereby not requiring
product release strategies. Product release is usually done by disrupting the cells or
causing permeability changes to the cell membranes (Balasundaram et al., 2009a). Most
of these strategies have been applied to other biotechnological processes but are quite
unusual in antibody production.
Figure 1.6
of antibody fragments expressed in
recovery strategies for the different products. Inclusion bodies and soluble proteins are
expressed in the cytoplasm and periplasm, respectively. (Adapted and modified from
Spitali, 2009).
Overview of process sequences in the industrial production and purification
~
E. coli
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. Shaded region illustrates the primary
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1.3.3 Lean manufacturing and single-use systems
Given the current situation in biopharmaceutical manufacture, particularly for Mabs as
shown in Section 1.3.1, a direct consequence of increasing production titres is the
decrease in manufacturing scale. The size of the unit operations in the production and
recovery sections in Figure 1.4 will decrease while size requirements for the
chromatographic steps for product capture increases. To produce the same amount of
Mab product, the total number of batches per year will also decrease thus resulting in a
situation where a production facility may be underutilised unless multiple products are
produced within the facility. There are, however, risks for a multi-product facility. An
important one, particularly in regulatory and safety terms, is cross-contamination. In
this regard, there has been an increased interest in lean and flexible manufacturing
(Kelley, 2009). This requirement has been addressed in part by single-use systems, also
known as disposable technologies. The use of disposables have been promoted to have
numerous advantages such as reduced capital expenditure and risk; potential to
downgrade room classifications; economic benefits in terms of downsizing water
systems and simplifying the facility; regulatory impact: as the FDA supports the use of
disposables due to less risk of cross contamination; speed-to-market (as a result of the
ability to set-up new processes very quickly) and flexibility in production capacity and
product changeovers (Sinclair and Monge 2010).
At present, available disposable systems include mixing systems, bioreactors, aseptic
connectors, sampling systems, freezing, and fill-finish (Sinclair and Monge 2008). For
primary recovery strategies including cell debris removal and clarification, as well as
concentration and buffer exchange, membrane filtration systems are now mostly
available as disposables. For example, the large membrane manufacturers such as GE
Healthcare (Chalfont, UK), Merck Millipore (Massachusetts, USA), Novasep (Pompey,
France), Pall (New York, USA), and Sartorius Stedim (New York, USA) all have
disposable membrane filters specifically for crossflow filtration. Some have fully
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integrated crossflow filtration systems like Millipore which has the MobiusTM Flexible
Filtration system which is marketed as out-of-the-box, modular and fully optimised
assemblies for single-use crossflow filtration operation. In this regard, membrane
filtration processes, unlike centrifugation, offer the possibility of choosing between the
traditional stainless steel and disposable technologies to fill the requirement of
manufacturing groups according to production requirements. In the next section, a focus
on membrane filtration processes as applied to biopharmaceutical production is
discussed.
1.4 Membrane filtration for biopharmaceutical processes
Membrane filtration, a pressure-driven separation process, is an established unit
operation and has long been used to recover and concentrate biotechnological products
(van Reis and Zydney, 2007). Although other novel separations are currently being
investigated, membrane filtration remains a key unit operation in bioprocessing. In the
case of large scale production of monoclonal antibodies for example, Kelley (2007)
stressed that the conventional unit operations, including membrane filtration, still
appear to be the separation processes of choice due to reduced risks in scale-up,
technology transfer and process robustness.
Membrane filtration processes separate components according to size in which the
primary role of the membrane is to act as a selective barrier for the different
components of the feed stream. As opposed to conventional filtration processes, which
are usually applied to the separation of fine and course particles greater than 10
microns, membrane filtration is a classification of filtration processes involving
particles less than 10 microns using membrane filters that are usually less than 10
microns as well (Mulder, 1996). Figure 1.7 illustrates the typical classification of
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membrane filtration processes. This figure demonstrates that microlfiltration and
ultrafiltration processes are applicable in biopharmaceutical manufacturing. Thus,
concepts presented here are limited to these two filtration processes.
1.4.1 System design and mode of operation
The design of a membrane filtration process requires consideration of certain key
process elements: (1) the size of the material that has to be retained on or be allowed to
permeate through the membrane; (2) the type of filter required in terms of pore size,
whether microporous filter or ultrafilter; and (3) the mode of operation of the separation
process.
Although, historically, membrane filtration processes were mostly performed using
ultrafiltration membranes, increased use of microfiltration membrane processing has
become evident since the late 1990s (Cheryan, 1998; Foley, 2006a). Table 1.2 shows
some of the different membranes currently available for microfiltration and
ultrafiltration of suspensions and solutions. When choosing membrane filters, the type
of material of the membrane should be compatible to the feed stream which is going to
be processed and that it could provide the desired separation. It is necessary that the
membranes do not bind to the product as this will decrease recovery. Some of the
membrane materials in Table 1.2 are naturally hydrophobic (PVDF and PTFE).
Therefore, modified versions of these membranes should be used. Most manufacturers
will have hydrophilic PVDF membrane, for example, which is the suitable type of
membrane for cell harvesting and clarification.
Figure 1.7
materials according to membrane pore sizes or molecular weight cut
modified from: www.gelifesciences.com)
Classification of membrane filtr
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Table 1.2 Common membrane filters for biopharmaceuticals processing*
Material Microfiltration Ultrafiltration
Polyvinylidene fluoride (PVDF ) X
Polyethersulfone (PES ) X X
Polytetrafluoroethene (PTFE ) X
Regenerated cellulose (RC) X
Polysulfone (PS ) X X
*Material data from Cheryan (1998); application data cross-checked from online catalogue of different
manufacturers
For their practical application, membranes are packaged according to the design of the
equipment housing. Typical membrane filtration configurations in industrial
bioseparation are as flat-sheet membranes in cartridges (similar to the plate-and-frame
type for particulate filtration) or flat-sheets in spiral wound; and as bundles of hollow
fibre membrane (Ladisch, 2001). In recent years, membrane separations in
bioprocessing have mostly focused on the use of flat-sheet and hollow fibre membranes
for cell harvest or cell debris removal (van Reis and Zydney, 2007). A survey of the
online product catalogue of some of the large membrane suppliers revealed that flat-
sheet membranes in cassette format is the most common format sold. However, not all
the different membranes are available in the different formats sold by the manufacturer.
It is therefore very important to select membrane formats which have available
filtration systems at different scales of development, i.e., from laboratory to pilot and
then to manufacturing scale.
The classical mode of operation of membrane filtration processes is via normal flow
(NFF) or dead-end filtration (DEF). This has followed from conventional filtration
processes which were also operated in this way (Cheryan, 1998). However, since dead-
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end filtration results in low permeate flux, different strategies for increasing flux were
developed. With the evolving understanding of the fundamentals of membrane
separation, crossflow microfiltration has found more application in industrial
bioseparation because of improved permeate fluxes (Belfort et al., 1994; Meltzer and
Jornitz, 1998). Figure 1.8 illustrates these two modes of operation. DEF is a process
where the feed flows perpendicular to the membrane surface. As a result, retained
components build up on the feed/retentate side and lead to membrane fouling and
concentration polarisation. The permeate flux during dead-end filtration decreases over
time. Tangential (TFF) or crossflow filtration (CFF) have the feed stream flowing
parallel to the membrane. The feed flow then allows the retained components to be
brushed off along the membrane surface and out of the CFF device.
1.4.2 Theories and models of membrane filtration
A key performance indicator of membrane filtration processes is the permeate flux, Jt,
which is the measure of volume of liquid, Vt, which has permeated through the
membrane of a certain area, Am, for a certain period, t. Based on Equation 1.1, once
the flux is known, the processing time for certain volume of material can be determined
for a given membrane area, or if given a fixed processing time, the required membrane
area can be determined. Thus, flux modelling has been an important undertaking in
understanding membrane filtration processes. This section will present the common
models for predicting flux as well as the theories behind these models.
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Figure 1.8
operation typically used in biopharmaceutical production: (A) dead
(B) crossflow filtration.
Schematic illustration
~
of the different modes of membrane filtration
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1.4.2.1 Hagen-Poiseuille flow through a membrane pore: ideal flux
In the most ideal and simplest situation, flow through a membrane can be treated as a
fluid flow situation analogous with viscous flow through pipes as in fluid transport
problems (Bird et al., 2001). Figure 1.9 is a schematic representation of this situation.
If the Hagen-Poiseuille flow equation is applied to flow of fluid through a membrane
pore, Equation 1.2 is derived.
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Where: J is the permeate flux; is the membrane porosity; dch is the channel diameter
or membrane pore size; PTM is the transmembrane pressure; l is the membrane
thickness; and  is the viscosity of the fluid.
The Hagen-Poiseuille equation assumes that the fluid flows through a constant circular
cross-section with the diameter that is very small compared to the length. Also, in this
situation, the flow is viscous, incompressible and laminar. The fluid follows Newtonian
law and that there is no slip of fluid particles at the boundary (Bird et al., 2001).
1.4.2.2 Flux modelling based on flow resistances
The determination of flux through a series of resistances is commonly encountered in
heat transfer in the form of Fourier’s law of conduction (Bird et al., 2001). Modelling
flux by the resistance model takes the general form of:
resistanceTotal
forceDrivingFlux 
(1.3)
Figure 1.9
permeate
Schematic representation of flow through membrane pores to model
flux by the Hagen-Poiseuille equation.
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Different resistances are considered for flows through a membrane filter (Mulder, 1996;
Cheryan, 1998). Figure 1.10 illustrates these which include: (A) the clean membrane;
(B) the fouled membrane; (C) the fouled membrane with a gel layer; (D); the fouled
membrane with a boundary layer; (E) the fouled membrane with a boundary layer and
gel layer; and (F) the fouled membrane with a boundary , gel and cake layer. From
Figure 1.10, it can be seen that the different levels of resistances should be determined
if flux is to be known using the general equation in Equation 1.4. In the following
paragraphs, the determination of these resistances is discussed.
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Where: RT is the total resistance which could be:
(A) the clean membrane
RT = Rm (1.5)
(B) the fouled membrane
RT = Rm + Rf (1.6)
(C) the fouled membrane with a gel layer
RT = Rm + Rg (1.7)
(D) the fouled membrane with a boundary layer
RT = Rm + Rbl (1.8)
(E) the fouled membrane with a boundary layer and gel layer
RT = Rm + Rbl + Rg (1.9)
(F) the fouled membrane with a boundary , gel and cake layer
RT = Rm + Rbl + Rg+ Rc
(1.10)
Figure 1.10
resistances in series for membrane filtration processes.
Schematic representation of the different situations showing flow through
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 Membrane resistance
Predicting a pure solvent flux, e.g. for water, is straightforward if the membrane
resistance is known. Rm can be determined from experimental flux measurements and
calculated by using Equation 1.4 and Equation 1.5. Rm can also be determined by
employing the Kozeny-Carman equation in Equation 1.11 (Modise et al., 2005).
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In Equation 1.11, K is the Kozeny-Carman constant which depends on membrane
morphology, m is the membrane surface porosity, xm is the membrane thickness and
Sm is the pore internal surface area per unit volume. The membrane resistance can be
estimated using the Kozeny-Carman equation under the assumption that each
membrane consists of closely packed spheres. According to this equation, a small
difference in porosity may have a significant effect on the calculated membrane
resistance.
 Fouled membrane resistance
The fouled membrane resistance (Rm + Rf) is determined by performing the water flux
experiment, as described above, before and after passing through to the membrane the
feed suspension of interest. The first water flux experiment is to determine the clean
membrane resistance, Rm, and the second to determine the total resistance RT. From
Equation 1.4 and Equation 1.6, Rf can be determined.
 Boundary layer, concentration polarisation layer and gel layer
The retention of certain components on one side of the membrane results in the
phenomenon called concentration polarisation. At a certain distance from the
membrane, the concentration of particles or solutes starts to deviate from the bulk
concentration. This concentration increases, with the highest near the surface of the
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membrane (Cheryan, 1998). For certain feeds, the concentration near the membrane
becomes very high such that a layer of particles become viscous and gel-like, hence the
term gel layer. This is schematically shown in Figure 1.10C. The resistance of the gel
layer is calculated from Equation 1.4 and Equation 1.7.
The boundary layer on the other hand is formed at a distance away from the membrane
where the concentration changes from the bulk concentration towards the highest (gel
concentration) concentration near the membrane. This is schematically shown in Figure
1.10D. The resistance of the gel layer is calculated from Equation 1.4 and Equation 1.8.
Figure 1.10E also illustrates a situation of concentration polarisation wherein the
resistance is contributed by the resistances due to both the gel and the solutes within the
boundary layer. This is also shown schematically in Figure 1.11A. Mulder (1996) has
shown this differentiation between resistances of boundary layer and gel layer while
Cheryan (1998) did not distinguish between the two and simply referred to this layer
separate from the membrane as the concentration polarisation layer.
A disadvantage of this approach is the difficulty of distinguishing between these
different layers. Okamoto et al. (2001) have shown a step by step determination of the
different resistances of E. coli broth components. This type of investigation though is
not practically applicable particularly when studying feed stocks that have interacting
solutes and particles and with the interaction being different under actual filtration
conditions.
 Cake resistance
Equation 1.11 is based on the classical cake filtration theory that was supported by the
influential work of Grace (1953a). This was developed based on the Poiseuille law of
viscous flow. It has become one of the most important equations in classical cake
filtration which only assumes that aside from the membrane resistance, the other
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contribution to resistance to flow is the cake which formed due to particles being
deposited on the membrane surface. For membrane filtration, there has been no clear
distinction between a “cake” layer, “gel” layer, “boundary” or “concentration
polarisation” layer (Cheryan, 1998). It has been commonly applied to dead-end
microfiltration analysis (Foley, 2006b).
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Simple integration of Equation 1.11 yields the widely known parabolic law of constant-
pressure filtration in Equation 1.12. From Equation 1.12, the average specific cake
resistance, , can be determined if o is known or can be estimated (Tien, 2008).  is a
measure of how easily a feed can be filtered (Foley, 2006b). With Equation 1.13, and
Equation 1.4, the permeate flux can be predicted if it could be assumed that the
resistance is due to cake formation.
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1.4.2.3 Theories of concentration polarisation
In the previous section, the concept of concentration polarisation has been described.
There are different theories that aim to describe this phenomenon although the basic
premise of this is covered by the mass transfer film theory model (Belfort et al., 1994).
Based on this model, the transport of solutes or particles towards the membrane is by
convective transport mechanism due to permeate flow through the membrane while
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transport away from the membrane may be by diffusion, inertia or shear forces
(Romero and Davis, 1991). At steady state, these two opposing transport mechanisms
reach a balance thus resulting in a steady flux. Table 1.3 summarises the key theories
for concentration polarisation and the inherent assumptions. Other models not included
in the table were also reviewed by Ripperger and Altmann (2002). The models in Table
1.3 are usually applied in CFF mode since this allows for the application of certain back
transport mechanisms such as shear (Ripperger and Altmann, 2002). The classical
models in this table were initially developed for ultrafiltration processes and their use
extended in explaining microfiltration data (Song and Eiimelech, 1995). Figure 1.11
illustrates the situations described by the models in Table 1.3. Figure 1.11 A and C
shows the concentration polarisation layer, either without (A) or with (C) cake
formation, as stagnant or non-flowing and thus, the flow field shows the typical velocity
flow field of most concentration polarisation models (e.g. Models 1, 2 and 5 in Table
1.3). Figure 1.11 B and D illustrate a flowing concentration polarisation layer, beside a
membrane (B) or a cake layer (C), as in Models 6 and 7 in Table 1.3.
Table 1.3 Key concentration polarisation models and their assumptions.
Model
[1] Film theory or traditional concentration polarization model
(Back transport by Brownian diffusion)
Porter (1972) in Belfort et al. (1994)
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Table 1.3 Continued
Model
[1] Film theory or traditional concentration polarization model (continued)
For dilute suspensions wb   or 1.0b
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Key assumptions
 strictly valid for only for very small permeate flux compared to longitudinal flux;
 no particle interaction
 cake is immobile
 laminar flow
 diffusivity is independent of shear rate
[2] Film theory or traditional concentration polarization model
(Back transport by Shear-induced diffusion)
Zydney and Colton (1986) in Belfort et al. (1994)
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For dilute suspensions wb   or 1.0b
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Key assumptions
 strictly valid for only for very small permeate flux compared to longitudinal flux;
 no particle interaction
 cake is immobile
 laminar flow
 diffusivity is dependent of shear rate
 ignores viscosity effects
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Table 1.3 Continued
Model
[3] Back transport by Shear-induced diffusion
Romero and Davis (1988)
  QJu
L
blocalb
fl
 
00
dLdy 

 ststflflmF
TM
local RRR
P
J
 


(see number [4] for conditions)
[4] Back transport by Shear-induced diffusion
Davis and Sherwood (1990)
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 valid for very small permeate flux compared to axial flux;
 cake resistance dominates (low permeability)
 no particle interaction
 cake is immobile
 laminar flow
 dilute suspensions
 shear rate is dependent on particle concentration ( due to concentration
dependence of viscosity
 diffusivity is dependent on particle concentration
 C = 0.0604 if particle concentrations between: 0 <b <0.5 and particles are
monodisperse , rigid spheres in maximum random packing
[5] Film theory or traditional concentration polarization model
(Back transport by Inertial lift)
Drew et al.(1991) in Belfort et al. (1994)
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 fast laminar flow
 immobile cake
 dilute suspensions
 independent of filter length and particle concentration
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Table 1.3 Continued
Model
[6] Concentration polarization model
(Back transport by Brownian diffusion and shear induced diffusion)
Song and Eiimelech (1995)
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 Defines a filtration number, NF, which is the ratio of the energy needed to bring a
particle from the membrane surface to the bulk suspension to the thermal
(dissipative) energy of the particle.
[7] Non-equilibrium filtration (Cake formation)
Song and Eiimelech (1995)
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 Assumes immobile cake
 Fluid field in the channel is undisturbed by the cake layer
 Nc is the cake thickness factor which reflects the effect of the cake layer thickness
on the accumulation of the retained particles in the polarization layer
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Table 1.3 Continued
Model
[8] Back-transport with cake filtration
Schulz and Ripperger (1989)
For turbulent flow:
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 Combines fluid transport treatment in the presence of cake that may cause
resistance to flow.
[9] Suspension flow model
Kromkamp et al.. (2005)
Hydrodynamics components:
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 Flow model resolved by Lattice Boltzmann method by computational fluid
dynamics
 Does not assume Poiseuille flow for pressure.
 Viscosity is a function of particle volume fraction ()
 Diffusion coefficient, D is f()
Figure 1.11
field in the steady state situation during crossflow microfiltration.
Schematic diagram
~
of the particle concentration distribution and fluid flow
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1.4.2.4 Application to biological materials recovery and purification
The complicated nature of modelling filtration processes is obvious from Table 1.3 and
Figure 1.11. This is not surprising considering the dynamic nature of membrane
filtration and with the many aspects to be considered which may affect the filtration
process. Key here are the operating conditions such as crossflow velocity (shear-rate),
and the transmembrane pressure; the properties of the membrane such as material, pore
size; and the possible interactions of feed components (soluble or particles) with the
membrane under filtration conditions (Russotti et al., 1995). Most of the models in
Table 1.3, however, are still simplistic representation of actual membrane filtration
processes involving complex biological solutions. For example, the classical models
(e.g. Models 1-5 in Table 1.3) generally ignore the impact of cake formation,
membrane fouling due to physico-chemical interaction, and adsorption of some of the
soluble components in the feed suspension. Some of these models also do not take into
account the resistance to permeate flow of the presence of a cake or gel, or even the
resistance of a concentration polarisation layer. For particles greater than 0.1 m, cake
formation is known to dominate flux behaviour and that pressure dependence becomes
weak with the presence of concentration polarisation and cake formation (Song and
Eiimelech, 1995). Additionally, the classical models also do not include:
 any interactions between particles, solutes and the membrane or the fact that
these interactions could change depending on operating conditions (Hodgson et
al., 1993; Russotti et al., 1995; Keskinler et al., 2002);
 the effect of particle size in the preferential deposition on the membrane (Foley
et al., 1995; Kromkamp et al., 2006);
 the effect of cake compressibility or the compressibility of the concentration
polarisation layer (Reismeir and Kula, 1989; McCarthy et al., 1998); and
 the impact of pore blocking on flux (Song, 1998).
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The general assumption in most of the classical models in Table 1.3 is that bulk flow is
fully developed Poiseuille flow with time-independent flowrate is not valid in actual
filtration conditions due to, among others, the complex geometry of the flow path (e.g.
presence of turbulence promoter) or with the variation of cake layer height along the
channel length (Kromkamp et al., 2005). Furthermore, these models were derived from
a single mass balance equation with the permeate velocity and particle concentration
distribution over the membrane as the unknowns, thus, as is often made, it is assumed
that the concentration of the stagnant layer along the membrane is constant (Song and
Eiimelech, 1995). More accurate modelling is therefore promoted to cover the
complexities of membrane systems. An accurate and detailed solution of the flow field
is now possible with the use of computational fluid dynamics (CFD) as was shown by
Wiley and Fletcher (2003), Kromkamp et al. (2005), and Ghidossi et al. (2006).
Recently, Foley (2006a) cited that the complexities of the crossflow microfiltration
processes can be captured from small, targeted experimental data and together with
dimensional analysis can provide useful empirical correlation to explain and predict
crossflow microfiltration data. Dimensional analysis has been traditionally applied to
describe the complex relationships in fluid flow, heat and mass transfer in chemical
engineering processes (Foley, 2006a).
Belfort et al. (1994) has stressed the difficulty in modelling crossflow filtration
processes. Even with CFD, it is still necessary to assess the CFD models against actual
crossflow filtration data. This could be done by retrospective analysis of previous
studies or combining modelling studies with experimentation. Both of these have their
drawbacks. First, on previous data, Foley (2006a) reviewed the data available in
literature and concluded that while there are a large number of papers on crossflow
microfiltration, only a few provide extensive information on the effect of process
parameters on the steady state flux. Most studies were found to be on membrane fouling
and flux decay. A similar conclusion has been reached in assessing the literature for this
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thesis. Additionally, it could be said that the available data in literature on crossflow
microfiltration were using feed systems that are simple (such as harvest broths or
reconstituted Baker’s yeast in buffer) and often times diluted or at low concentration.
Very few reflect the kind of complexity which is inherent in biopharmaceutical
feedstocks, for example high titre cell culture in complex media or cell lysates. Second,
on experimentation, comprehensive experiments to cover extensive experimental space
and conditions require a lot of feed material. The production of biopharmaceutical
feedstock is inherently expensive making extensive experimentation impractical.
Given this background, it is proposed in this thesis to create microscale bioprocessing
techniques for membrane filtration which will address the need to understand
microfiltration processes. This membrane filtration platform will enable
experimentation with real, complex feedstocks because the cost of performing
experiments with the microscale approach is not prohibitive due to the relatively
smaller feed requirements. In tandem with laboratory automation, the automated
microscale approach has the potential to rapidly explore wider experimental space thus
enabling in-depth analysis of the extensive microscale data to understand membrane
filtration mechanism. In the subsequent section, the current microscale unit operations
and the available membrane filtration systems are reviewed.
1.5 Overview of Microscale (Scale down) Unit Operations
Most of the earlier microscale studies in microscale processing have mainly focused on
upstream operations particularly in high-throughput miniature bioreactors (Betts and
Baganz, 2006). In order to maximise the potential of this approach, however, Jackson et
al. (2006) identified the need to establish more microscale downstream processing
operations. In this regard, Titchener-Hooker et al. (2008) highlighted in their review the
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strong interaction between the complex biological materials and the engineering
environment within the downstream process steps. A comprehensive analysis of the
various micro-biochemical engineering design of downstream processes revealed that
scale-down methods are available for a wide range of operations including disc and
tubular centrifugation, dead-end microfiltration, leaf filtration, high pressure
homogenisation, expanded bed adsorption and chromatography. In scaling down, the
key effects that dominate the unit operation were maintained across the scales. For
example, shear was found to play an important role in various process operations and its
effects should be reflected at all scales. Other examples of criteria for scaling are linear
velocity in chromatography and power per unit volume or volumetric mass transfer
coefficient in bioreactors. This scale down method has been applied to a variety of
systems (microbial fermentation, mammalian cell culture, precipitation, high cell
density cultures) and recently applied to a centrifugation study using industrial process
feedstocks (Zaman et al., 2009).
Coffman et al. (2008) developed a high-throughput screening methodology to
investigate hydrophobic interaction and anion-exchange chromatographic separations
using microwell filter plates. Chhatre et al. (2009) employed commercially available
chromatographic pipette tips for the automated microscale investigation of column
performance. Successful prediction of industrial scale clarification of mammalian cell
broth have been obtained by Tait et al. (2009) using microwell technology in
combination with ultra scale-down centrifugation techniques. Other downstream
process technology developments include the use of Adaptive Focused Acoustics to
simulate the product and contaminant profile produced by the larger-scale high pressure
homogenization process (Wenger et al. 2008). Microplates have also been successfully
employed in the optimization of protein freeze-drying formulations (Grant et al., 2009).
Most of the reports on microscale downstream processes mentioned above are
amenable for parallel experimentation and automation within a laboratory robotic
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platform thereby increasing the number of experimental variables that could be
investigated and facilitating studies on linked-process sequences.
Until the beginning of this work in 2007, very few filtration studies have been
conducted at the microscale and most operate as dead-end filtration processes as
summarised in Table 1.4. Low-volume tangential flow filtration modules are also
commercially available. However, the modules are not readily adaptable into automated
workstations and may not be easily used for parallel membrane testing or multiple feed
processing. More recently, a miniature rotating disc device was used to simulate a
larger scale diafiltration process (Guijun et al., 2010).
Table 1.5 describes the available commercial membrane modules which may be fitted
in the filtration systems given in Table 1.6. Aside from the specified membrane
modules, the membrane devices mentioned in Table 1.6 can also be fitted with custom-
made membrane modules. Among the available platforms, Jackson et al. (2006) were
able to show quantitative parallel analysis of DEF processes within an automated
environment. They were able to show that filtration processes at the microscale yield
comparable data with standard laboratory membrane cells but with less amount of feed
and with more ease and higher degree of reproducibility since their format also allows
for parallel testing. Furthermore, a custom-made system integrated into an automated
platform enabled the quantitative collection of process engineering data.
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Table 1.4 Previous studies on microscale filtration system
[Ref.] Format Operation/Application Filter area (cm2)
[1] 96-well plate syringe filter discs Dead-end filtration/
microfiltration
0.28 to 4.26
[2] 16-well filter discs (custom-made) Dead-end filtration/
nanofiltration
12.6
[3] 8 to 24-well filter discs (custom-made) Dead-end filtration/
microfiltration
0.79
Ref.: [1] Chandler and Zydney (2004); [2] Vandezande et al. (2005); [3] Jackson et al. (2006)
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Table 1.5 Commercial filter modules for miniature or automated tangential flow filtration
Manufacturer and product Membrane material Operating
pressure
Hold-up volume Remarks
Millipore (www.millipore.com)
Pellicon® XL 50 Cassette
(membrane area = 50 cm2)
1. Polyethersulfone
2. Composite regeneratre
cellulose
3. Hydrophilic PVDF
5600 kPa
(maximum)
3.2 mL The same path length and
channel height exist for all filters
of the Pellicon cassettes. This
allows for linear scale-up.
PALL Life Sciences (www.pall.com)
Minimate™ TFF Capsule
(membrane area = 50 cm2)
Modified polyethersulfone 4000 kPa
(maximum)
1.6 mL Allows for linear scale-up
A limitation of this module is
that it is only available in one
type of membrane
GE Healthcare Life Sciences
(www.gehealthcare.com)
a.) Hollow fibre Start AXM Crossflow Cartridge
(membrane area = 50 cm2)
b.) Hollow fibre Start AXH Crossflow Cartridge
(membrane area = 40 cm2)
c.) MidGee™ Hoop Crossflow Cartridges
(membrane area = 29-73 cm2)
Polysulfone-based
1-1.5 mL (Lumen
side)
1 mL (Shell side)
< 1mL
(Lumen or shell side)
A limitation of this module is
that it is only available in one
type of membrane
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Table 1.6 Available miniature filtration systems or devices
Reference Filter module Flow rates/ Recirculation volume Remarks
Millipore (www.millipore.com)
Labscale™ TFF System
Pellicon XL 50 Feed flow rate: 10-100 mL/min
Min Recirculation volume: 20 mL
The system can hold up to 3 Pellicon cassettes
which makes it useful for simultaneous
membrane testing.
Has one feed reservoir.
PALL Life Sciences
(www.pall.com)
Minimate TFF System
Minimate TFF Capsule Recirculation rate: 10-240 mL/min
Min system working volume: < 5mL
The system can only hold 1 capsule.
Has one feed reservoir.
GE Healthcare Life Sciences
(www.gehealthcare.com)
ÄKTAcrossflow™
Any modular membranes
(commercial e.g. AXH/AXM
Crossflow cartridges or even
Pellicon XL 50 or Minimate TFF
Capsule, or costum made)
Feed flow rates: 8.5 – 600 mL/min
(depending on membrane format)
Min working volume: 22 mL
Fully automated system.
A software controls the process and allows some
electronic data logging.
Has one feed reservoir.
Petersen and Wolk (2007)
US Patent/ European Patent
Assigned to Millipore Corp. USA
Automated low-volume TFF device
Any modular membranes
(commercial e.g. Pellicon XL 50 or
Minimate TFF Capsule, or costum
made)
Min recirculation volume: < 20 mL Fully automated system.
Has a feed reservoir with distinct mixing zone.
System allows for electronic data processing.
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1.6 Aims of the Project
The overall aim of this thesis is to establish a microscale bioprocessing platform for the
evaluation of both dead-end and crossflow filtration operations and the impact of
upstream operations on filtration performance. The dead-end filtration studies will
extend the previously published method of Jackson et al. (2006) described earlier in
Section 1.5. Establishment of a microscale crossflow operation will require the design
of a novel filtration device compatible with the automation platform on which linked
fermentation – cell disruption – filtration sequences will be established.
The context of this work is within biopharmaceutical product development described in
Sections 1.2 and 1.3 as well as industry collaborative studies within the UCL Innovative
Manufacturing Research Centre (IMRC) for Bioprocessing. Where ever possible
therefore, care has been taken to utilise products and expression systems that are
representative of the complex biological feeds encountered by industry in this sector. In
particular, an E. coli strain expressing humanised antibody Fab’ fragments (kindly
supplied by UCB Celltech) was used as a case study for evaluation of the microscale
filtration methodologies. Given the potential of antibody Fab’ fragments to be
developed into novel therapeutic molecules and the new challenges brought about by
being expressed inside microbial cells (Section 1.3.), this particular expression system
(referred to from here on as E. coli Fab’) was chosen to be an ideal system for process
development studies using the microscale bioprocessing approach.
In order to achieve the overall project aim a series of objectives were defined as
described below.
 Building on the work of Jackson et al. (2006), where a microscale dead-end
filtration device was created and which was shown to produce comparable results
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with larger scale dead-end filtration systems, the first objective was to further
simplify and reduce the volumes of feed needed to perform microfiltration studies.
A new method was thus developed and its suitability to investigate microfiltration
performance was first assessed. This was to confirm reproducibility and show that
the improved method could also capture differences in feed preparation and
operating conditions. The results of this work are presented in Chapter 3 of this
thesis.
 Having established the new microscale dead-end filtration methodology the next
objective was to demonstrate how this methodology can be employed to assess
process interactions affecting primary product recovery using membrane filtration.
In particular, it was used to investigate two consecutive process steps: antibody
Fab’ fragment extraction from E. coli cells and their subsequent recovery by dead-
end microfiltration. The results are presented in Chapter 4 of the thesis.
 The third objective was to expand the range of operations that can be studied at the
microwell scale and entailed the design of a novel, automation compatible,
microscale crossflow filtration (CFF) device. Once constructed, the associated
methodologies for the operation of the microscale CFF device were developed. Its
operation was then compared to the performance of a larger scale CFF module,
initially using a model process feed of Baker’s yeast with bovine serum albumin
(BSA) in phosphate buffer. These results are presented in Chapter 5 of the thesis.
 The final objective was to demonstrate the application of the microscale CFF
device in informing bioprocessing options by predicting larger scale performance
using an industrially relevant E. coli Fab’ feedstock. In particular, the impact of
DNA hydrolysis by using either exogenous or endogenous nucleases on crossflow
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microfiltration processes was investigated. The results are presented in Chapter 6
of the thesis.
Once each of the component elements of the microscale filtration platform has been
established their performance characteristics and wider application throughout the
biopharmaceutical bioprocessing sector was reviewed. This evaluation is described in
Chapter 7 along with recommendations for future work. Figure 1.12 is a schematic
representation of the application of the microscale bioprocessing approach in this thesis
for membrane filtration processes, particularly in studying the linked process sequences
involving primary recovery.
Figure 1.12
filtration for the investigation
Fab’ fragments.
Application of the microscale bioprocessing platform for membrane
(Image credit:
~
of bioprocess routes for the primary recovery of antibody
Pilot scale centrifuge from www.pneumaticscale.com)
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2. Materials and Methods
This chapter describes common materials, routine experimental methodologies and
analytical procedures used throughout this work. Details specific to certain experiments
are described in the following chapters.
2.1 Materials
Membrane materials were purchased from Millipore (Hertfordshire, UK) and Pall
(Portsmouth, UK). All analytical reagents were purchased from Sigma-Aldrich (Dorset,
UK) unless otherwise stated and were of the highest purity available. Purified water,
conductivity < 0.2 mS cm-1, from a Millipore Elix 10 water purification system
(Hertfordshire, UK) was used in all experiments. The industrial Escherichia coli strain
W3110 containing plasmid pTTOD A33 was kindly provided by UCB-Celltech
(Slough, UK) and was from a working cell bank prepared as described by Bowering et
al. (2002). The strain expresses humanised antibody Fab’ fragments with each antibody
chain preceded by the E. coli OmpA signal peptide which directs secretion of the Fab’
fragments into the periplasm of the cells (Tustian, 2008). Baker’s yeast, Saccharomyces
cerevisiae, was purchased in powder form from Sigma-Aldrich (Dorset, UK).
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2.2 Pilot-scale production of antibody fragments
2.2.1 20 L Fermentation vessel
A 20 L stainless steel, jacketed fermentor (Applikon Biotechnology B.V., Schiedam,
The Netherlands) was used in the production of recombinant E. coli that expresses
antibody Fab’ fragments (Section 2.1). The fermentor has a top driven, three-stage, six-
bladed Rushton-type impeller, and four-equally spaced baffles. It has ports for
sampling, reagent addition and harvest. The main vessel, with the fermentation media,
all ports and ancillary lines were steam sterilised in place at 121oC for 20 minutes. The
fermentation operation (i.e. control of impeller speed, temperature and pH) was
controlled by Applikon’s process control software BioXpert. The impeller was on
cascade control initially set at 400 rpm (1400 rpm max) and changes according to the
measured dissolved oxygen tension (DOT). The DOT probe was calibrated with
nitrogen and air for 0% and 100% readings, respectively. Dissolved oxygen was
maintained at 30%, using gas blending with enriched oxygen (40:60 O2:N2) when
necessary. pH was measured with a pH probe that was calibrated off-line at pH 4.0 and
7.0 prior to fermentation. Both DOT and pH probes were sterilised during fermentor
sterilisation. Temperature was maintained by passing steam or cooling water through
the jacket.
2.2.2 E. coli fed-batch fermentation
Recombinant E. coli production routinely followed the method previously described by
our laboratories based on the earlier work of Tustian (2008). Starter cultures were
grown in 2xPY complex media containing 10 g mL-1 tetracycline, 16 g L-1 phytone, 10
g L-1 yeast extract, and 5 g L-1 NaCl shake flasks at 37°C, 200 rpm shaking speed for
about 4 hours. These were used to inoculate (10% v/v) shake flasks with SM6Gc
defined media containing 112 g L-1 glycerol and 10 g mL-1 tetracycline and adjust to
pH 6.95. These were then incubated at 30 °C for about 20 hours at 200 rpm shaking
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speed. One litre of this defined media shake flask cultures inoculated 10 L of SM6Gc
defined media in the fermentor described in Section 2.2.1. DOT was maintained at
30%; pH was maintained at 6.95 using 50% (w/v) ammonia solution and 20% (v/v)
H2SO4 and temperature at 30 oC. After 32 h, the temperature was reduced to 25°C.
Glycerol feeds, Mg2+, and PO42- were added to the culture at certain intervals when
OD600 was between 40-90. Isopropyl--D-thiogalactopyranosid (IPTG) was then added
after approximately 36 hours to induce Fab’ production. During the Fab’ production
phase, glycerol was continuously fed (at feed rates between 10-25 mL h-1) to the
fermentor until harvest. The culture was harvested from the fermentor when Fab’
started to be secreted into the culture media, which was approximately 36 h after the
addition of IPTG. Typical cell growth of this culture is shown in Appendix 1.1. The
time profile of the extra- and intra-cellular Fab’ content is also shown.
2.2.3 Cell harvest by laboratory scale centrifugation
20-millitre aliquots of the fermentation broth were spun at 4000 rpm for 45 minutes in a
bench top centrifuge (Centrifuge 5800, Eppendorf, Germany). The supernatant was
removed from the cell paste and both were separately stored as described in Section
2.2.5.
2.2.4 Cell harvest by pilot scale centrifugation
Pilot scale cell harvest was performed using a pilot scale tubular bowl centrifuge
(CARR™ P6™ Powerfuge, Pneumatic Scale, Clearwater, FL, USA). Fermentation
broth was first collected from the fermentor using 20 L holding vessels.Whole cells
were then immediately recovered by centrifugation at a feed rate of 30 L h-1 and a bowl
speed of 15,000 rpm. The collected cell paste was either used immediately or stored as
described in Section 2.2.5.
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2.2.5 Storage of cell paste
Harvested cells which were not immediately used for primary recovery experiments
were stored in clear bags at -20oC until further use. When required, a portion of the cell
paste is obtained and allowed to thaw at room temperature for 1- 4 hours depending on
the amount. This sample is referred to as, from here onwards, freeze-thawed samples.
2.3 Methods for Fab’ release
2.3.1 Fab’ release by continuous homogenisation
Cell disruption was performed to release the Fab’ fragments from E. coli cells which
are either fresh from cell harvest (Section 2.2.4) or freeze-thawed (Section 2.2.5). Cells
were first resuspended in 100 mM Tris buffer at the desired pH. Cell disruption by
continuous homogenisation was performed using a pilot scale APV Manton-Gaulin Lab
60 (APV International, West Sussex, UK) high pressure homogeniser which was
operated at 500 bar and at a constant flowrate of 60 L h-1 (or 1 L min-1). At this rate, a 2
L cell suspension was processed through the homogeniser for four minutes before
collection in order to achieve homogenisation equivalent to 2-passes. The Lab 60
homogeniser was operated with no temperature control although ethylene glycol was
used as coolant. Samples were immediately used in subsequent microfiltration
experiments (Section 2.6.2 or Section 2.7.2) or routinely stored overnight at 4oC.
2.3.2 Fab’ release by batch homogenisation
Using the cells fresh from cell harvest (Section 2.2.4) or freeze-thawed (Section 2.2.5),
cells were resuspended in 100 mM Tris buffer at the desired pH. Batch cell disruption
operations were performed using an APV Manton-Gaulin Lab 40 homogeniser (APV
International, West Sussex, UK). The homogeniser has a maximum capacity of 40 mL
per batch with minimum feed volume of 35 mL. Disruption operations were performed
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for 2 passes per batch of cells at 500 bar. At this pressure, maximal Fab’ release is
achieved in 2 passes. No significant release of Fab’ was observed by increasing the
number of homogenisation passes (Balasundaram et al., 2009a). Samples were
immediately used in subsequent microfiltration experiments (Section 2.5.3, Section
2.6.2 or Section 2.7.2) or routinely stored overnight at 4oC.
2.3.3 Fab’ release by thermo-chemical treatment
Using the freeze-thawed cells (Section 2.2.5), the periplasmic Fab’ fragments were
extracted from the cells by applying a combined heat and chemical treatment. This was
done by incubating the cells resuspended in 100 mM Tris / 10 mM EDTA solution,
adjusted to the desired pH (pH 7.0, 7.4 or 7.8) using concentrated HCl, and pre-heated
to the desired temperature as required. The resuspended biomass concentration varied
between 22-52 gDCW L-1. The cell suspensions were filled into a 24-well, round bottom,
polypropylene microplate (Whatman-GE, UK), sealed with aluminium film:
AlumaSealTM (Excel Scientific, USA) and incubated for up to 20 hours in a
thermomixer (Eppendorf ThermomixerComfort, Eppendorf AG, Germany) at 800 rpm
shaking speed. The treated cells were immediately used in subsequent microfiltration
experiments (Section 2.5.3).
2.3.4 Fab’ release by sonication
Using the freeze-thawed cells (Section 2.2.5), sonication was performed using an MSE
Soniprep 150 apparatus (Sanyo Electric, Osaka, Japan) operated at 3 cycles of 20 s on,
10 s off at 8 um amplitude, using 1 mL sample volumes. The sonicator was operated at
ambient temperature. Samples were then pooled to make-up at least 8mL of sonicated
cells. The pooled samples were immediately used in subsequent microfiltration
experiments (Section 2.5.3).
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2.3.5 Fab’ release by adaptive focused acoustics (AFA)
Fab’ fragments were quantified to monitor production during E. coli fermentation
(Section 2.2.2). For Fab’ quantification during this period, cells were disrupted by
adaptive focused acoustics (AFA) using the Covaris E210 (Woburn, MA). 1.5 mL of
fermentation broth samples in borosilicate glass tubes were placed on a sample rack
onto the Covaris’ degassed water bath which was maintained at 8oC. A duty cycle of
20%, acoustic radiation intensity of 85W and 500 cycles per burst were used. These
settings are known to achieve complete cell disruption comparable with high pressure
homogenisation (Perez-Pardo et al., 2011).
2.4 Microwell automation platform: Tecan Genesis™
A Tecan Genesis™ liquid handling platform (Tecan, Reading, UK) was the automation
platform used in this work. The lay-out of the platform deck is shown in Figure 2.1(A).
The key element is the vacuum separation manifold (Te-VacS™) shown in position on
the deck in Figure 2.1A(1) and in more detail in Figure 2.1(B). This is where the
automated microwell filtration processes were performed. There are two vacuum block
positions in this manifold which are connected to a high-performance vacuum pump via
separate extractor and vent lines. Platform operation is controlled and programmed
through the Tecan Gemini™ software. A sample Gemini™ program is shown in
Appendix 1.2. Actual differential pressures between the atmospheric pressure and the
pressure inside the vacuum block were measured by a digital manometer (Manometer
840080 series, SPER Scientific, Scottsdale, AZ) attached via a T-connector to one of
the vent lines. Differential pressures were continuously recorded at 60 Hz by a data
logging system (Handheld, SPER Scientific) on a PC.
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2.5 Microscale dead-end microfiltration
2.5.1 Microscale dead-end filtration device
The custom filter plate used in this study was described previously by Jackson et al.,
(2006). A picture of the filter plate is shown in Figure 2.1 (B) while Figure 2.2 shows
a schematic diagram of the set-up for microscale dead-end filtration experiments. The
plate dimensions are 128 x 86 x 31 mm and accommodate up to 24, 14 mm diameter
wells that can fit removable membrane inserts. Removable collection tubes were
obtained by modification of Durapore Ultrafree-CL centrifugal filters (Millipore, UK).
The membranes were either pre-fitted within the centrifugal filters or were cut to size
and manually fitted into the filter inserts.
2.5.2 Water flux experiments by dead-end filtration
The membrane resistances were determined by measuring the amount of water that
permeated through the membrane over a set filtration time. The permeate weights were
converted to volume by assuming a density of water of 1.0 g mL-1. The viscosity of
water at 23oC [ = 1.0 x10-3 N s m-2 (Perry and Green, 1997)] was used in all
calculations. The membranes were prepared before use by soaking in deionised water
for at least five minutes followed by passage of at least four millilitre of water through
the membrane under 65 kPa pressure gradient. Digital pressure measurement was
acquired as described in Section 2.4. Replicates were performed in all experiments.
2.5.3 Microfiltration of disrupted E. coli cells
Membranes were prepared as described in Section 2.5.2. The volume of feed used in
each well was between 400-500 L, the volumes remaining constant for each parameter
tested e.g. temperature, pH etc. Time and permeate mass data were gathered during
stepwise filtration at 65 kPa transmembrane pressure. Full details of the stepwise
method devised to quantify cake resistance are described in Chapter 3.
Figure 2.1
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2.6 Laboratory scale crossflow filtration
2.6.1 Laboratory scale CFF module
Primary recovery at laboratory scale was performed by crossflow filtration (CFF) using
a Millipore Proflux™ M12™ Tangential Filtration System with a Pellicon-2™ Mini
membrane module as shown in Figure 2.3 (0.22 m rated hydrophilic Durapore
poly(vinylidene fluoride) or PVDF, with 0.1 m2 membrane area, type V-screen). The
membrane module is held in a stainless steel Pellicon-2™ mini-holder which is
vertically orientated; therefore the feed entered via a bottom port and exited at the top in
the retentate port.
2.6.2 Laboratory scale CFF operation
Crossflow filtration experiments were performed at constant transmembrane pressure
(PTM) conditions where PTM is defined as:
P
RF
TM P
PP
P 


2
(2.1)
where PF is the feed pressure, PR is the retentate pressure and PP is the permeate
pressure. The permeate pressure can be neglected while the feed and retentate pressures
were measured by digital manometers and logged onto a data acquisition system as
described in Section 2.4.
Lab-scale filtration experiments were run in total recycle mode where the retentate and
permeate lines were recycled back to the feed reservoir. Permeate was periodically
collected from the top permeate port for flux measurements. The permeate flux was
determined by monitoring the time (t) needed to collect a certain volume of permeate
(Vt) and can be expressed in terms of LMH or litres per m2 of membrane area (Am) per
hour. The temperature of the permeate was measured so that the appropriate viscosity
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corrections (F) can be applied. These viscosity correction factors were taken from
Millipore Maintenance Procedures for Pellicon™ and Pellicon-2™ Cassette Filters.
Permeate flux (Jt) was then calculated at different filtration times using Equation (2.2).
tA
FV
J
m
t
t
Δ
Δ



(2.2)
Normalised flux versus time plots were generated to determine the steady state flux
where steady state is defined as the state at which subsequent flux decline is less than
five percent per hour.
2.7 Microscale crossflow filtration
2.7.1 Microscale CFF device design
As part of this project a microscale crossflow filtration device was fabricated at the
UCL Biochemical Engineering Workshop. Full details of the engineering design and
operational features are described later in Chapter 5. In summary, the device consists of
a filter plate with a microplate footprint (126 x 86 mm) and was designed so that its
operation could be easily integrated with the Tecan vacuum filtration manifold shown
in Figure 2.1 (B). Pictures of the prototype device are shown in Figure 2.4.
The filter plate is made out of a cast acrylic sheet (polymethylmethacrylate) and
consists of two parts: the top has the feed/retentate channels and the bottom portion has
the permeate channels. The two identical filtration channels have a U-shape form with
sharp edges and nominal length of 225 mm, channel height of 1.7 mm and channel
width of 4.6 mm.
Figure 2.3
diagram of the CFF process with permeate recycling; (B) Millipore ProFlux™ M12™
Tangential Filtration System showing: (1) Pellicon
Pellicon
timer; (5) control panel; (6) feed flow pressure tap; (7) feed line to membrane; (8) L/S
Easy-Load
(11) feed/retentate reservoir.
Laboratory module used in larger scale CFF experiments: (A) Schematic
TM stainless steel holder; (2) retentate flow pressure tap; (3) retentate valve; (4)
® II pump; (9) retentate line to reservoir; (10) permeate line to reservoir; and
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The available membrane area given this configuration is 100-fold smaller than the
larger scale Pellicon-2™ module at 0.001m2. The bottom plate has o-rings made out of
a nitrile o-ring cord with an outside diameter of 1.6 mm (RS Components LTd.,
Northants, UK), located around the permeate channels to ensure no leakage. The flow
in the permeate channel is directed towards an outlet tubing into a permeate reservoir
within the vacuum manifold. The test membrane was a 0.22 m PVDF membrane, cut
to shape and sandwiched between the top and bottom plates by a set of screws.
2.7.2 Microscale CFF operation
Microscale CFF experiments were automated by setting and controlling the filtration
time and vacuum pressure on the permeate side via the Tecan Gemini™ software. The
feeds were pumped to the respective channels by a multi-channel Bredel™ pump with
two snap-fit 313X extension pump heads (Watson & Marlow, Cornwall, UK). The
retentate line was directed back to the reservoirs. The feed and vacuum permeate
pressures were measured using the same digital manometers and data acquisition
software as described in Section 2.4. For a given filtration condition (at a specific
transmembrane pressure and crossflow rate) filtration runs were performed at different
times (30 minutes maximum). After each filtration run, the permeate receiver of each
channel was weighed and the temperature noted. The permeate was returned back to the
feed reservoirs then the filtration process was repeated for a longer filtration time. The
determination of steady state flux by the microscale CFF method is described in detail
in Chapter 5.
Figure 2.4
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2.8 Quantification of filtration performance
2.8.1 Membrane resistance
Equation 2.3 was used to calculate Rm where PTM is the pressure gradient across the
membrane and P is the viscosity of the permeate at the measured temperature. This
equation is derived from Equations 1.4 and 1.5 which is based on flux modelling for
flow through resistances (Cheryan, 1998). Equation 2.3 is used with water flux
experiments, described in Section 2.5.1, wherein the resistance to water flux is
attributed to the membrane only.
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2.8.2 Normalised water permeability
The normalised membrane permeability (NWP) was related to Rm by Equation 2.4. A
correction factor is applied based on the viscosity of water at certain temperature. In
this case, the reference viscosity was taken at 25 oC (25C).
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(2.4)
2.8.3 Membrane solids rejection
The membrane solids rejection coefficient is defined as:
sR
sP
s C
C
,
,1
(2.5)
where CP,s and CR,s are solids content in the permeate and retentate streams,
respectively, calculated from the optical density readings at 600 nm (Section 2.9.2).
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2.8.4 Transmission
Percentage transmission is defined as:
100% 
i,R
i,P
C
C
T
(2.6)
where subscript i is either Fab’or total soluble protein and CP and CR are concentrations
in the permeate and retentate streams, respectively determined as described in Section
2.9.3 (for total protein quantification) or Section 2.9.4 (for Fab’ quantification).
2.8.5 Apparent transmission
Percentage transmission is defined as:
100% 
i,F
i,P
C
C
T
(2.7)
where subscript i is either Fab’or total soluble protein and CP and CF are
concentrations in the permeate and feed streams, respectively determined as described
in Section 2.9.3 (for total protein quantification) or Section 2.9.4 (for Fab’
quantification).
2.9 Analytical methods
2.9.1 Quantification of biomass concentration (Dry cell weight)
Biomass dry cell weight was determined by centrifuging 1 mL fermentation broth
samples in pre-weighed Eppendorf tubes at 13,000 rpm for 30 minutes. The supernatant
was discarded and the weight of the wet cells measured before the cell paste was dried
in an oven at 100 oC for ~72 hours until a constant weight was reached. This was then
used to determine the dry cell weight (DCW) of each sample. A total of eight
measurements were made. The coefficient of variation (CV), which is the ratio of
standard deviation to mean, was calculated to be 4 %. Appendix 1.3 provides a
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calibration curve of dry cell weights versus wet weight of E. coli cells produced as
described in Section 2.2.2 and Section 2.2.3.
2.9.2 Quantification of biomass concentration (Optical density)
Fermentation broth samples (Section 2.2.2) or the cell paste (Section 2.2.3) were diluted
in deionised water so that the optical density measured by the spectrophotometer
(Amersham Biosciences/GE Healthcare, UK) was between less than 1.0 OD units. The
optical densities of the samples were measured at a wavelength of 600 nm with a UV-
Vis spectrometer. The OD was measured in triplicate and maximum CV of 3 %.
Appendix 1.3 shows a calibration curve of the optical density versus dry cell weight for
E. coli cells.
2.9.3 Quantification of total protein concentration
One millilitre samples of the disrupted cells in Eppendorf tubes were centrifuged
(Centrifuge 5800, Eppendorf, Germany) at 13000 rpm for 30 minutes. The total protein
content was determined using the Bradford colorimetric assay according to the method
by Sigma-Aldrich (technical notes) using their Bradford reagent and calibrated using
bovine serum albumin (BSA) protein standard (Sigma-Aldrich, USA). Assays were
performed in triplicate and the maximum CV was 3 %. A typical protein calibration
curve is shown in Appendix 1.4.
2.9.4 Quantification of antibody Fab’ fragment concentration
Fab’ concentrations in the supernatant of disrupted cell suspensions and permeates from
microfiltration experiments were determined by affinity chromatography using a
HiTrap Protein G HP 1 mL column (GE Healthcare, UK) on an Agilent liquid
chromatography system (Agilent, USA). Binding and elution buffers (20 mM sodium
phosphate) were at pH 7.4 and pH 2.5, respectively, and run through the column at a
flowrate of 2 ml min-1. The wavelength used for sample detection was 220nm. The
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samples were passed through 0.22 m syringe filters prior to analysis. Appendix 1.5
and Appendix 1.6 show typical chromatograms and calibration curve, respectively.
2.9.5 SDS PAGE analysis of proteins
Disrupted broth samples, prepared as described in Sections 2.3.1, 2.3.3, and 2.3.4, were
centrifuged at 13000 rpm for 30 minutes. The pellets were then discarded and the
supernatants used as samples for electrophoresis. SDS PAGE was performed using the
Mini-Protean II System (Bio-Rad Laboratories, Inc., Helmel Hempstaed, UK) with gels
prepared from Protogel resolving and stacking buffers (National Diagnostics, USA).
The preparation of 8% monomer gels and 4% stacking gel were made according to the
manufacturer’s specification (Protogel protocol, Methods for SDS-PAGE). Gel image
was captured by GelDoc-ItTM imaging system using an Ultraviolet Transilluminator,
BioImaging System (UVP Upland, USA).
2.9.6 DNA sample purification
An equal volume of isopropanol was added to clarified samples to precipitate the DNA.
The mixtures were immediately centrifuged at 13 000 rpm for 10 minutes. The
supernatant was discarded and the pellet washed with 70% ethanol before
centrifugation for another 5 minutes. The washed pellet was then dissolved in buffer
containing 10 mM Tris-HCL/ 1 mM EDTA at pH 8. One microlitre of Ribonuclease A
RNase (Qiagen) was added to each sample to degrade unnecessary RNA and the
mixtures were left for 1 hour at 37oC. Material from this preparation step are
subsequently called “DNA samples” in this thesis and used for both gel analysis
(Section 2.9.7) and nucleic acid quantification (Section 2.9.8).
2.9.7 DNA gel analysis
15 L of ethidium bromide (500 µg ml-1) was added to a 1% (v/v) agarose gel. Once the
gel had set, DNA samples were loaded on each well. A 1 kb DNA ladder (Gene
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RulerTM, Fermentas) was used as marker to determine the size of the DNA samples.
Electrophoresis was run for 1 hour at 100 volts with 1xTris Borate EDTA
electrophoresis buffer (9mM Tris, 9mM boric acid, 1mM EDTA). Images of the gel
were taken using a UV gel camera (BioRad Geldoc 2000, BioRad).
2.9.8 Nucleic acid quantification
A nanodrop UV spectrophotometer ND-1000 (Nanodrop, DE, USA) was used to
determine the concentration and purity of all DNA samples. The absorbance of each
sample was measured at 260 nm and 280 nm. The concentration of DNA (in g mL-1)
was estimated by multiplying the absorbance at 260 nm by a factor of 50 (Sambrook &
Russel, 2001). In all cases, the ratio of absorbance at 260 nm and 280 nm was 1.81 ±
0.19, indicating that samples were sufficiently pure to apply this calibration factor.
2.10 Physical methods
2.10.1 Particle size measurement by laser diffraction
Particle size measurement was performed by laser diffraction using a Mastersizer 2000
(Malvern Instruments Ltd., Malvern, UK) with a small volume sample dispersion unit
at a detection range of 0.01 – 2000 m. Samples were added dropwise until the
‘obscurance’ was within the acceptable range of 10-15%. The output is size
distribution in terms of particle volume percentage. d10 and d90 values were those given
by the instrument. The d10 (d90) is a value of particle size indicating that 10% (90%) of
the total volume of analysed particles has a diameter equal to or less than this reference
value. For d10 or d90 determination, measurements were made in triplicates and the
maximum coefficient of variance is 5%.
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2.10.2 Viscosity measurement
A Brookfield Cone and Plate DV-II programmable viscometer (Brookfield, Stoughton,
MA, USA) was used to quantify the rheological behaviour and viscosity of E. coli
fermentation broths. Before the sample was loaded, the instrument was set to auto-
zero; 500 L of sample was then loaded on the sample chamber. The re-circulating
water bath set at 20oC. The shear rate and shear stress at for at least eight different
speeds were read and manually recorded for each sample. A typical shear rate – shear
stress curve is shown in Appendix 1.7. To assess reproducibility, the viscosity
measurements of three selected samples were repeated. The maximum coefficient of
variation for a measured shear stress is 26% while the maximum coefficient of variation
for the calculated absolute viscosity is 12%.
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3. Creation of an Improved Microscale
Dead-end Filtration Methodology‡
3.1 Introduction and aims
The benefits of the microscale bioprocessing approach in speeding development of
robust and scaleable processes were described in Section 1.1. To further enable
microscale bioprocessing studies the need for creation of new microscale unit
operations was highlighted. Special attention is given here to membrane processes.
These are widely used in biopharmaceutical product development, yet an area less
studied at microscale, but, which could benefit from this approach. Available scale-
down membrane devices were summarised in Table 1.4. A common feature of these
devices is multiple or parallel analysis of processes and the consumption of small
quantities of feed material. Among the available platforms, Jackson et al. (2006) were
able to show quantitative parallel analysis of dead-end filtration processes using small
volumes of feed (< 2 mL) within an automated environment. By incorporating the
device within an existing laboratory robotic platform, rapid evaluation of process
studies was facilitated. This initial UCL work has demonstrated that data from the
microscale device is comparable with data obtained from a larger scale dead-end
filtration rig.
____________________________
‡ The methodology presented in this chapter has previously been published as: Rayat ACME, Micheletti M, Lye GJ.
(2010). Evaluation of cell disruption effects on primary recovery of antibody fragments using microscale bioprocessing
techniques. Biotechnology Progress 26:1312-1321.
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This chapter will present work done based on the microscale dead-end filtration device
developed by Jackson et al. (2006). The aim is to establish an improved microscale
dead-end microfiltration method which requires an even more reduced feed volumes
and simplified to be more compatible for automated operation, and to demonstrate that
this method could capture differences in feeds preparation and operation conditions.
Figure 3.1 illustrates the context of the experimental studies performed in this chapter
to achieve the aims, as set above, and the contribution of the chapter in the overall
framework and aim of this thesis in the application of microscale bioprocessing
platform for membrane filtration. The specific objectives of this chapter are:
 to demonstrate adequate vacuum pressure control within the Tecan vacuum
separation manifold (Te-VacS™) over different periods and set differential
pressure during vacuum filtration;
 to establish and demonstrate reproducible quantification of automated,
microscale dead-end microfiltration data; and
 to establish the suitability of the automated microscale dead-end filtration
method in determining microfiltration performance, particularly the specific
cake resistance ().
3.2 Experimental approach
Microscale dead-end microfiltration experiments were performed on the deck of a
Tecan Genesis200™ laboratory workstation using the custom filter plate described in
Section 2.5.1. Water flux experiments outlined in Section 2.5.2 were performed to
determine membrane resistances (Rm); to ascertain the reproducibility of the filtration
process using the Te-VacS™ and to assess well-to-well variability. Durapore
poly(vinylidene fluoride) PVDF membranes (Millipore) with 0.1, 0.22 and 0.45 m
rating were used throughout this chapter.
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Dead-end microfiltration of thermo-chemically treated E. coli cells was initially
performed to develop automated experimental procedures allowing further reduction in
the volumes of feed used. The E. coli cell paste material was previously stored at -20oC
and allowed to thaw as described in Section 2.2.5. The cells were then prepared for
microfiltration studies as described in Sections 2.3.2 to 2.3.4. The microscale dead-
microfiltration method is described in Section 2.5.3 and in more detail in Section 3.3.3.
Statistical analysis was performed using Microsoft Office Excel™ Analysis Toolpak™
(ANOVA: single factor).
3.3 Results and discussion
3.3.1 Quantification of clean membrane resistance
To demonstrate reproducible quantification during microscale filtration experiments,
initial studies focused on evaluation of Rm for PVDF membranes with different pore
sizes. Constant pressure filtration was performed with the feed side exposed to
atmospheric pressure and the membrane side to vacuum pressure set within the Tecan
Gemini™ software. Since this pressure is automatically measured and logged every
second, pressure profiles were generated for each filtration run. Representative pressure
profiles during short (30 s) and long (> 15 min) period of pump operation at low (20
kPa) and high (70 kPa) differential pressures are shown in Figures 3.2, 3.3, and 3.4.
These figures demonstrate how quickly the set pressure was achieved once the vacuum
pump starts and the stability of the measured pressure at the set value. Integration of
these profiles over process time corresponds to the PTM of the respective filtration
runs.
Figure 3.2
kPa for a period of 1600s using the Tecan vacuum manifold.
reading for the initial 120s. Experiments were performed as described in Section 2.5.2
using the automation platform and the microscale dead
in Section 2.4 and Section 2.5.1, respectively.
Typical pressure profile obtained by setting the pressure difference at 20
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Bottom graph shows the
-end filtration device described
Figure
kPa for a period of (A) 30s and (B) 60s using the Tecan vacuum manifold. Experiments
were performed as described in Section 2.5.2 using the automation platform and the
microscal
respectively.
3.3 Typical pressure profile obtained by setting the pressure difference at 35
e dead-end filtration device described in Section 2.4 and Section 2.5.1,
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Figure 3.4
maximum (70 kPa) for a period
graph shows the reading for the initial 120s. Experiments were performed as described
in Section 2.5.2 using the automation platform and the microscale dead
device described in Section 2.4 and
Typical pressure profile obtained by setting the pressure difference at
~
of 2000s using the Tecan vacuum manifold. Bottom
Section 2.5.1, respectively.
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As indicated in the experimental set-up (Figure 2.1), there are two blocks on the Tecan
vacuum manifold which are separately connected to the vacuum pump, hence, could be
used for alternate filtration runs during automated experiments. To show that the
applied pressure in each block is uniform, separate water flux experiments were
performed and the Rm values of membranes of the same batch of material were
compared. Figure 3.5 demonstrates that the calculated membrane resistances do not
vary between vacuum blocks and are statistically not different (F-test, p > 0.05). This is
particularly useful as it eliminates the effect of plate position when evaluating or
comparing data gathered from the two different blocks.
The variation of Rm values for the same piece of membrane measured in two different
wells within the same plate was also determined. The plate orientations in Figure 3.6
illustrate the positions of the membrane inserts during a single filtration operation.
Figure 3.6 shows that plan B is just the result of the re-arrangement of plan A by
rotating the plate 180o. Rm values of a single plate filtration experiment are shown in
Figure 3.7 and indicate that there is a variation of Rm between the membrane materials
in each well. However, the Rm values of the same membrane material remains
reasonably constant, and are statistically not different (F-test, p > 0.05), even when the
membrane insert was placed in a different position on the filter plate.
Table 3.1 summarises the calculated membrane resistances determined in this work.
The coefficient of variation between different wells was found to be 6, 3, and 8% for
0.1, 0.22, and 0.45 m membranes, respectively, and was independent of position on
the plate.
Figure 3.5
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same well position of the membranes on the filter plate was maintained. Error bars,
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flux experiments were
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Section 2.4 and Section 2.5.1, respectively.
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~ 101 ~
-end filtration device described in
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Figure 3.6
single plate indicating position relative to vacuum source. The number within the wells
indicates a unique membrane insert. For example, membrane 1 in Plan A is in position
W5, while in Plan B this same membrane is in W4. Exp
described in Section 2.5.2 using the automation platform and the microscale dead
filtration device described in Section 2.4 and Section 2.5.1, respectively.
Details of the two plate orientations used
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Table 3.1 Calculated membrane resistances from microscale water flux measurements.
All experiments performed as described in Section 2.5.2 using PVDF membranes with
an effective filtration area of 0.8 cm2. Values indicated were calculated according to
Equations 2.3 and represent one standard deviation about the mean (n=8).
Source
Membrane
pore size
(m)
Sample
volume
(mL)
ࢂ࢙
࡭࢓
ratio
(mL cm-2)
Membrane resistance
Rm (x 1010 m-1)
This work
0.1
2.20 2.78
12.0 ± 0.9
0.22 4.8 ± 0.2
0.45 1.2 ± 0.1
Jackson et al.
(2006) 0.22 0.83 1.05 5.2 ± 0.2
The results obtained by Jackson et al. (2006) for a 0.22 m PVDF membrane are also
listed in Table 3.1 and a difference in Rm values of just 8% is noted. This level of
variation is acceptable and could be due to variation in the batches of membranes used.
These results, therefore, agree with those obtained by Jackson et al. (2006). Note that
in this earlier work, the comparability of the microscale Rm values with data from a
larger scale laboratory system, having a membrane area of 3.8 cm2, has been
demonstrated and so this scale comparison is not repeated here. Chandler and Zydney
(2004) have also calculated the membrane resistance of 0.45 m PVDF membrane,
having membrane areas between 0.2 950 cm2, to be between 0.8 2.4 x 1010 m-1
which is, on average, the same as the Rm value given in Table 1.3 for this type of PVDF
membrane.
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3.3.2 Observations on calculated clean membrane resistances
It can be seen from Table 3.1 that the average Rm calculated for the 0.1 m membrane
is more than twice the corresponding value obtained with the 0.22 m membrane and
ten times larger than the Rm value obtained with the 0.45 m membrane. According to
the manufacturer’s specifications, these membranes should all have the same porosity
(~70%) and membrane thickness, hence, can be expected to have similar Rm values. If
this is the case, then for the membranes that have been studied here, which all have
similar effective area and membrane thickness, it can be expected that membrane
resistances should be the same. However, membrane manufacturing characteristics may
vary from batch to batch and as does the porosity and morphology of membranes of
different pore sizes.
From the Kozeny – Carman equation (Equation 1.11), a small difference in porosity
may have a significant effect on the calculated membrane resistance. Furthermore,
membranes with different morphology and pore sizes may have different pore internal
surface area per unit volume, resulting in the membranes with smaller pore sizes having
greater resistance to the flow. In the latter case, the corresponding water flux would be
slower resulting in higher values of Rm. This observation is confirmed by the results
obtained in this study where the membrane resistance increases with decreasing pore
size. As a result of this evaluation, the PVDF membrane with the largest nominal size
(0.45 m) was used in all subsequent work in this chapter.
3.3.3 Improved cake resistance quantification: (1) single plate method
The classical method for determining specific cake resistance () values as described in
Section 1.4.2.2. This method is also called the dynamic method, as opposed to the
steady-state method, wherein filtration data is acquired during actual cake filtration
conditions (McGuire et al., 2009). This method was first adapted to an automated
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workstation by Jackson et al. (2006). Since the collected permeate is inside the Tecan
vacuum block, continuous collection of permeate volume and time data is not possible.
In the previous work of Jackson et al. (2006), cake resistance quantification was
therefore based on two identical filtration plates being operated in parallel where the
collected permeate volume was measured at different time points for each plate. If the
filtration process is performed after sufficient initial time, two sets of ௧௏
஺ൗ
and ௏
஺
data
would be sufficient to determine  according to Equation 3.1 (derived from Equation
1.12). In order to estimate the specific cake resistance from the data collected using a
high throughput methodology, Jackson et al. (2006) suggested to approximate 0 with
the dry solids concentration (c) in the feed.
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Here, this earlier technique is improved to enable quantification of cake resistance from
a single plate thus allowing the experimental throughput to be doubled and the volume
of feed required halved. In the new method, time and permeate mass data were gathered
during stepwise vacuum filtration, a schematic representation of which is shown in
Figure 3.8. After a filtration time t1, the filtration process was stopped and the plate
containing the permeate collection tubes was removed from the vacuum manifold
assembly and replaced with a new plate containing empty collection tubes. The
filtration process of the original feed was then resumed at constant applied pressure for
an extended time t*. The volumes were determined from the permeate weights: V1 (t1)
and V* (t*). The two filtration times are indicated by t1 and t2 where:
*
12 ttt  (3.2)
Figure 3.8
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The cumulative volume of permeate V2 can be obtained from Equation 3.3. Thus, from
the same filter plate, two cumulative volumes of permeate at two different filtration
times were collected. The resulting data points were then used in Equation 3.1 to
calculate values.
*
12 VVV  (3.3)
This method assumes that the cake, initially formed during the first filtration step, was
not significantly altered when the pressure was released. In order to validate this
assumption and the improved step-wise procedure, the permeate flux for one 800s long
filtration run was compared with the flux obtained from the cumulative volumes of
filtrate when the filtration process was terminated at t1= 300s and then resumed for an
additional t*=500s. Figure 3.9 shows the typical permeate flux variation with process
time using a feed of thermo-chemically extracted E. coli cells. The difference between
the two fluxes obtained using the previously described method was found to be 9%.
This resulted in a difference of 13% between the calculated specific cake resistances.
Statistically, this variation is not significant (p> 0.05) which confirms the utility of the
new method.
Calculated values for two different process feedstocks are shown in Figure 3.10.
Both feedstocks were prepared by thermo-chemical extraction of E. coli cells. This
figure compares the values determined by the two-plate method described by Jackson
et al. (2006) and the single plate, two-step method described here. The variations of
values using these two methods for both process feeds in Figure 3.10 are statistically
not significant (p>0.05). Therefore, the single plate method developed here can reliably
be used in subsequent microscale dead-end microfiltration experiments for specific
cake resistance determination.
Figure 3.9
thermo
the two
according to Section 2.3.3 at 50
Filtration experiments performe
0.45 
(n=4).
Quantification of permeate flux versus time for dead
-chemically extracted
-step filtration method (300s + 500s) shown in Figure 3.8. Extraction performed
m PVDF membrane. Error bars represent one standard deviation about the mean
E. coli
~
cells. The filled circle data point was acquired by
oC for 16 h, pH 7.4 with 32 g
d according to Section 3.3.3 at
109 ~
-end microfiltration of
DCW

L-1 solids loading.
PTMP= 65 kPa using
Figure 3.10
chemically extracted
(2006) (
feed 1 has solids loading of 32 g
buffer at pH 7.4 at 50
extracted with 100 mM Tris/ 10 mM EDTA buffer at pH 7.0 at 50
dead-end filtration was performed at
as described in Section 3.3.3.
bars represent one standard deviation about the mean (n=4).
Comparison of calculated specific cake resistances (
) and the improved single
E. coli cells by the two
oC for 16 h. Process feed 2 has a solids loading of 27 g

~
-plate method developed in this work (
DCW L-1, extracted with 100 mM Tris/ 10 mM EDTA
PTMP
values were calculated according to Equation 3.1. Error
110 ~
- plate method employed by Jackson et al.
= 65 kPa, using 0.45
o

) of thermo
). Process
C for 2 h. Microscale
m PVDF membranes
-
DCW L-1,
~ 111 ~
3.3.4 Application of the single plate microscale filtration method
The previous section demonstrated a new automated microscale dead-end filtration
method for quantitative evaluation of the microfiltration performance of cell
suspensions such as E. coli cells. This section shows how this new method is able to
capture differences in microfiltration performance, as indicated by values, for
different feed stream preparations. Experiments were performed as in Section 3.3.3 and
used thermo-chemically treated E. coli cells with Tris-EDTA, for a range of pH values,
as extraction buffer. It is expected that the different conditions of Tris-EDTA plus heat
treatment will result in suspensions with different soluble components (Weir and
Bailey, 1997). Therefore, the specific cake resistance is also expected to change
depending on the characteristics of the cell suspension.
The results of these experiments are summarised in Table 3.2. Experiments
investigating the effect of extraction time from 2 h to 16 h (Expt. 1) showed that these
two feeds give  values that are statistically different (F-test, p<0.05). Another
filtration experiment (Expt. 2) was performed where three feeds were prepared under
the same extraction conditions except for the pH (either pH 7.0, 7.4 or 7.8). Results
again indicate that slight differences in extraction pH lead to significant difference (F-
test, p<0.05) in filtration performance as indicated by the specific cake resistances.
These results clearly illustrate that the  values of thermo-chemically treated E. coli
cells are affected by the way the Fab’ extraction process is performed. Although the
results can not be directly explained at present, these show the capability of the
microscale dead-end device and the associated methodology in depicting the
microfiltration performance of various feeds.
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Table 3.2 Application of the single plate, two-step microscale filtration method.
Filtration experiments were performed as described in Section 3.3.3 at PTMP= 65 kPa,
using 0.45 m PVDF membranes. Values indicated were calculated according to
Equations 3.1 and represent one standard deviation about the mean (2 < n < 4).
Expt.
Solids
loading
(gDCW L-1)
Extraction conditions 
(x 1012 m kg-1)
Variation
between
values
oC pH h
(1) 27 60 7.4
2 4796 ± 2625 Statisticallydifferent
( p < 0.05)
16 1498 ± 146
(2) 32 55
7.0
20
503 ± 90 Statistically
different
( p < 0.05)7.4 396 ± 43
7.8 964 ± 182
3.3.5 Improved cake resistance quantification: (2) steady-state method
In the preceding section, the dynamic method of measuring the average specific cake
resistance was described and an improved method for quantification of  values shown.
This section will discuss a second method that has been used to further simplify and
expedite the experimental procedure.
Some research groups, as initially reported by Nakanishi et al. (1987) and followed by
several others like Chandler and Zydney (2004), Meireles et al. (2004) and Foley
(2006b), have used what they call the ‘steady state’ method to determine  values. In
this approach, a suspension of known solids concentration is allowed to form a cake
layer over a membrane. When all the solids are deposited onto the cake, a buffer or a
saline solution is passed through the pre-formed cake. The filtrate flux is then recorded
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until such time that it reaches a constant value (hence the term ‘steady state’). To
explore values at various PTM , different experimental approaches were performed
by these authors. For example, Foley (2006b) suggested stepping up the pressure after
steady state is achieved at each lower pressure. Filtration continues at the higher
pressure until steady state is again reached at which point, the filtrate is returned to the
filtration cell, the pressure is further increased, and the cycle continues until the highest
operating pressure studied. Chandler and Zydney (2004) on the other hand, used freshly
formed cake for each pressure measurement.
The specific cake resistance is then determined by Equation 3.4 with Rm being the clean
membrane resistance. This equation is derived by integrating Equation 1.12 at steady
state conditions.
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Recently, this method was criticised since it was argued that it does not accurately
describe cake formation during filtration but rather a compression process by flow of
liquid through a cake (Tien and Ramarao, 2008), i.e. it describes cake consolidation
instead of cake filtration. Key differences lie in the different compressive stresses
experienced by the cakes during filtration and consolidation processes. The cake
formed in situ during filtration is subjected to a range of compressive stress from zero at
the cake-suspension interface to the applied total pressure at the cake-membrane
interface (Tien and Ramarao, 2008). During cake compression on the other hand, the
compressive stress at the cake-suspension interface is greater than zero and should
therefore be known. The process of determining this, however, is reported to be
complex. To support this argument, McGuire et al. (2009) more recently performed
microfiltration experiments with Baker’s yeast using both the dynamic and steady state
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methods to determine values. They found that the steady state methods produce larger
values than the dynamic method, by between 30-120%, and concluded that the steady
state method should not be used in determining values. The over-estimation of the
values increases proportionally with PTM.
In this context, the application of the automated microscale methodology described in
Section 3.3.3 becomes more appropriate for microfiltration studies if the purpose is
rapid experimental determination of  values. The microscale dead-end filtration device
and the methodology that was designed allows ease of experimentation even with
multiple feeds and with small volumes. If it is necessary to determine the dependence of
specific cake resistance with pressure, actual microfiltration experiments should be
performed at the desired pressure range and measure  by Equation 3.1. Indeed, when
the steady state method was attempted to be used with the microscale device in filtering
heat-treated E. coli suspensions, it was found that it was not possible to obtain a pre-
formed cake for a reasonable duration of filtration since the liquid (from a total feed
volume of 300 L) does not fully permeate through the cake even at the highest setting
of pressure difference (70 kPa).
It might even be possible to simplify the microscale process further by performing
single step, single plate filtration. According to Tien and Ramarao (2008), as long as
sufficiently long filtration time has elapsed, or  values are large, Rm can be ignored in
Equation 1.13. Calculation of  values could then be simply achieved by a set of t and
V data from a single step, single plate filtration experiment. To test this proposition, this
method was performed, using thermo-chemically extracted E. coli cells, and the
resulting  values compared with the two-step, single plate method described in Section
3.3.3. Results are shown in Figure 3.11. Statistical analysis shows that these two
methods give  values that are not significantly different (F-test, p > 0.05). This method
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thus further reduces the amount of feed required for microfiltration experiments and
simplifies the experimental procedure, making it even easier for automated
methodology to be applied.
3.3.6 Observations on actual Rm and  values of biological feeds
During cake filtration, the actual membrane resistance may not be the same as the clean
membrane resistance. Tien and Ramarao (2008) explain that Rm will increase due to the
presence of the cake layer over the membrane. The membrane resistance increases
during filtration and will increase with increasing applied pressure (Teoh et al., 2006).
The correlation between the membrane resistance and applied pressure is even more
pronounced if surface adsorption is the main mechanism of clogging (Teoh et al.,
2006). According to Equation 1.12, the actual membrane resistance can be determined
in this case from the y-intercept of the plot of ௧௏
஺ൗ
against ௏
஺
.
An inspection of these plots in the published literature (e.g. Okamoto et al., 2001;
Hodgson et al., 1993) shows that some biological samples used in dead-end
microfiltration studies show plots that have very steep slopes resulting in negative
values of the y-intercept. In this case, Equation 1.12 could not be used to determine
actual values of Rm. This behaviour was also seen with the E. coli samples used here
where plots of ௧௏
஺ൗ
against ௏
஺
of the process feeds show negative y-intercept values.
This seems to be a phenomenon common to biofiltration (i.e. filtration of biological
materials: cells, cell debris components etc. in broth, buffer or saline).
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Membrane filtration of non-biological particles like polystyrene latex, talc, CaCO3,
kaolin etc., show  values less than 1 x 1012 m kg-1 (Grace, 1953b; Tiller, 1953;
McCarthy et al., 1999). On the other hand, biofiltration experiments have resulted in 
values that are usually greater than 1 x 1012 m kg-1. Some have really high  values of
the order > 1014 m kg-1 like E. coli and C. Glutamicum (Jackson et al., 2006; Okamoto et
al., 2001; Ohmori and Glatz, 1999). The most common cell material used in dead-end
microfiltration studies is yeast for which reported  values are of the order of 1 x 1011 m
kg-1 (Nakanishi et al., 1987; McCarthy et al., 1998; Chandler and Zydney, 2004). Thus
when investigating microfiltration behaviour with yeast, the plots of ௧௏
஺ൗ
against ௏
஺
are
not very steep and will show positive y-intercept values as expected.
The negative y-intercept values obtained from the studies using other microorganisms
aside from yeast could indicate that actual membrane resistances is a function of time or
permeate volume depending on the fouling mechanism. Although the actual Rm values
may not be calculated without knowing the exact correlation of ௠ or ௠
that can be substituted in the Rm in Equation 1.11, plots of
௧
௏
஺ൗ
against ௏
஺
still
provide valuable insights on the microfiltration behaviour of biological feeds by
providing reasonable estimates of  values as well as an indication of the fouling effect
of the feed suspension on the membrane through the sign of the y-intercept.
3.4 Conclusions
The aim of this chapter was to describe the development of a microscale dead-end
microfiltration method (Section 3.3.3) which is compatible for operation within an
automated workstation, requires small volumes of feed and enables parallel
experimentation. The quantitative reproducibility of the microscale experiments on the
Te-VacS™ was demonstrated (Section 3.3.1). The reasonable sensitivity of the
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microscale dead-end filtration device and associated methodology in capturing the
different microfiltration performance of various feeds was also established (Section
3.3.4). It was also shown that the developed method suitably reflects the theoretical
considerations in evaluating  values (Section 3.3.5). Finally, by analysis of the largely
different microfiltration performance between non-biological and biological feeds, and
the difference between yeast (as a common model process feed) and other
microbiological systems (Section 3.3.6) as feeds in microfiltration studies, the case for
the microscale bioprocessing approach for microfiltration is even more emphasized.
Because of the very small feed requirement (~500 L) for microscale dead-end
microfiltration, it is now possible to study feed-specific microfiltration performance
instead of relying on model yeast feeds which may not necessarily represent the
microfiltration behaviour of these industrially relevant feedstocks. This type of
investigation is illustrated in Chapter 4 in the evaluation of the impact of the type of
unit operations and conditions of Fab’ extraction on Fab’ fragments recovery by
microfiltration.
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4. Evaluation of Microscale Filtration
Methodology for Primary Recovery
of Antibody Fragments‡
4.1 Introduction and aims
In the previous chapter, a single-plate filtration method to investigate microfiltration
performance, particularly the quantification of specific cake resistance (), was
established. This chapter, as illustrated in Figure 4.1, demonstrates the application of
this method (Section 3.3.3) and the microscale dead-end fitration device (Figure 2.2)
to study the interaction between intracellular product release and subsequent recovery
by dead-end microfiltration. The product of interest is an antibody Fab’ fragment
produced in E. coli. Recombinant proteins overexpressed in E. coli are often produced
in the form of inclusion bodies especially proteins containing complex disulfide bonds
or mammalian proteins requiring post-translational modification for activity (Choi and
Lee, 2004). This is due to its cytoplasm having a reducing environment that does not
permit disulfide bonds formation resulting in the aggregation of certain disulfide bond-
rich proteins such as antibody fragments. To overcome this situation, complex proteins
can be engineered to be secreted in the periplasm where correct formation of disulfide
bonds can be facilitated (Baneyx and Mujacic, 2004).
____________________________
‡ The majority of the methodologies and results presented in this chapter have previously been published as: Rayat
ACME, Micheletti M, Lye GJ. (2010). Evaluation of cell disruption effects on primary recovery of antibody fragments
using microscale bioprocessing techniques. Biotechnology Progress 26:1312-1321.
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Process recovery for intracellular products such as Fab’ involves additional unit
operations to release the products from the cells before recovery by solid-liquid
separation can be performed. The extraction of intracellular products requires cell
disruption wherein the cellular structure is broken apart and product is released
(Middelberg, 1995). For antibody fragments, industrial-scale product extraction
involves disruption of host cells by chemical lysis or by mechanical disruption
techniques (Spitali, 2009).
Following cell rupture, solid-liquid separation is required and is usually performed
using centrifugation or microfiltration. The choice of cell disruption method is usually
based on the optimisation of the amount of product recovered from the cell while less
attention is paid to the characterisation of the process stream properties. However, such
properties have been shown to have a strong impact on the subsequent unit operations
(Siddiqi et al., 1995; van Hee et al., 2004; Clarkson et al., 1993). Cell disruption
methods are known to substantially affect subsequent recovery operations due to
variations in contaminant concentrations, differences in particle size distribution and
surface properties (Quirk and Woodrow, 1984; van Hee et al., 2006). Furthermore, the
effect of pH, ionic strength and preconditioning of the feed before filtration processes
have also been reported to influence performance (Ohmori and Glatz, 1999; Okamoto et
al., 2001).
The aim the chapter is to show how the methodology developed in Chapter 3 can be
employed to assess process interactions affecting primary product recovery using
membrane filtration. Specifically, the objectives of this chapter are:
 to demonstrate the application of the microscale dead-end filtration device
(Section 2.5.1) to investigate two consecutive bioprocess steps: antibody Fab’
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fragment extraction from E. coli cells and their subsequent recovery by
microfiltration;
 to study the impact of the choice of cell disruption operation on the
microfiltration performance of disrupted E. coli suspensions;
 to demonstrate a two-step microscale process sequence: thermo-chemical
extraction and dead-end microfiltration; and
 to study the impact of extraction and filtration conditions on optimisation of
the linked unit operations.
4.2 Experimental Approach
Cell paste previously prepared according to Section 2.2.2 – 2.2.3 and stored at -20oC
was first thawed at room temperature. The periplasmic Fab’ fragments were then
extracted either by high pressure homogenisation, thermo-chemical extraction or
sonication. These are described in Sections 2.3.2, 2.3.3 and 2.3.4, respectively.
Microscale dead-end microfiltration experiments were performed, according to Section
2.5.3, on the deck of Tecan Genesis200™ using the custom filter plate described
previously in Section 2.5.1. All experiments were replicated (n > 2). Membrane
materials used were either Durapore poly(vinylidene fluoride) PVDF membranes
(Millipore, Hertfordshire, UK) or Supor polyethersulfone (PES) membranes (Pall,
Portsmouth, UK) with 0.1, 0.22 or 0.45 m rating.
Prior to and after microfiltration, samples were collected for total protein and Fab
quantification by spectrophotometry (Section 2.9.3) and HPLC (Section 2.9.4). Samples
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were also collected before microfiltration for SDS PAGE analysis and particle size
described in Sections 2.9.5 and 2.10.1, respectively.
Statistical analysis was performed using Microsoft Office Excel™ Analysis Toolpak™
(Anova: single factor). Design Expert 7 (Stat-Ease, MN, USA) was used to analyse
multiple factor interactions.
4.3. Results and discussion
4.3.1. Impact of cell disruption technique on filtration performance*
Choice of various cell disruption operations will result in differences in product and
impurity profiles which may affect subsequent primary recovery operations like
microfiltration (Balasundaram et al., 2009a). To examine this here, three methods were
investigated: high pressure homogenisation (Section 2.3.2), sonication (Section 2.3.4)
and a combined heat and chemical extraction (Section 2.3.3). Homogenisation is one of
the most common process scale cell disruption methods (Balasundaram et al., 2009a)
while sonication is often the preferred cell disruption method at the laboratory scale
(Wenger et al. 2008). For antibody fragments in particular, thermo-chemical extraction
is used at industrial process scale for the release of periplasmic Fab’ fragments (Spitali,
2009). This latter extraction process is readily compatible with the microwell format
and so was established in this study.
Table 4.1 shows the Fab’ and total soluble host cell protein (HCP) content of the
differently disrupted cell suspensions. As expected, the homogenised sample yielded
the highest Fab’ content however it also has the highest amount of HCP released. This
high HCP load is known to cause a burden for the subsequent downstream processing
steps and is considered a significant disadvantage for large scale operation.
______________________________
* Acknowledgements are due to: R. Hanif, for providing the homogenised E.coli cells; A. Wong, my
student, for her assistance in the sonication experiments as part of her project under the Nuffield
Foundation Science Bursary in 2008.
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Table 4.1 Impact of various laboratory and microscale E. coli cell disruption operations
on protein composition of Fab’ suspensions.
Cell disruption operation* Total host cell
protein
(mg L-1)
Fab’ content
(mg L-1)
Purity**
Homogenisation (H) >5700 > 1062 ~20%
Sonication (S) 3500 312 10%
Thermo-chemical extraction (T) 1000 197 20%
*Disruption conditions: (H) – solids load of 30 gDCW L-1 in 100 mM Tris-HCL pH 7.0, 2-pass at 500 bar
(according to Section 2.3.2); (S) – solids load of 22 gDCW L-1 in 100 mM Tris/ 10 mM EDTA pH 7.0, 3 x 20s
cycle (according to Section 2.3.4); (T) – solids load of 22 gDCW L-1 in 100 mM Tris/ 10 mM EDTA pH 7.0 for 16h
at 50oC (according to Section 2.3.3). **The indicated purity of Fab’ is with respect to total protein content.
Bradford assay and Protein G chromatography were performed to quantify total protein and Fab’ content,
respectively (according to Section 2.9.3-2.9.4).
Figure 4.2 illustrates the microscale specific cake resistance values, , subsequently
measured using each of these different upstream cell disruption operations. As
expected, these values are about five times higher than previously reported values for
non-disrupted E.coli cells. The results show that the homogenised samples have an
average  of almost an order of magnitude larger than the thermo-chemically treated
cells (this corresponds to a two-fold decrease in permeate flux). On average, the  value
of the sonicated samples is also four times larger than the heat-extracted cells and is
approximately half that of the homogenised samples.
When the particle size data of the respective feed samples were investigated, results
showed rather different particle size distributions. Figure 4.3 illustrates these size
distributions. Sonicated samples showed the presence of only one population size while
the heat-extracted cells resulted in a bi-modal distribution. The latter can be explained
by the presence of smaller debris, probably consisting of fragments of broken outer
membrane, and by larger cellular debris.
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The d10 for both heat-extracted and sonicated samples was found to be 1m while d90
values were 23m and 9 m for the thermo-chemically extracted and sonicated
samples, respectively. Typical particle sizes for similar E. coli homogenates show a d90
of around 4m or smaller (Balasundaram et al., 2009a). In this case, d90 for the
homogenate sample is 1 m. These differences in particle size data partly explain the
outcome of the microfiltration process presented in Figure 4.2. During microfiltration,
suspensions with smaller particle sizes (such as the homogenate suspensions used in
this work) will form a more compact cake structure resulting in a higher specific cake
resistance (Grace, 1953b).
SDS-PAGE results presented in Figure 4.4* (lanes 1, 2, and 6) confirmed that
homogenised and sonicated samples (lanes 1 and 2) contain a larger quantity of
impurities than the thermo-chemically extracted cells (lane 6). Note that the
homogenised sample is from a cell suspension with a cell dry weight of 30 gDCW L-1
while the sonicated and heat extracted samples had cell content of 22 gDCW L-1. Thus,
comparing the two samples from cell suspensions with the same level of cell content,
Figure 4.4 shows that the thermo-chemically extracted sample (lane 6) is relatively
“cleaner” than the sonicated sample (lane 2). On the other hand, the sonicated sample,
although from a sample of lower cell content, appears to have similar profile and level
of contaminants as the homogenised sample. These results illustrate that cell disruption
operations (as in homogenisation and sonication) will lead to the release of more
contaminating proteins. This is in contrast to the permeabilising action to the cell
membrane by the heat-extraction step which appeared to have resulted in the limited
release of contaminants. As shown later in Section 4.3.2, the presence of these
contaminating solutes (mostly host cell proteins) may have a profound negative effect
on the microfiltration performance of the E. coli cell suspensions.
_____________________
P. Morris is acknowledged for her assistance in the gel analysis in Figure 4.4.
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From Table 4.1, Figure 4.2 and Figure 4.3, it can also be observed that sonicated
samples do not match the properties of the homogenised samples in terms of Fab’ yield,
total protein release, and microfiltration performance. This emphasises that sonicated
samples are not representative of homogenised material either in terms of composition
or particle size distribution. Consequently, the outcome of processes conducted using
sonication at laboratory scale will not accurately represent the process scale outcomes
using homogenised materials. In contrast, the microscale thermo-chemical extraction
method does give comparable results to pilot scale (10 L) thermo-chemical Fab’
extraction (unpublished data, Alison Tang, UCL).
A final consideration for process characterisation is the release of incorrectly assembled
or unfolded Fab’ which provide difficult purification challenges further downstream.
The thermo-chemical extraction step was designed to destabilise the outer membrane of
the E. coli cells and release only the components present in the periplasmic space (Weir
and Bailey, 1997). The high pressure homogenisation and sonication methods may
provide higher Fab’ yields but they also contain larger proportions of incorrectly
assembled or unfolded Fab’, as well as many other contaminating proteins, from the
cytoplasm. It is common that fermentation processes will produce a proportion of these
unfolded, incorrectly assembled or incomplete Fab’ (Baneyx and Mujacic, 2004;
Spitali, 2009). These Fab’ species are also included in the quantification of Fab’ content
(for example as in Table 4.1) since the Protein G assay used (Section 2.9.4) detects
both the complete, functional Fab’ species as well as the incomplete and non-functional
antibody fragments (Bowering et al., 2002). Thus, even if it appears that the
homogenised and thermo-chemically extracted samples have similar purities based on
Table 4.1, it is the preparation from the periplasmic extraction which will contain the
highest purity of correctly assembled, disulphide bond-rich antibody Fab’ fragments.
Further analysis of the Fab’ species were not done in this work. However, with
increased interest on the understanding of antibody fragments, analytical techniques
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have now emerged in order to quantify specific species. For example, Roque et al.
(2005) have studied affinity chromatography using Protein L resin which could
differentiate between species of antibody fragments. From Table 4.1, the Fab’ content
obtained thermo-chemical extraction is the lowest among the three Fab’ release
methods. Yield improvement for Fab’ release using thermo-chemical extraction may be
achieved by coupling this method with mild homogenisation (Spitali, 2009).
Overall, the results in this section indicate that a trade-off between quantity and quality
of product release and subsequent efficiency of recovery should be considered in
deciding the preferred process route. Although some cell disruption methods were
shown to be more efficient in releasing the product, the properties of the suspension
may not be beneficial for the subsequent unit operation in the downstream process
sequence. This observation emphasises the need for a whole bioprocess approach,
linking upstream and downstream process operations, when assessing different
bioprocess flowsheet options.
4.3.2 Impact of disruption conditions on Fab’ recovery by microfiltration
One of the advantages of the microscale approach is the ability to link different
operations together in a defined process sequence thus allowing investigation of unit
operation interactions. Consequently, the effects of different conditions during thermo-
chemical extraction on the microfiltration performance of E. coli cells were investigated
in detail as indicated in Figure 4.5. This enables the effects of a range of extraction
conditions to be investigated for their impact on the filterability of the resulting
suspensions.
4.3.2.1 Influence of cell concentration and extraction pH
It was deemed important to first study the effect of cell concentration as this is one of
the factors which may affect the release of intracellular products during a chemical
Figure 4.5
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extraction step (Choe and Middleberg, 2001). At the same time, a narrow pH range was
studied to test the sensitivity of Fab’ recovery with small pH variations which may
occur during processing. Statistical analysis showed that the pH of the Tris-EDTA
solution does not have a significant effect (F-test, p>0.05) on Fab’ release over the pH
range 7.0 - 7.8. Figure 4.6 shows the Fab’ concentration obtained at the different cell
loadings. The Fab’ concentration increased with increasing cell loading, however, the
amount of Fab’ released per gram of cell was found to decrease with increasing
biomass concentration. The thermo-chemically treated cell suspensions were
subsequently used in microfiltration experiments to characterise their filterability in
terms of cake resistance. Figure 4.7 shows the calculated  values and the
corresponding Fab’ transmission after undergoing sequential extraction and filtration.
Statistical analysis (F-test, p<0.05) shows that pH has a significant effect on  values
while the cell concentration or solids loading does not have a significant effect. This
result is in contrast to the effects of pH and cell loading on the release of Fab’
fragments during the preceding extraction step (Figure 4.6) and illustrates the need to
consider the impact of a process parameter like pH on subsequent downstream
operations. The  values of heat-extracted cells were also affected by the interaction
effects between pH and solids loading. On the other hand, Fab’ transmission data have
been shown to have a negative correlation with , the magnitude of correlation
depending on the solids concentration.
Particle size distribution analysis (PSD) of these thermo-chemically extracted cells
(Figure 4.8) showed the presence of a bimodal size distribution; one peak for particles
having diameters smaller than 2 m and the other for diameters larger than 2 m.
Typical dimensions of E. coli are 0.5 by 2 m (Miao et al., 2003). The data obtained
indicates that particle size distributions are very similar for the different cell
suspensions at the same cell concentration even at different pH values. The particle size
Figure 4.6
extracted
100 mM Tris/10 mM EDTA solution, pH 7.0
Section 2.3.3. Error
Impact of cell concentration on Fab’ release from thermo
E. coli cells. () Fab’ content; (
represent one standard deviation about the mean (n=3).
~ 133 ~
) Yield of Fab’. Periplasmic e
-7.8, at 50oC for 16 h as described in
-chemically
xtraction in
Figure 4.7
(B) apparent permeate transmission of thermo
Extraction in 100 mM Tr
pH 7.4; (
65 kPa using a PVDF 0.45
represent one standard deviation
Impact of cell concentration on (A) calculated specific cake resistance and
) pH 7.8 as described in Section 2.3.3.
is/10 mM EDTA solution, at

~
m membrane as described in Section 3.3.3. Error bars
about the mean (n=3).
134 ~
-chemically extracted
Filtration was performed at
50oC for 16 h:
E.coli
() pH 7.0; (
cells.
)
PTMP=
~ 135 ~
distribution of the untreated cells resuspended in the original fermentation broth shows
that the whole cells tend to form more aggregates than the treated ones (Figure 4.8 A).
The untreated whole cell suspensions have 50% of particles larger than 10 m while
only 30% of the heat-extracted cells are larger than 10 m (Figure 4.3). The treated cell
suspensions have therefore smaller size aggregates than the untreated whole cells
indicating the probable effect of Tris-EDTA on cell-cell interactions.
Tris is known to alter the outermembrane permeability of E. coli cells resulting in a
limited release of components from the cell envelope (Irvin et al., 1981). On the other
hand, EDTA treatments have been reported to alter cell surface properties by changing
the morphological structure of the outermembrane surface, releasing
polyliposaccharides and increasing envelope permeability (Bayer and Leive, 1977).
These cell surface properties are known to affect both cell-cell as well as cell-solutes
interactions in a suspension (van Hee et al., 2006) and so will impact on filtration
performance in a number of ways. Hodgson et al. (1993) have demonstrated that a
modified extracellular matrix on the cell surface reduced the specific cake resistance of
the Gram-negative marine bacterium SW8. This kind of effect of cell surface changes
on filtration performance was also found in this study where the  values for whole
cells in the fermentation media are several orders of magnitude larger than the heat-
extracted, Tris-EDTA treated cells.
The microfiltration performance of these cells (Figure 4.7) may have also been affected
by the presence of different components in solution. These are the solutes that were
released from the cells together with the antibody Fab’ fragments. Considering that
solution components affect cell-cell and cell-protein/solute interactions as well as the
cells’ state of aggregation (Ohmori and Glatz, 1999), it is clear that these components
may consequently affect the cake structure being formed and therefore the permeate
Figure 4.8
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flux during filtration. If these interactions have a large influence on the cake formation
process, they will also affect the packing and cake porosity.
The cake porosity is known to largely influence the cake resistance (Foley, 2006b) and
is likely to impact on the permeation of Fab’ fragments through the filter cake (van Reis
and Zydney, 2007). The cake structure has also affected the apparent transmission
which is the ratio of Fab’ concentration in the permeate to the concentration of Fab’ in
the feed (Equation 2.7). The Fab’ transmission was 80% (w/w) which is low in
comparison to the high permeation expected of proteins and other soluble components
through microporous membranes. This may be due to the treated cell suspension having
an environment that (a) causes the formation of a cake layer that become impermeable
to the Fab’ fragments or (b) results in the adsorption of Fab’ onto the remaining cells or
cell debris. A number of studies cite reduced protein transmission during
microfiltration due to adsorption onto cell debris (Ohmori and Glatz, 1999; Le et al.,
1984; Yamasaki et al., 1993).
4.3.2.2 Influence of extraction temperature and time
In order to understand further the mechanism of the heat extraction process, similar
microscale experiments were performed to examine the effects of temperature and time
on Fab’ recovery. The time profiles of Fab’ and protein release for two extraction
temperatures (35 and 50oC) and two cell concentrations (22 and 32 gDCW L-1) are shown
in Figure 4.9. For both solids loading, the Fab’ release from cells in Tris-EDTA
solution increases with time. Results show that Fab’ release was relatively fast since
Fab’ concentration values measured after one minute incubation were already higher
than half the concentration values for the longest incubation time (16 h). Fab’ content
was also higher at the higher extraction temperature although the maximum difference
in Fab’ fragments concentration between the two temperatures is only 9%.
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A similar profile of fast release of total protein content can be observed at the lower
extraction temperature. However at 50oC, the protein content decreases with time. The
disappearance of these proteins is also evident in the SDS PAGE gel shown in Figure
4.4 (lanes 8 and 6). Fab’ fragments are reported to be thermally stable (Weir and
Bailey, 1997) hence they are not degraded at 50oC. The heat extraction step employed
here is also designed to cause denaturation of the more labile host cell proteins causing
them to precipitate from solution and further decrease the HCP load on subsequent
chromatographic downstream process steps. These precipitated proteins are therefore
not detected during the total protein assay and SDS PAGE because the samples used
were from clarified supernatants of the extracted cell suspensions.
The cell suspensions extracted at 2 h and 16 h at temperatures of 35oC and 50oC were
next used as feeds to subsequent microfiltration operations. The measured  values
with these cell suspensions are shown in Figure 4.10. The results show that 
decreases as the extraction time and extraction temperature were increased. The
reduction in specific cake resistance corresponds to the lower contaminating soluble
protein levels in the cell extracts from 50oC, a further indication that contaminating
proteins present in solution were contributing factors in the microfiltration of the heat-
extracted E. coli cells. At the lower temperature, Fab’ and protein release is not as
efficient hence, the contaminating protein profiles were different for the two extraction
temperatures investigated as illustrated in Figure 4.4.
The differences in the release of cellular components during heating of E. coli cell
suspensions can be explained by the mechanism of heat destruction of the outer cell
membrane. The effect of heating on E. coli W3110 cells has already been reported.
Katsui et al. (1982) found that release of outermembrane components such as lipids and
polyliposaccharides was induced by heating the cells (at 55oC) in Tris buffer. The
pattern of release obtained is similar to the Fab’ release shown in Figure 4.10 wherein
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the initial rapid release of these components was followed by a secondary release at a
slower rate. It is noteworthy that the authors did not detect a substantial release after
incubating the cells at 37oC. Tsuchido et al. (1985) reported that increasing the
concentration of Tris buffer above 100 mM enhances its toxic effect on both the intact
and heated cells. This may explain the differences in the released soluble components
at the two temperatures investigated. With the higher concentrations of Tris-EDTA
used here it can be expected that the release of cellular components, particularly from
the periplasmic space, is more efficient at 50oC than at 35oC. These results show that
there is a clear advantage in increasing the temperature of extraction to 50oC even if the
lower temperature at 35oC may release similar amounts of Fab’ fragments at extended
extraction periods. The advantage is the cleaner preparation of the extracts which
results in better filterability (and therefore more efficient recovery) of the extracted cell
suspensions at the higher temperature. As Bowering et al. (2002) also noted, Fab’ is
released after 10 minutes but the extended time period at a higher temperature (60oC in
their study) allows for the complete degradation of incomplete Fab’. In this case, it was
also shown that this prolonged extraction time not only improved the purity by
eliminating these contaminating proteins and non-functional Fab’ fragments, but more
importantly the process produced an extract that has better filterability and therefore,
improved the recovery from the linked process sequence.
4.3.3 Impact of filtration conditions on Fab’ recovery by microfiltration
Sections 4.3.1 and 4.3.2 have shown how a preceding unit operation, such as cell
disruption, could impact on the performance of a subsequent dead-end microfiltration
process. This section will now present results on the impact of the operating conditions
employed during the microfiltration of disrupted E. coli cells. Operating conditions
investigated include the type of membrane material, pore size, and the transmembrane
pressure.
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4.3.3.1 Influence of membrane material
In Section 1.4, a selection of various types of membrane material and pore sizes
together with their common usage were presented. The choice of the most appropriate
membrane material and correct pore size is important in ensuring high permeate flux,
minimal product adsorption and therefore reduced product loss. Thus in this section, the
use of different pore sizes and membrane material is investigated.
It was shown in Table 3.1 that the membrane resistances of PVDF membranes rated
0.1, 0.22 and 0.45 m differ by as much as 90%. The one with the smallest membrane
resistance, 0.45 m, was therefore used in the rest of Chapter 3 and in the previous
sections here in Chapter 4. When PVDF membranes with smaller pore ratings were
used in the microfiltration of thermo-chemically heat treated cells (data not shown),
results illustrated no significant difference in the microfiltration performance, both in
terms of specific cake resistance and Fab’ transmission. The difference in membrane
resistance as a result of the difference in pore size (and possibly porosity and internal
surface area, as discussed in Section 3.3.2) is therefore not a key factor in the
microfiltration of E. coli cells. This is in agreement with the mechanism and
assumptions used in cake filtration studies, particularly in deriving Equation 1.12 where
membrane resistance is assumed negligible compared to cake resistance (Teoh et al.,
2006).
Microfiltration of the same heat treated cells was performed using a different membrane
material namely 0.45 m-rated hydrophilic polyethersulfone (PES) membrane filters.
Results are shown in Table 4.2. The membrane resistance of the PES membrane is 1.5
± 0.3 x 1010 m-1, which is similar to the membrane resistance of a PVDF membrane of
the same pore rating. The measured membrane resistance is also similar to the one
reported in literature for PES (McGuire et al., 2009).
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Table 4.2 Specific cake resistances () of cell disrupted E. coli cells using 0.45 m
PES filters. Conditions for (A): cell loading of 32 gDCW L-1, incubation was at 50oC for
16 h as described in Section 2.3.3. Conditions for (B) is: 22 gDCW L-1 as described in
Section 2.3.4. Filtration was performed at PTMP= 65 kPa as described in Section 3.3.3.
values calculated according to Equation 3.1. Values inside brackets are percent
difference to PVDF data with negative values indicating lower values.
Cell disruption technique 
( x 1012 m kg-1)
Fab’ transmission
(%, w/w)
(A)
Thermo-
chemical
extraction
pH 7.0 673 ± 132 [-41%] 88 [-8%]
pH 7.4 1009 ± 156 [-29%] 86 [-4%]
pH 7.8 1140 ± 36 [-12%] 82 [-1%]
(B)
Sonication 4201 ± 632 [-4%] 98 [-2%]
In comparison with the microfiltration performance using hydrophilic PVDF
membranes, the specific cake resistances from PES filters are smaller. Statistical
analysis shows that this difference is significant (F-test, p<0.05) at pH 7.0 and 7.4. Both
manufacturers of these two filters mention that the filters offer low protein binding. So
on the basis of specific cake resistances, it was expected that transmission through PES
filters will give slightly larger transmission of Fab’. However, the PES data shown in
Table 4.2 are slightly smaller than Fab’ transmission through PVDF filters.
It is believed that this lower transmission is primarily due to the binding of Fab’
fragments on the PES membrane. As part of the protocol in HPLC analysis (described
in Section 2.9.4) samples have to be filtered using syringe filters. The same result was
also observed by the Fab’ concentration data (not shown) from the supernatant of the
feeds prior to filtration. An inspection of Fab’ concentrations from these supernatants
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show that, using PES syringe filter, concentrations are 2-9% lower compared to PVDF-
filtered samples even if the samples come from the same pool of supernatant.
Table 4.2 also shows the result of microfiltration using PES membranes for disrupted
E. coli cells suspensions by sonication. In contrast to the thermo-chemically extracted
cells, the disrupted cells from sonication gave comparable microfiltration performance
with either PES or PVDF membranes. As discussed in Section 4.3.1, the sonicated and
heat extracted samples differ in their Fab and total soluble protein content. This may
explain why these two cell suspensions have different microfiltration behaviour using
PVDF or PES membranes. Thermo-chemically extracted cells may have properties that
resulted in a different interaction with PVDF than PES membranes. On the other hand,
the sonicated samples may have properties that neither interact with PVDF or PES
membranes, thus the microfiltration behaviour is the same even with different
membrane type. These properties include cell-cell interaction type resulting in a certain
cell – membrane interaction, or soluble component interactions with the membranes.
4.3.3.2 Influence of transmembrane pressure
Being a pressure driven process (Section 1.4), membrane microfiltration depends on a
transmembrane pressure difference (PTM) to achieve the separation and permeation of
the desired solute from the undesired components in a suspension. The relationship of
permeate flux versus PTM is commonly known to be positively correlated. However,
during microfiltration of microbial cell suspensions, there is a phenomenon called filter
cake compressibility which may also influence the permeate flux. Foley (2006b)
explains that the packing structure of compressible cakes cannot sustain the viscous
drag caused by the pressure gradient in the fluid at the particle-fluid interface. A new
stable packing structure is required and this is achieved, in the case of microbial
suspensions, by particle re-arrangement either with or without particle deformation. The
re-arrangement or deformation of particles may also result in the change in cake
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porosity, thereby influencing not only the permeate flux but also the transmission of
permeable components. Thus it is necessary to investigate the relationship of  versus
PTM since this will provide the basis for determining the extent of compressibility of
microbial suspensions.
One of the practical problems associated with the determination of cake compressibility
is the number of experiments required, which translates to a certain amount of feed
volume. The amount required is even greater when the microfiltration behaviour of
several feed preparations is examined (Sections 4.3.1 and 4.3.2). In this regard, a
method was developed (Section 3.3.5) where a single plate microscale dead-end
filtration experiment is performed for an adequate period of time. The method was
shown to conform to cake filtration theory, while enabling experimentation with
minimal amount of feed. The single plate, single-step method was used here to
determine the  versus PTM behaviour of thermo-chemically treated cells (Figure
4.11).
As shown in Figure 4.11, the specific cake resistances of feeds with different cell
loading and extraction conditions increase with transmembrane pressure. The linear
relationship (r2 > 0.98) indicates the compressible nature of thermo-chemically
extracted E. coli cells which is in agreement with findings in literature for E. coli
suspensions (Riesmeier et al., 1989). The figure also illustrates that the extent of
dependence of  with PTM is affected by the feed preparation (in this case, the
extraction temperature).
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4.4 Conclusions
In this chapter, microscale methods for E. coli thermo-chemical extraction and filtration
(Figure 4.5) were established and effectively used to gather quantitative engineering
data for the primary recovery of antibody fragments in a linked process sequence.
Using these techniques, it has been shown that thermo-chemically extracted cell
suspensions gave better microfiltration performance than the disrupted cell suspensions
prepared by homogenisation or sonication (Figure 4.2). Although the latter disruption
methods were more efficient in releasing the Fab’ product (Table 4.1), the quality of
the feed, in terms of the levels of contaminating host cell protein and misformed Fab’
fragments, was poorer and hence detrimental for the subsequent downstream processing
step. The conditions of thermo-chemical extraction such as pH, extraction temperature
and time, not only affect the yield of the extracted Fab’ but also impacts on the
microfiltration performance (Section 4.3.2). Finally, the differences in microfiltration
behaviour using different membrane types were compared. It was demonstrated that
depending on the type of cell disruption method, there may or may not be any
difference in filtration behaviour using either PVDF or PES membranes (Section 4.3.3).
Overall these results demonstrate how microscale bioprocessing techniques can identify
early key issues related to operation of linked bioprocess sequences. The parallelization
of microscale experiments and integration within an automated platform allowed the
acquisition of process information with relative ease and reproducibly, thus providing
the possibility to explore and optimise a broader spectrum of process conditions than is
normally possible manually. Specifically, this approach facilitated a better
understanding of the mechanism of the Fab’ extraction process which can then be used
in the design and optimisation of the primary recovery sequence. In the following
chapter, the microscale approach is extended to show a novel design and automated
microscale methodology for the rapid evaluation of crossflow microfiltration operation.
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5. Design and Evaluation of a
Microscale Crossflow Filtration Device‡
5.1 Introduction and aims
A unique feature of the automated microscale approach is the potential to establish
linked bioprocess sequences in order to rapidly investigate the effect of upstream
process conditions on downstream operation efficiency. The previous chapters have
described an example of this highlighting the impact of Fab’ extraction conditions on
microscale dead-end filtration performance. Dead-end membrane filtration is
commonly used for small volume laboratory applications or with single-use processes.
In contrast, crossflow filtration (CFF) processes are more frequently recommended for
larger scale process applications (Belfort et al., 1994; Yavorsky et al., 2003). As shown
in Section 1.5 very few studies to date have examined microscale CFF devices which
mimic the operation of larger-scale processes. The best example has been to use a
miniature rotating disc-membrane device to simulate the performance of a larger scale
diafiltration process (Guijun et al., 2010). However, this approach is not readily
amenable to parallel experimentation and automation. The creation of a novel
crossflow device which is appropriately designed for operation and integration within
a robotic laboratory platform will gain the benefits of increased number of
experimental variables that could be investigated and facilitate the study of linked
__________________________
‡ Majority of the results presented in this chapter is to be submitted for publication as: Rayat, ACME, Craig, A, Lye,
GJ, Micheletti, M. (2011). A novel microscale crossflow filtration device for the rapid evaluation of microfiltration
processes.
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bioprocess sequences. To date, the full potential of crossflow microfiltration has not
yet been fully exploited commercially due to the difficulty in describing and modelling
process performance a priori. Several attempts have been made to model the crossflow
microfiltration operation in order to predict process performance particularly in terms of
the steady state permeate flux. Belfort et al. (1994) reports that there are models which
combine mass and momentum transport equations and are solved with sophisticated
numerical techniques. The complexity of the phenomena occurring during crossflow
microfiltration meant that no unified framework could accurately describe the process.
Due to this, and partly because of the complicated analyses required to solve the
models, these were not used in actual design or online prediction of the process
performance (Belfort et al., 1994). Given this background, the merit of extending the
microscale approach to crossflow microfiltration is evident. It is precisely this kind of
unit operations that could greatly benefit by this approach: where models could not
satisfactorily describe and predict process performance, adequate data from microscale
experiments could be quickly collected covering a wide range of conditions for
prediction of larger-scale processes (Titchener-Hooker et al., 2008).
The aim of this chapter, therefore, is to design a novel microscale crossflow filtration
(CFF) device and to show its capability to test process conditions relevant to larger
scale operations. This device will complement the developments on microscale
upstream operations (Jackson et al., 2006) and constitute a valuable option to the
already available microscale unit operations. Figure 5.1 illustrates the context of the
creation of this device within the overall aim of this thesis.
Figure 5.1
for the investigation
device and method development. (
www.pneumaticscale.com)
Application of microscale bioprocessing platform for membrane filtration
of bioprocess routes: creation of microscale crossflow filtration
~
Image credit: Pilot scale centrifuge from
150 ~
~ 151 ~
The specific objectives are as follows:
 to determine key design considerations and criteria for mimicking
commercially available flat-sheet based membrane filtration modules that is
able to operate in parallel on a Tecan™ platform;
 to design, fabricate, and evaluate the design performance of the microscale
CFF device based on these criteria;
 to establish an automated microscale CFF methodology for predicting larger-
scale microfiltration operation for steady state flux determination; and
 to establish the comparability of the microfiltration performance (steady state
flux) when using the microscale CFF device to that of the larger-scale
laboratory CFF module.
5.2 Microscale CFF design criteria
It is important to achieve consistent results across scales for scale-down or scale-up
mimics of unit operations. These mimics have been widely employed for the validation
of processes, trouble shooting, and process optimisation studies (van Reis et al., 1997).
Van Reis et al. (1997) have listed the important parameters that must be considered for
different CFF systems. Among the different operating parameters, the fluid dynamics in
the membrane modules is considered an important factor in the effective operation of
crossflow microfiltration (Belfort et al., 1994). It is therefore essential to maintain the
same hydrodynamic conditions when scaling-up or scaling-down CFF operations.
For flat-sheet membrane module designs as will be used here, such as the Pellicon-2™
(Millipore, Hertfordshire, UK) (Figure 5.2), a key criterion for scale translation (scale-
up or scale-down) is to maintain a constant channel length (van Reis et al., 1997).
Figure 5.2
experiments: (A) Pellicon
illustration of the membrane configuration within the module and the different ports for
(1) feed and (2) retentate pressure measurements, and (3) permea
schematic representation of the cross section of the module showing a suspended screen
between membranes (screen illustration courtesy of Millipore)
The laboratory CFF module used in larger scale
-2™ Mini sandwiched between stainless steel holders; (B)
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Friction along the channel length causes the hydraulic fluid pressure to decrease along
the channel. As a result, the permeate flowrate through the membrane also decreases
along the channel. Both of these actions result in an increase in concentration of solutes.
Therefore when channels of filtration cassettes have different lengths, there will be a
variation between their fluid velocity and concentration profiles, resulting in filtration
performances that are not comparable. Using this approach to scale translation, the
membrane area could be increased by designing parallel membranes within a membrane
module or increasing the width of the membrane while maintaining the length.
Another key design factor in scale translation is the channel height (van Reis et al.,
1997). In the Pellicon-2™ system effective channel height is mainly controlled by the
module design and channel height compression (as a result of flow through parallel
feed/retentate channels). Compression, in turn, is a function of physical deformation of
the membrane, spacer screen, encapsulant and gaskets (van Reis et al., 1997). These
two scale translation criteria, channel (hydraulic) length and channel height, are
fundamental to the design aspect of the microscale device established in Section 5.4.1.
5.3 Experimental approach
The microscale crossflow microfiltration device shown in Figure 5.3 was fabricated in-
house in the Department of Biochemical Engineering at UCL. Preliminary evaluation
involved performing water flux experiments to test the device for leaks and
reproducibility of performance. Following these initial tests, crossflow microfiltration
experiments were performed first with a model biological process feed consisting of
Baker’s yeast.
Figure 5.3
work: (A) on top of the Tecan vacuum block beside a 96
(B) Top view of the membrane module; and right side view of membrane module
showing (C) feed
section of the vacuum block showing (1) top plate (feed/retentate channels), (2)
membrane, (3) bottom plate (permeate channels and o
permeate receiver, and (6)
Details of the microscale crossflow microfiltration device designed in this
/retentate channels and (D) permeate channels; (E) Detailed cross
feed/retentate ports.
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– deep square well microplate;
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~ 155 ~
Active Baker’s yeast from Saccharomyces cerevisiae was purchased in powder form
from Sigma-Aldrich (Dorset, UK) and was added with bovine serum albumin (BSA) to
10 mM sodium phosphate buffer at pH 6.4. Yeast and BSA concentrations were
approximately 30 g L-1 dry weight and 6 g L-1, respectively. Once prepared, the yeast
suspension was used immediately for the crossflow microfiltration experiments.
Laboratory scale crossflow microfiltration experiments were performed using a
Millipore Proflux™ M12™ Tangential Filtration System (Section 2.6.1) and operated
according to the procedure described in Section 2.6.2. Microscale crossflow
microfiltration experiments were performed using the novel device as shown in Figure
5.3 and operated according to Section 2.7.2. Details of the CFF methodology are
described in Section 5.4.3. Statistical analysis of permeate flux data from both
membrane modules was performed using Microsoft Office Excel™ Analysis
Toolpak™ (Anova: single factor).
5.4 Results and discussion
5.4.1 Design considerations
An important consideration in the design of the microscale CFF device (Figure 5.3) is
the Tecan platform on which the device is to be operated. Two things are affected as a
result of this. One is the physical design of the filter plates. The length of the filter
channels were limited by the available length within a standard microtitre plate. Also,
since the filtration process has to be performed under negative applied pressure this
influenced the methodology of CFF operation on the Tecan platform.
The main principle followed while designing the microscale CFF device is the linear
scaling concept; adopted to simulate the process performance of the Pellicon-2™
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system. As earlier mentioned in Section 5.2, it is important to consider the channel
length because of its effect on the axial pressure drop (Paxial), and therefore the
velocity and concentration profiles along the channel. In addition, the hydrodynamics
inside the channels, mainly affected by the design of the channel height and width,
should also be kept similar. Therefore, the CFF channels were designed so that the
resulting total hydraulic length would result in Paxial along the channel that is similar
to the pressure drop experienced in laboratory scale membrane modules with open or
suspended screens. The U shape channel was designed so as to give the necessary
length to meet the expected Paxial since the total length of the plate (12 cm) is shorter
than the 21 cm channel length of the lab-scale module. The channels in the microscale
and larger scale device have rectangular cross-sections.
The actual membrane material is placed on the bottom side of the feed/retentate channel
while the top side is the etched portion of the acrylic sheet that forms the channel
(Figure 5.3 (C)). Consideration was given to the practical fabrication limitations to
ensure that the height of the channels would be uniform along the lengths of both
channels on the filter plate. While the channel height should be made similar in
magnitude as that of the Pellicon-2™ membrane, if not smaller, a smaller channel
height could result in improved hydrodynamics at a given crossflowrate and this could
compensate for the lack of turbulence promoter in the microscale device. Based on
these practical and theoretical considerations, the design specifications for the channel
height and width were selected. The Paxial and wall shear rate (wall) were calculated for
a range of fluid velocities at a given channel hydraulic length using Equations 5.1 – 5.8.
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Equation 5.1 is the Fanning equation which relates the axial pressure drop and velocity
in a channel and straight pipe. Equations 5.2 and 5.3 can be used to calculate the
friction factors for a given channel geometry in laminar or turbulent flow, respectively
(Mulder, 1996). In the equations, Re is the Reynolds number for which Re < 2000
indicates that fluid flow is laminar while flows with Re > 3000 are in the turbulent
region (Bird et al., 2001). DH is the hydraulic diameter, S is the circumference or
wetted perimeter, L is the channel length, Ac is the cross-sectional area of the channel,
F and  F are the density and viscosity of the process stream, respectively, v is the fluid
velocity, w is the channel width and h is channel height.
Table 5.1 summarises the important dimensions of the Pellicon-2™ Mini- system, the
basis of the design of the microscale CFF device and the actual microscale device
dimensions. Some of the information regarding the Pellicon-2™ system was estimated
from established Millipore data sheets and actual module dimensions, including
auxiliary tubing. The calculations to estimate these entries are shown in Appendix 2.1.
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Table 5.1. Design features of the laboratory scale and microscale crossflow microfiltration systems.
Parameter
PelliconTM 2-Mini
(V-screen)
Microscale CFF Remarks on Microscale Design
Design Actual
Screen/channel type Suspended screen Open/U-shaped Design specification 1
Length (cm) 21   Design specification 2
Width (cm)    Design specification 3
Height (cm) 2.2   Design specification 4
Membrane area (cm2) 1000 9 10 Design output: a result of spec 2,3
Channels per device 5* 1 1 Design specification 5
Membranes per device 10* 1 1 Design specification 6
Parallel experimentation per device No Yes*** Yes*** Design specification7
Hydraulic length (cm) 85** 37.5 55 Design output: a result of spec 1-4
Active membrane length (cm) 16.5 18.5 21.5 Design specification 8
Active membrane width (cm) 60* 0.5 0.46 Design specification 9
Axial pressure drop (bar) < 0.4 (typical) 0.01-1.8 < 0.2 Design output: a result of spec 1-4
Crossflow velocity (cm s-1) 25 (typical) 10-500 30-50 Operating variable
* estimated from given information in published Millipore technical data sheets
** estimated from given information in published Millipore technical data sheets and dimensions including holder and tubing before/after pressure taps
*** two independent channels per filter plate
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The Pellicon-2™Mini system was chosen as the larger scale crossflow filtration module
to be mimicked in this work because its design allows it to be linearly scaled-up to pilot
scale (from the available 0.1 m2 for Pellicon-2™, this can be scaled up to 2 m2 and even
up to 80m2, information found at www.millipore.com).
5.4.2 Preliminary experiments
Initial experiments with the microscale CFF device involved checking for the presence
of leaks and performing water flux quantification. Actual Paxial measured during these
water flux experiments was 30 mbar which is in good agreement with the calculated
Paxial value (27 mbar) using Equation 5.1. This is also comparable with the measured
Paxial for the larger scale module which was 40 mbar. This indicates that the designed
hydraulic length of the channels in the microscale CFF device, in the form of a U shape,
matches the hydraulic length of the larger scale module.
Data from water flux experiments were used to calculate membrane resistances using
Equation 2.3. A typical flux versus transmembrane pressure (PTM) curve obtained from
the microscale CFF water flux experiments is shown in Figure 5.4. The slope represents
the normalised water permeability (NWP) and is related to the membrane resistance Rm
by Equation 2.4. It can be observed from Figure 5.4 that the measured membrane
resistance is constant across the range of PTM values examined.
Table 5.2 compares the calculated Rm values, calculated for the two channels of the
microscale device, and previous data obtained for the same membrane material but
using the microscale dead-end filtration method (Section 3.3.1). The Rm values for both
channels are comparable and are also similar to the ones previously reported for this
0.22 m PVDF membrane. The clean membrane resistance is a property inherent to the
membrane and therefore should not change with the mode of membrane filtration used
(i.e. crossflow as opposed to dead-end mode).
Figure 5.4
module. (
two different membranes. Experiments used the microscale CFF device described in
Section 2.5.1 and were performed as described in Section 2.7.2. Solid line represents
linear fit (r
Typical permeate data from water flux experiments with the microscale CFF
) Data from one membrane channel at different
2 = 0.99)
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Table 5.2 Comparison of calculated membrane resistances from water flux experiments
using microscale crossflow and dead-end filtration devices. Error bar represents one
standard deviation about the mean (n> 3).
Membrane type;
pore size
PVDF
0.45 m
PVDF
0.22 m
Experimental System Rm (x 1010 m-1)
Channel 1 Crossflow 0.9 5.2 ± 0.7
Channel 2 Crossflow 1.0 5.8 ± 0.6
Dead-end filtration 1.2 ± 0.1 4.8 ± 0.2*
*from Section 3.3.1
In contrast to the microscale data, it was found that the larger scale device yields a larger
membrane resistance by approximately one order of magnitude. The Rm of the Pellicon-
2™ Mini (V-screen) was determined to be 5 x 1011 m-1. Membranes of the same type
should normally give similar clean membrane resistances. However, communication
with the membrane manufacturer’s (Millipore) technical support has confirmed that the
PVDF membranes purchased as disc membranes (used for the microscale CFF device)
were the same as the PVDF membranes inside the Pellicon-2™. Three reasons are
thought to cause this difference in Rm: (1) variations in membrane thickness; (2)
variation in membrane porosity; and (3) additional hydraulic resistance being measured
together with the membrane resistance. The manufacturing variations of the membranes
inside the module could result in thickness differences as large as 50% (Millipore
Technical Support). Based on the Kozeny-Carman relationship (Equation 1.11), this
could result in as much as 50% difference in the measured Rm between these membranes.
Considering there are, at least, 10 membranes inside the Pellicon-2™ module (Table
5.1), it is quite possible to achieve such high membrane resistance overall.
A Millipore technical specialist (personal communication) also mentioned that
membranes for the lab-scale Pellicon-2™ system and the bioscience cut discs (used in
the microscale devices) may also have slight differences in the bubble point pressure
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(PB). The membranes in the lab-scale module have higher PB than the cut discs (28 psi
as opposed to 22 psi). The bubble point test is normally used to measure the maximum
pore size in a given membrane (Mulder, 1996). The test measures the pressure required
to blow air through a wet membrane. The relationship between this pressure and pore
diameter (d) is given by the Laplace equation in Equation 5.9.


d
cosPB 4
(5.9)
where d is the pore diameter,  the surface tension at the liquid/air interface, and  is
the contact angle. A higher PB means a smaller pore diameter. From previous
membrane resistance calculations, smaller pore diameter gives larger membrane
resistance.
In addition, the difference between the calculated Rm values could be due to the lab-scale
module containing spacer screens whereas the channels in the microscale CFF device do
not have these. Membrane resistance for a similar module, Pellicon™ (Durapore 0.45
m PVDF), has been reported to be 4.0 x 1011 m-1 (Hooper et al. 1998), a value close to
the one obtained in this study for Pellicon-2™ which they have reported to be affected
by the additional hydraulic resistance caused by the spacer screens.
5.4.3 Steady state flux determination
Based on the results obtained in Section 5.4.2 the microscale CFF device provides
reproducible and comparable process data for the two membrane channels in water flux
experiments. Before the device could be used to evaluate filtration performance of
cellular suspensions, a comparable crossflow filtration methodology had to be first
established to determine steady state flux for each of the lab-scale and microscale
systems. The steady state flux, Jss, is usually obtained by running crossflow
microfiltration experiments at constant PTM conditions. Jss is a key membrane filtration
performance criterion as it provides information required for scaling-up filtration
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processes (Bacchin et al., 2006). Information on the required membrane area is
important in evaluating the capital and operating costs required in setting up a filtration
process.
For the lab-scale Pellicon-2™ system, flux determination follows established
experimental procedures as permeate samples can be collected at defined time intervals
throughout the filtration run. Figure 5.5 shows an example of permeate flow rate versus
time data obtained in this larger scale system. It shows that a steady state permeate flow
is achieved within one hour of operation.
With the microscale CFF assembly the permeate receiver is inside the Tecan vacuum
block (Figure 5.3) the amount of permeate can only be measured upon termination of
the filtration run. As a result, permeate measurements were made over several sequential
filtration runs which terminated at different times. Each measurement thus represents the
cumulative amount of permeate collected from the start of the filtration run. In this way
the flux measurements do not represent the “true” instantaneous flux at a specific
filtration time. In order to measure the “real” flux, the difference between permeate
values for two different filtration times need to be used.
To analyse the microscale data, the cumulative permeate values are first plotted for each
filtration time. The resulting plot resembles a logarithmic function showing a steep rise
in cumulative permeate during the initial stages of filtration followed by a slower rate
towards the end. An example of this plot is shown in Figure 5.6. This type of plot
showing normalised permeate values with respect to time can then be used to determine
the actual steady state flux. This steady state condition is represented by the slope of the
portion of this plot after the steep rise in cumulative permeate. This linear part (usually
after t = 0.2 h) represents where the change in permeate with time is already constant,
hence demonstrating a steady state flux.
Figure 5.5
experiments with Baker’s yeast and BSA.
= 0.1 m
Section 2.7.2.
then calculated using Equation 2.2. Inset shows in detail the
the first hour of operation.
Typical permeate flowrate data from lab
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Data points were calculated using Equation 2.3. The steady state flux is
m PVDF membrane. Experiments were performed as described in
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Table 5.3 shows how the microfiltration data points in Figure 5.6 were derived. The
steady state flux is calculated from Equation 5.10. The slope in this equation is the slope
of the line as indicated in the inset of Figure 5.6. The linearity was judged by a value of
the regression coefficient, r2 > 0.95. Figure 5.6 shows the regression analysis of the data
set from Channel 1. From the slope data, Jss is 21.6 L m-2 h-1.
aveTMss PslopeJ . (5.10)
The water flux line in Figure 5.6 was estimated using Equation 5.11 and using the Rm
value given in Table 5.1 for 0.22 m PVDF membrane.
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For the Baker’s yeast/BSA feed stream, Figure 5.6 shows that the permeate flow almost
instantaneously deviates from the water flux line (dashed line). This type of filtration
behaviour is an indication that the resistance could be due to surface or pore adsorption
building up at the onset of the filtration run in addition to the membrane resistance
(Field et al., 1995). The cumulative permeate flow over time quickly slowed down. In
general, steady state fluxes were achieved in less than thirty minutes in the crossflow
microfiltration experiments in this work.
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Table 5.3 Sample calculation for the microscale microfiltration data points plotted in Figure 5.6. Data is shown for the final three points in the figure as
indicated. For each filtration time [A], the feed [f] and permeate [p] pressures were measured. The PTM [B] were then calculated. At each filtration time [A],
the amount of permeate [E] is calculated by subtracting the weight of the receiver [C] from the measured weight of permeate+receiver [D]. The mass of
permeate is converted to volume by dividing with the permeate density [G]. The correction factor [H] is applied to calculate the normalised permeate [J] to
account for flow differences due to differences in temperature [F].
Filtration
time (h)
Feed pressure
(kPa)
Permeate
pressure
(kPa)
PTM (kPa)
p
rfB 
Permeate +
receiver (g)
Permeate (g)
CDE 
Permeate
temperature
(oC) [F]
Correction
factor
Normalised
permeate
(L kPa-1 m2)
IB
H
G
E
J














1000
[A] [f] [p] [B] [D] [E] [F] [H] [J]
0.169 5.3 19.6 22.2 95.6 17.1 19.5 1.138 85
0.335 5.3 19.7 22.3 99.6 21.1 19.8 1.130 103
0.502 5.2 19.7 22.3 102.8 24.3 20.4 1.114 118
Retentate
pressure [r] ---
Receiver (g)
[C]
78.5
Permeate
density,(g mL-1)
[G]
1.0 Am, (m
2)
[I] 0.001
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5.4.4 Characterisation of the fluid dynamics in the membrane systems
As mentioned previously in Section 5.4.1, maintaining the same fluid dynamic
conditions in different membrane systems is crucial to achieve consistent crossflow
microfiltration performance across the scales. In this work, this was achieved by
appropriately designing the geometry of the microscale CFF device to ensure that the
axial pressure drop (Paxial) and the wall shear rate (wall) were similar to those typical
of the larger scale Pellicon-2™ system. This section illustrates the establishment of the
comparable fluid dynamics between the crossflow microfiltration devices at the two
different scales.
The wall obtained during a crossflow microfiltration experiment can be estimated using
Equation 5.12.
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If the Hagen-Poiseuille equation for horizontal flow is used in Equation 5.12 for Q,
Equation 5.8 is obtained. The effective channel height (h) can then be determined for
each membrane system. In the Pellicon-2™ system, the effective channel height was
calculated using Equation 5.13, derived from the momentum balance (Appendix 2.2)
along the membrane module, under the assumptions of laminar flow, full rectangular
channels and by taking into account the vertical upward direction of the flow.
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In Equation 5.13, C is a constant, and is equal to 12 for Millipore devices (Technical
document from Millipore Technical Support), Q is the feed volumetric flowrate, g is the
~ 169 ~
acceleration due to gravity, F and F are the viscosity and density of the process fluid,
respectively.
In the microscale CFF device the effective channel height can be determined by
Equation 5.14, which takes into account the main horizontal flow direction in the
device.
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These equations were initially derived for single-phase flow in non-porous walls, and
only represent a simplification of the complex multi-phase flow phenomena occurring
in membrane processes in porous walls. Therefore, it is emphasized that Equations 5.13
and 5.14 can only be used to provide estimates of wall shear rate (wall) and not actual
values.
It is noteworthy that the Pellicon-2™ system was operated at crossflow rates less than
or equal to 135 L h-1 which is within the range of recommended by the manufacturer
(30 – 210 L h-1). Actual flowrates depend on the feed properties such as cell
concentration and viscosity. Typical crossflow flowrates for whole cell filtration are 30-
70 L h-1 (Millipore data sheets). These recommended crossflow rates correspond to
typical shear rates between 3000 - 10000 s-1 calculated according to Equations 5.12 and
5.13. Initial experiments with Baker’s yeast suspension showed that experimental shear
rates achieved were between 3900-9900 s-1. During crossflow microfiltration of Baker’s
yeast in the Pellicon-2™, it was observed that neither the crossflow rate nor the PTM
significantly changed the measured permeate flux. This is illustrated in Figure 5.7.
Although in the lab-scale system the shear rate is coupled with the PTM, the
corresponding increase in PTM for an increase in shear rate of 7000 s-1 is just 70 mbar.
To further increase the PTM, the back pressure needs to be increased.
Figure 5.7
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For the microscale CFF device, in order to have comparable process conditions with the
larger scale system, it was important to also determine the range of crossflow rates that
could provide similar shear rates at the small scale. The effect of crossflow rate using
the microscale device was investigated for a range of transmembrane pressures and the
results are presented in Table 5.4. wall is 3000, 7000 and 13000 s-1 at crossflow rates 3,
8 and 14 L h-1, respectively. These shear rates are similar to the range obtained in the
Pellicon-2™ system. However, as Table 5.4 indicates, the microscale device should be
operated at crossflow rates larger than 3 L h-1 since only the faster crossflow rates (8
and 14 L h-1) show a similar trend with the lab-scale system where there are no
significant changes in the permeate flux across the range of PTM used. These data are
plotted together with the lab-scale data in Figure 5.7.
Table 5.4 Effects of PTM and crossflow rate using the microscale CFF device (Am =
0.001 m2) on permeate flux during crossflow microfiltration (0.22 m PVDF) of
Baker’s yeast with BSA in phosphate buffer.
Crossflow
rate (L h-1)
Nominal
PTM
(kPa)
Jss
(L m-2- h-1)
Coefficient
of
Variation
Variation
between Jss
values
Variation
between Jss
values
3 20 7 9
Statistically
different
(p<0.05)
3 40 18 21
3 60 2 28
8 20 21 9 Not
statistically
different
(p>0.05)
Not
statistically
different
(p>0.05)
8 50 18 20
8 70 18 0
14 20 24 3 Not
statistically
different
(p>0.05)
14 50 23 12
14 70 20 21
~ 172 ~
Section 5.4.2 established that the microscale device has Paxial similar to that of the lab-
scale module during water flux experiments. In this section, the examination of the fluid
flow characteristics between the two crossflow microfiltration devices at different
scales have shown that for actual microfiltration experiments using Baker’s yeast/BSA,
the microscale CFF device has to be operated at shear rates > 7000 s-1 (corresponding
to > 8 L h-1) to match the microfiltration performance of the lab-scale module. On this
basis, the microscale CFF device is suggested to be operated at crossflow rates > 8 L h-1
in order to confidently predict the microfiltration performance of the lab-scale module
at the same PTM.
5.4.5 Scale comparison of the crossflow microfiltration of Baker’s yeast
From the characterisation of the membrane systems in Section 5.4.4, comparison of
filtration performance between the two systems can now be made on the basis of
matched PTM and optimal range of operational shear rates for each of the membrane
systems (i.e. for the Pellicon-2TM and microscale CFF device, shear rates of at least
3000 s-1 and 7000 s-1, respectively). Microfiltration data using Baker’s yeast and BSA
obtained from experiments with matched operating conditions at the lab- and
microscale will now be discussed in this section.
The crossflow microfiltration of Baker’s yeast cells achieved a high degree of
clarification, resulting in a solids rejection coefficient of one in all the experiments. As
shown in Figure 5.7, data from the microscale CFF device are in good agreement with
data obtained from the lab-scale membrane module. At both scales, PTM did not affect
the normalised permeate flux values. The observed independence of the crossflow
microfiltration performance of Baker’s yeast on PTM is not in agreement with the
commonly accepted notion of proportional flux increase with PTM (Bacchin et al.,
2006). Previous studies have shown that flux increases with increasing transmembrane
pressures and crossflow rates (and hence, crossflow velocity). However, most of the
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studies were performed at low pressures, low feed concentration and high velocity
(Cheryan, 1998; Bacchin et al., 2006). Any deviation from these conditions results in
pressure-independent fluxes, even at quite low pressures (Cheryan, 1998). In this
regard, it is important to note that the feedstocks used in this study is characterised by
high cell concentrations (in this work, about 30 g L-1 dry cell weight, corresponding to
100 g L-1 wet weight) and by the presence of macromolecules (soluble BSA).
The measured fluxes also appear to be independent of crossflow rates at both scales.
This observation could be explained by the module design where laminar flow
conditions occur for both the larger-scale Pellicon-2™ system and the microscale CFF
device. Laminar flow systems such as these are reported to not benefit by an increase of
crossflow velocity as much as turbulent flow systems (Cheryan, 1998). This further
suggests the resulting hydrodynamic conditions during crossflow microfiltration at
these flow rates may not be significantly different in each device thus producing similar
filtration performance.
Overall, the results obtained clearly indicate that the microscale CFF operation is a
good mimic of the Pellicon-2™ system, as shown by the permeation flux results
obtained for Baker’s yeast. The flux data from the microscale is consistent with the
data obtained from the larger scale module to within ± 10%. This is considered to be an
adequate simulation of the flux data at larger scale considering that variation of
manufactured membranes could result to 30% difference in filtration performance for
small filters (Roush and Lu, 2008).
Note that the presence of screens in the Pellicon module was ignored in this work.
Spacer screens were reported to improve fluxes in ultrafiltration (Da Costa et al., 1991).
However, it was found that for microfiltration, the presence of flow barriers, such as the
spacer screens, have no beneficial impact on steady state fluxes (Kromkamp et al.,
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2005). This was also observed in the outcome of this work wherein the microscale
device consistently produced similar microfiltration performance as the Pellicon-2™
even if the microscale CFF device had no screens. Table 5.5 shows a summary of
attributes of crossflow microfiltration modules for both scales.
Table 5.5 Summary of attributes of the Pellicon-2™ Mini crossflow filtration system
(lab-scale) and the novel microscale crossflow filtration device.
Attributes Lab-scale Microscale
Turbulence promoters Present
(suspended screens)
None
(open channel)
PTMP and Paxial Coupled Not coupled
Pressure driving force Positive (gauge) Negative (gauge)
Membrane orientation Vertical Horizontal
Membrane area A 0.01A
Channel width B 0.007B
Nominal channel (path) length C 0.9C
Nominal channel height D 4D
Membrane resistance E 0.1E
Process volume requirements F 0.1F
Typical axial pressure drop
(kPa)
< 30 < 30
Shear rates (s-1) 3,000-10,000 4,000-10,000
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5.5 Conclusions
In this chapter, the design (Table 5.1 and Figure 5.3), characterisation (Sections 5.4.2
and 5.4.4) and testing of a novel microscale crossflow filtration device for the
automated evaluation of the primary recovery of biological process feeds, in this case, a
model feed of Baker’s yeast in phosphate buffer has been demonstrated. An associated
microscale crossflow filtration methodology was established for operation of this novel
device on a TecanTM robotic platform (Table 5.3 and Figure 5.6). Preliminary
evaluation showed a high level of consistency between the two channels of the device
and reproducibility between filtration runs (Table 5.2). This has allowed parallel
experimentation in investigating the microfiltration performance of the process feed. A
comparison of the crossflow microfiltration performance at two scales illustrates that
the device mimics the performance of the Pellicon-2™ membrane module in terms of
hydrodynamics and transmembrane pressure (Section 5.4.4) and as a result achieved
comparable steady state permeate flux values (Figure 5.7). This was achieved with a
microscale device which has a 100-fold smaller membrane area and obtained a 10-fold
reduction in process feed volumes. The next chapter will demonstrate the application of
the microscale CFF device in investigating bioprocess options for the primary recovery
of a complex biological feedstock E. coli Fab’.
______________________
A. Craig is acknowledged for the fabrication of the microscale CFF device that was designed in this
work.
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6. Microscale Technology Evaluation
of the Impact of DNA Hydrolysis
on Primary Recovery Operations‡
6.1 Introduction and aim
The design and development of a novel microscale crossflow filtration (CFF) device as
well as the associated microscale methodologies were shown in Chapter 5. Initial
evaluation of this device showed its capability to mimic the crossflow operation of a
larger scale filtration module, specifically for the determination of steady state permeate
flux of a model feed system (Figure 5.7). The creation of this device complemented the
microscale dead-end filtration strategies established in Chapter 3 and their application
in an automated manner demonstrated in Chapter 4. This final results chapter will now
illustrate the application of the microscale CFF device to bioprocess development with
a particular focus on the primary recovery by crossflow microfiltration of antibody Fab’
fragments produced in E. coli.
6.1.1 Background microscale information
Microscale data in Chapters 3 and 4 have shown that dead-end microfiltration can
provide high quality process stream of antibody Fab’ fragments. The permeate has no
detectable particulates and the data demonstrated that the filtration process has a certain
level of selectivity towards Fab’ fragments over other host cell proteins enabling
primary purification (Section 4.3).
__________________________
‡ Majority of the results presented in this chapter is to be submitted for publication as: Rayat, ACME et al. (2011).
Impact of DNA Hydrolysis in the Primary Recovery of Antibody Fab’ Fragments from an Industrial E. coli Strain.
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However, fluxes achieved were very low (<10 L m-2 h-1) even with the use of the best
Fab’ release method (thermo-chemical extraction). The flux of the homogenised sample
is twice as small as the thermo-chemically extracted E.coli Fab’ suspension (Section
4.3.1). A major reason for this is the large hydraulic resistance of the filter cake which
formed during the dead-end microfiltration process.
The problem of cake formation can be avoided by running the filtration process in
crossflow mode. In this regard, it is expected that crossflow microfiltration will provide
improved fluxes due to reduced cake formation. It is also expected that CFF will handle
higher cell concentrations of suspensions than dead-end microfiltration. Crossflow
microfiltration is therefore employed in this chapter as an alternative to dead-end
filtration and centrifugation as means for primary clarification and recovery of antibody
Fab’ fragments.
6.1.2 Selection of Fab’ extraction method
Section 4.3.1 illustrated that the method of cell disruption influences the microfiltration
performance of E. coli Fab’ suspensions. In this chapter, the chosen cell disruption
method is homogenisation for two reasons. Firstly, homogenisation is widely used as a
cell disruption method at process scale, including in the isolation of antibody Fab’
fragments (Balasundaram et al., 2009a; Spitali, 2009). Secondly, given the poor
performance of the E. coli homogenate in dead-end filtration (Section 4.3.1), it is
thought that the benefits of using CFF will be best demonstrated when using difficult-
to-filter feedstocks such as the E. coli homogenate.
However, a known disadvantage of homogenisation as a cell disruption method is the
concurrent release of chromosomal DNA along with the host organism’s cellular
proteins and the desired recombinant product. The release of chromosomal DNA during
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this process results in an increase of the viscosity of the process stream; the higher
viscosity consequently impacts the subsequent processing steps (Boynton et al., 1999).
6.1.3 DNA hydrolysis for process feedstock conditioning
Viscosity is an important rheological parameter which affects unit operations such as
centrifugation and filtration (Perry and Green, 1997). In a study by Balasundaram and
co-workers (2009b), it was shown that a more efficient centrifugation process may
follow after a reduction in viscosity of the feed stream. In membrane filtration,
reduction of viscosity of the feed stream affects the process in two ways. First, the
reduced viscosity of the process stream across a filtration channel will result in a higher
Reynolds number (Equation 5.4) leading to an increased turbulence of the process
stream and also a higher wall shear rate (Equation 5.8). The result is a hydrodynamic
situation wherein cell deposition could be limited, thus reducing cake formation leading
to improved permeate flux. In addition, a reduced viscosity of the feed stream may
result in the reduction of viscosity of the permeate stream, in which case the flow
through the membrane is enhanced, thus also increasing the flux. As shown in Equation
1.4, the permeate flux is inversely proportional with permeate viscosity.
DNA hydrolysis has been suggested to alleviate the effect of increasing viscosity due to
the release of chromosomal DNA during homogenisation. DNA digestion could serve
as a feed pre-conditioning step for unit operations after homogenisation. Auto-
hydrolysis of host DNA can be achieved by endogenous nucleases such as the co-
expression of Staphylococcal nuclease (Boynton et al., 1999; Cooke et al., 2003;
Balasundaram et al., 2009b) or by the addition of exogenous nucleases (e.g.
Benzonase® nuclease) to hydrolyse chromosomal DNA (Lee et al., 2004). The
degradation of these nucleic acids improved unit operations such as centrifugation
(Balasundaram et al., 2009b) and crossflow microfiltration (Lee et al., 2004).
Additionally, the benefit extends to the regulatory point of view as DNA hydrolysis
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prevents the inclusion of heterologous genetic sequences in biopharmaceutical
products, the presence of which could introduce undesirable immune responses (Cooke
et al., 2003).
6.1.4 Aim and specific objectives
Given the aforementioned background, this chapter aims to demonstrate the utility of
the novel microscale CFF device, described in Chapter 5, in informing bioprocessing
options by predicting larger scale performance using an industrially relevant E. coli
Fab’ feedstock. In particular, the impact of DNA hydrolysis by using either exogenous
(Benzonase®) or endogenous (Staphyloccocal) nucleases on crossflow microfiltration
processes will be investigated. Figure 6.1 illustrates the context of this study in the
development of a bioprocess route for the primary recovery of antibody Fab’ fragments.
Specifically, the objectives of this final chapter are to:
 investigate the impact of DNA hydrolysis on the characteristics of the
bioprocess suspension (viscosity, Fab’ content, purity);
 to investigate the impact of DNA hydrolysis on crossflow microfiltration
performance criteria such as: the steady state permeate flux, Fab’ product
transmission and purity of the desired process stream;
 to use the information from the microscale CFF experiments in order to
establish the best process condition for E. coli Fab’ CFF; and
 to compare the large-scale primary recovery operations of CFF and
centrifugation as bioprocess options.
Figure 6.1
for the investigation
fragments. (Image credit: Pilot scale centrifuge from www.pneumaticscale.com)
Application of microscale bioprocessing platform for membrane filtration
of different options for the primary recovery of antibody Fab’
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6.2 Experimental approach
6.2.1 E. coli strains and fermentation
Two E. coli expression systems were used. One is the control strain (described in
Section 2.1) which produces periplasmic antibody Fab’ fragments only, hereafter
referred to as Control. The other is a cell engineered E. coli strain which co-expresses
Staphylococcal nuclease together with the Fab’ fragments, hereafter referred to as
SNase. These two strains undergo a series of processing steps as illustrated in Figures
6.1 and 6.2.
The plasmid construction and cell engineering of E.coli Fab’ to co-produce
Staphylococcal nuclease has been reported by Balasundaram and co-workers (2009a).
An IncQ plasmid was used to express the protein Staphylococcal nuclease B (nucB)
with the OmpA signal sequence added for secretion into the periplasm. In this way, the
nuclease can only access the chromosomal DNA in the cytoplasm once cell disruption
procedure has taken place (Balasundaram et al., 2009b). Cell cultivation and harvest
was the same for both strains and was performed according to Section 2.2.2 and 2.2.4,
respectively. When cell pastes were used instead of freshly harvested broth, freeze-
thawing procedures were performed according to Section 2.2.5.
6.2.2 Fab’ extraction and DNA digestion
The Fab’ fragments were extracted from the cells by high pressure homogenisation as
described in Section 2.3.1 or Section 2.3.2. In this sudy, the extraction buffer used was
10 mM sodium phosphate at pH 7.0. After homogenisation, the cells were either used
immediately for the Fab’ recovery (Section 6.2.3) and analytic steps (Section 6.2.4) or
routinely stored overnight at 4oC until further use.
Figure 6.2
as an option for primary recovery of antibody Fab’ fragments in
Bioprocesss flowsheet used in the study of crossflow microfiltration process
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E. coli.
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For the cell homogenates that are to be processed immediately, Benzonase® nuclease
(Merck KGaA, Darmstadt, Germany) was added to some of the homogenates from the
control strain (see Figure 6.2). Benzonase® nuclease (> 90% (w/w) purity, 250 unit
uL-1) came in buffered glycerol solution containing 20 mM Tris HCl, pH 8.0, 2 mM
MgCl2, and 20 mM NaCl. The amount of Benzonase® added was varied up to a
maximum of 17.5 L Benzonase® per mgDCW. These samples are referred to as BNase.
Alternatively, 10 mM CaCl2 was added to the SNase homogenates. The cell
homogenates (Control, BNase, and SNase) were incubated for two hours at room
temperature and then used for Fab’ recovery experiments. Table 6.1 describes the
various feedstocks prepared from these cell homogenates.
6.2.3 Fab’ recovery
6.2.3.1 Microscale dead-end microfiltration
Microscale dead-end microfiltration experiments were performed, according to Section
3.3.3, using the custom filter plate described previously in Section 2.5.1. The type of
membrane material used was Durapore poly(vinylidene fluoride) PVDF membranes
(Millipore, Hertfordshire, UK) with pore size of 0.22 m.
Table 6.1 Descriptions of the different bioprocess feedstocks used in this chapter.
Name Description
Whole broth E. coli cell suspension from fermentation harvest
Control Homogenised E. coli (expressing periplasmic Fab only)
#X BNase
e.g.10X BNase
Homogenised E. coli (expressing periplasmic Fab’ only)
plus10 times X Benzonase®.
X= 0.5 L Benzonase® per mgDCW
SNase Homogenised E. coli (expressing periplasmic Fab’ and co-
expressed Staphylococcal nuclease)
Fresh Refers to cells or cell pastes which were freshly harvested fromfermentation broth
Freeze-thawed Refers to cells or cell pastes which were stored frozen in -20
oC
after fermentation harvest
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6.2.3.2 Crossflow microfiltration
Laboratory scale crossflow microfiltration experiments were performed using a
Millipore Proflux™ M12™ Tangential Filtration System (Section 2.6.1) and operated
according to Section 2.6.2. Microscale crossflow microfiltration experiments were
performed using the novel device previously described in Chapter 5. Microscale CFF
was performed according to the methodology given in Section 5.4.3.
6.2.3.3 Pilot scale centrifugation
Fab’ fragments were recovered from the supernatant of a centrifugation process using a
pilot scale tubular bowl centrifuge (CARR™ P6™ Powerfuge System, Pneumatic Scale
Corp., Clearwater, FL, USA). The process runs at a feed rate of 30 L h-1 at 15,000
RPM.
6.2.4 Characterisation of process streams
Before and after each Fab’ recovery step (Section 6.2.3), samples were collected for
total protein and Fab’ quantification by spectrophotometry (Section 2.9.3) and HPLC
(Section 2.9.4), respectively. Samples were also collected for DNA gel analysis
(Section 2.9.7), DNA quantification by spectrophotometry (Section 2.9.8), and viscosity
measurement (Section 2.10.2).
Statistical analysis was done using Microsoft Office Excel™ Analysis Toolpak™
(Anova: single factor) and where necessary, Design Expert 7 (Stat-Ease, MN, USA)
was used to analyse multiple factor interactions.
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6.3 Results and discussion
6.3.1 DNA hydrolysis in homogenised E. coli strains
6.3.1.1 Effect of nuclease digestion on DNA fragments
The hydrolytic action of Benzonase® nucleases or Staphylococcal nucleases on the
DNA in homogenised E. coli cell suspensions is shown in Figure 6.3. The sizes of
chromosomal DNA fragments in the Control are mostly between 250 to 2000 base pairs
(bp) as indicated by the greater intensity of the gel bands within these DNA molecular
weights. For the 35X BNase and SNase samples, theDNA sizes are less than 250 bp.
The wells in each lane also appear to contain some DNA samples. The samples in the
wells are assumed to be intact DNA with sizes much greater than 10 kbp. Boynton et al.
(1999) have indicated the samples left in the wells of their DNA agarose gel are the
undigested chromosomal DNA with sizes of 23 kbp.
The corresponding DNA concentrations by spectrophotometry are shown on top of each
lane in Figure 6.3. The measured DNA concentrations are decreasing with respect to
the amount of Benzonase® added. SNase has the smallest measured DNA content. It is
expected, from material balance, that DNA quantification will show similar
concentrations of DNA albeit with smaller fragments due to nuclease digestion of DNA
in the samples. However, based on the quantification performed here, there seems to be
a loss of DNA material as shown by the decreasing concentration of measured DNA.
One explanation of the apparent loss of DNA is that smaller fragments of DNA may not
have been efficiently recovered during DNA analysis. It is thought that it is during the
alcohol precipitation step that the smaller fragments of DNA are lost. Since this step is
known to recover nucleic acids larger than 100 nucleotides (equivalent to 50 bp) (Strege
and Lagu, 1991). Also, during this process, the smaller fragments could take a longer
~ 186 ~
time to precipitate. Note that the same incubation time was used in the precipitation step
during DNA recovery from the samples (Section 2.9.6).
6.3.1.2 Effect of process shear on DNA fragments
To some extent, the number of homogenisation passes also affected the DNA fragment
sizes. The DNA gel (not shown) of the control homogenate after the first pass shows a
markedly denser smearing above 2000 bp, corresponding to larger DNA fragments, in
comparison with the Control in Figure 6.3 which went through 2-passes of
homogenisation. This observation conforms to the widely known observation that
genomic DNA degrades due to shear forces during processing.
6.3.1.3 Influence of cell age on DNA hydrolysis
The cell homogenates described above, except for SNase, are from freshly harvested
material. In a research setting, it is not unusual to freeze cells for storage after
fermentation harvest. For example, experiments in Chapters 3 and 4 used cell pastes
which were previously frozen and stored at -20oC. However, a freeze-thawing process
could alter the physico-chemical properties of the cells which in turn could also impact
process performance. In comparison with fresh Control homogenates, freeze-thawed
Control homogenate samples have smaller fragments of DNA with the intensity of
the DNA gel suggesting molecular weights between 250 and 1000 bp (Appendix 3.1
Lanes 2 and 3). In all cases, some traces of intact DNA can be seen in the wells of the
DNA gel although it is obvious in the DNA gel using the freeze-thawed control samples
(Appendix 3.1) that DNA digestion by Benzonase® treatment clearly reduces the
amount of the DNA fragments; this is indicated by the observed reduction in intensity
of the well as Benzonase® concentration increases.
Figure 6.3
E. coli
of 30% (w/w). Homogenisation performed according to Section 2.3.1. DNA hydrolysis
according to Section 6.3.1.
Agarose gel
of each lane represents the quantified DNA concentration (
spectrophotometry (Section 2.9.8.). N.M.
Agarose gel showing the hydrolysis of chromosomal DNAs in homogenised
cells as described in Table 6.1. Fresh cells were used with wet cell concentration
electrophoresis performed according to Section 2.9.7. The number on top
BP
~
DNA sample preparation according to Section 2.9.6.
–
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6.3.1.4 Influence of cell concentration on DNA hydrolysis
Compared to the above mentioned freeze-thawed Control homogenate which has 30%
wet cell weight, a freeze-thawed Control homogenate with 15% wet cell weight has
DNA fragments between 250 – 750 bp. No distinct differences can be seen between
samples with or without treatment with Benzonase® at the lower cell concentration
(Appendix 3.2).
6.3.2 Impact of DNA hydrolysis on viscosity of E. coli homogenates
6.3.2.1 Effect of nuclease digestion on viscosity
The purpose of performing DNA hydrolysis on the cell homogenates is to achieve a
reduction of viscosity in the samples. Figure 6.4 shows that there is a corresponding
decrease in viscosity as DNA is progressively hydrolysed as indicated in Figure 6.3.
Figure 6.4 also shows the viscosity of whole E.coli broth which is almost half the
viscosity of the Control homogenate. This is a confirmation that the release of DNA in
the Control homogenate is the cause of the rise in viscosity.
Each viscosity measurement presented in Figure 6.4 is the slope of a plot of shear
stress versus shear rate (see example in Appendix 3.3). This type of viscosity
determination is acceptable since the samples exhibit the properties of a Newtonian
fluid in the shear rates achieved in the unit operations used in this work. A Newtonian
fluid is one having a linear relationship between the shear stress and the shear rate
(Perry and Green, 1997). The constant of proportionality is the absolute viscosity of the
fluid. Newtonian fluids have apparent viscosities which do not change with the shear
rate. Figure 6.5 confirms that in all samples, the apparent viscosity is constant at shear
rates > 50 s-1. Calculated shear rates under actual crossflow filtration conditions in this
chapter exceeds 1000 s-1.
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6.3.2.2 Influence of cell age
Figure 6.4 also showed that freeze-thawed samples have lower viscosity than fresh
samples. This corresponds to the smaller size of DNA fragments for the freeze-thawed
cells shown in Section 6.3.1. However, the ratio of viscosities is the same between the
Control and the BNase samples with lower Benzonase® concentration (< 30X) for both
the fresh and freeze-thawed samples. This implies that further reduction of the viscosity
of these samples is a result of freeze-thawing. The relative viscosity of the hydrolysed
samples with respect to the viscosity of the Control appears to have a linear relationship
with the concentration of Benzonase® as shown in Figure 6.6. In this plot, the relative
viscosities of the freeze-thawed 30X BNase and SNase samples were calculated with
respected to the fresh Control.
Freeze-thawing does not seem to have an effect on the viscosity of samples with the
highest concentration of Benzonase as well as the sample with Staphylococcal nuclease.
This is illustrated by the similar viscosities of fresh and freeze-thawed samples for 30X
BNase and SNase. This may be due to these samples having an almost complete DNA
hydrolysis, such that no further hydrolysis is caused by the freeze-thaw process. In
practical terms, the linear relationship shown in Figure 6.6 would be useful in
extrapolating the extent of viscosity reductions for higher concentrations of Benzonase®
in homogenised E. coli Fab’ suspensions.
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6.3.2.3 Influence of cell concentration
The effect of cell concentration on the viscosity of homogenised E. coli cells is shown
in Table 6.2. The table shows that a higher cell concentration (in this case, 50%
increase) also increases the suspension viscosity. Moreover, there seems to be little
effect of DNA hydrolysis on viscosity at the lower cell concentration since the
suspension viscosities are within a small range of 0.92-1.07 mPa.s, similar to the
viscosity of water at ambient temperature. At the higher cell concentration, the effect of
DNA hydrolysis is more pronounced. The differences in viscosities between these two
cell concentrations are much less than for the cell homogenates with larger
concentrations of Benzonase® which suggests that DNA digestion at the higher
concentrations of Benzonase® is efficiently reducing the viscosity of the samples.
Table 6.2 Effect of a two-fold increase in cell concentration on viscosity of
homogenised E. coli from freeze-thawed cell paste. Experiments performed according
to Section 2.10.2. Feedstocks as described in Table 6.1.
Feedstock 15% (mPa.s) % Difference
Control 1.07 60
3X BNase 0.96 76
6X BNase 0.94 59
9X BNase 0.92 56
12X BNase 1.02 43
15X BNase 0.92 37
30X BNase 0.93 33
100Difference%
15%
15%30% 



 ;
(15% is absolute viscosity at 15% wet weight (w/w or 45 gDCW L-1 )
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6.3.3 Impact of DNA hydrolysis on Fab’ and protein release
6.3.3.1 Influence of DNA digestion on Fab’ release
It is important that the addition of exogenous Benzonase® nucleases should not affect
the extracted Fab’. Analysis of the Fab’ content of disrupted E. coli suspensions (30%
wet cell weight) which were freshly harvested from fermentation and immediately
followed by homogenisation show that the addition of Benzonase® does not affect the
Fab’ content. On average, Fab’ content is 986 ± 64 g mL-1 for the Control and BNase
samples.
6.3.3.2 Influence of cell age on Fab’ release
Benzonase® addition also did not affect the Fab’ content of the homogenised
suspensions from freeze-thawed cell paste having 15% wet cell weight. However, the
Fab’ content from these samples, which are on average 915 ± 73 g mL-1, is much
higher than the expected Fab’ content of about 500 g mL-1 (based on the amount of
Fab’ from the sample above with 30% wet cell weight). In a separate study using
freeze-thawed samples containing 45% wet cell weight, the corresponding Fab’ content
is 2800 g mL-1 (unpublished data, Bangaru Balasundaram, UCL). These two freeze-
thawed samples have about 21 mg gDCW-1 of Fab’ content while the homogenised
samples from fresh cells have a Fab’ content of only about 11 mg gDCW-1.
At first glance, it appears that the freeze-thaw process caused an increase in Fab’
content. However, considering that homogenisation is a very efficient method for
disrupting the cells it is logically expected that the method will be efficient in releasing
the periplasmic antibody Fab’ fragments. Besides, the freeze-thawing process occurred
before cell disruption and so its physical effects should only be minimal. The difference
in Fab’ content is therefore attributed to the difference in “available” Fab’ in the
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solution, unbound from the cell debris. Antibody Fab’ fragments could have interacted
with the cell debris causing some of the Fab’ fragments to be left bound to the debris
and therefore not recovered in the clarified liquid during solid-liquid separation. This
has also been observed during the recovery of Fab’ by centrifugation. Bowering (2004)
reported that Fab’ fragments preferentially partition to the heavy phase, incurring losses
to the supernatant. The cells which were freeze-thawed will have different cell surface
properties than the fresh cells. From the obtained result, it appears that the acquired
surface properties of the freeze-thawed cells caused the diminished Fab’-cell debris
interaction, leaving more Fab’ available in solution for primary recovery. This result,
together with the lower viscosity found in Section 6.3.2.2, gives freeze-thawing an
advantage over the use of freshly harvested cells. This benefit of the freeze-thaw
process, specifically in increasing the product yield, has been exploited in the
manufacture of recombinant antibodies (Sehdev and Spitali, 2006).
6.3.3.3 Total protein content of E. coli homogenates
The total soluble protein content of the homogenised samples represents the level of
host cell protein (HCP) contaminants in the E. coli Fab’ suspensions. Analysis of the
HCP levels (data not shown) demonstrated that the Control homogenates have
significantly larger total protein content (18% larger) compared with BNase samples.
Control homogenates from freeze-thawed cells have lower measured total soluble
protein content (300 mg gDCW-1) compared to the Control homogenates from freshly
harvested cells (491 mg gDCW-1). The freeze-thawing process has been reported to cause
damage in some proteins, particularly for long periods of frozen storage (> 24h), which
resulted in a decrease in measured protein content (Bakir and Hamamci, 1997).
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6.3.3.4 Fab’ and HCP content of E. coli with co-expressed Staphylococcal
nuclease
It is important to mention that the Fab’ content from the cell engineered E. coli strain
used in this study (freeze-thawed SNase) is about 80 g mL-1 (wet cell weight of 30%).
This corresponds to a Fab’ content of 0.9 mg gDCW-1 or 23 times smaller than the Fab’
content of the Control homogenates from freeze-thawed cells. It is 12 times smaller
than the Fab’ content of the Control homogenates from fresh cells. Fresh SNase has a
Fab’ content of 40 g mL-1 (Balasundaram et al., 2009b). The total protein content of
the cell engineered strain (SNase) is similar to the Control with less than 4% difference.
If the cell engineered strain is to be used for large-scale production of antibody Fab’
fragments, the Fab’ yield would need to be improved. The freeze-thawing process has
already resulted in a two-fold increase in Fab’ for the SNase sample. The improvement
in Fab’ yield for the SNase sample is important yet it is not the main focus of this work.
Furthermore, Section 6.3.2 demonstrated that freeze-thawed SNase homogenates have
similar rheological properties as fresh SNase. Therefore, the freeze-thawed SNase
homogenates will continue to be used in the subsequent Fab’ recovery operations
demonstrated in the next sections.
6.3.4 Comparison of microscale and large scale CFF performance
In this section, a comparison is made between the microscale and larger scale crossflow
microfiltration performance using the Control and the SNase homogenates. The
performance criteria used in assessing the scale comparison are the permeate flux, Fab’
transmission and total soluble protein transmission. Results are shown in Figure 6.7
with scale translation based on a matched PTM at 22 kPa and on matched shear rates.
The figure clearly shows that the microscale device mimics the performance of the
larger scale module. Percent differences between microscale and large scale values
~ 197 ~
were up to ± 25% for the permeate flux, up to ± 7% for Fab’ transmission, and up to ±
11% for protein transmission. These differences are considered acceptable considering
that membrane differences, particularly evident at microscale, can reach up to 30% due
to lot-to-lot variation (Section 3.3.1).
Having established confidence in the capability of the microscale CFF device to mimic
larger scale performance, the following section will present the results of the microscale
evaluation of the impact of DNA hydrolysis on the crossflow microfiltration
performance of homogenised E. coli cells. Based on the results shown in Sections 6.3.1-
6.3.3, only homogenates from fresh cells (apart from SNase) were used for the
subsequent microscale CFF study. In particular, only the Control, 1X and 10X BNase
samples were used. The 35X BNase was not further used since it is assumed that it will
provide similar process behaviour as the SNase given the similar DNA profiles and
viscosities of these two feedstocks as illustrated in Figure 6.3 and Figure 6.6.
Figure 6.7
feedstocks using the lab
novel microscale CFF device described in Section 5.4.1 (
Control; and (B) SNase, as
according to Section 2.3.1. DNA hydrolysis performed according to Section 6.2.2.
PTM
microscale systems, respectively.
operation was performed according to Section 2.6.2 and microscale CFF operation
according to Section 5.4.3.
Comparison of crossflow microfiltration performance of
is 22 kPa. Crossflow velocities are 80 and 14 L h
-scale Pellicon 2 Mini
~
described in Table 6.1. Homogenisation performed
Membrane use
198 ~
- Millipore TFF System (
d is 0.22
). Feedstocks are: (A)
-1 for the lab
m PVDF. Large
E. coli
) and the
-scale and
-scale CFF
Fab
~ 199 ~
6.3.5 Microscale CFF study of E. coli homogenates: flux behaviour
Filtration studies are performed by operating under constant transmembrane pressure
(PTM) when data is required for scaling-up filtration processes (Bacchin et al., 2006).
The steady state flux which could be measured at constant PTM conditions provides the
membrane area requirement to run a process. The size of the membrane area impacts on
the economics of the filtration process (Shukla and Kandula, 2009).
6.3.5.1 Impact of DNA hydrolysis on flux
The steady state permeate fluxes of the different homogenised feeds are presented in
Figure 6.8. Compared to the flux (< 5 L m-2 h-1) obtained during dead-end
microfiltration of a similar E. coli homogenate (Section 4.3.1.), the fluxes obtained
during crossflow microfiltration are greater than 10 L m-2 h-1. Higher fluxes were
achieved even if the cell concentration used during CFF is almost 3-fold larger than the
one used during dead-end microfiltration.
It can also be observed from Figure 6.8 that the fluxes are similar for all E. coli
homogenates. This result was unexpected since Figure 6.4 clearly shows that samples
with hydrolysed DNA by Benzonase® addition or Staphylococcal nuclease co-
expression have smaller viscosities compared with the Control. The differences in
process stream viscosities were expected to result in some benefit on permeate fluxes
for the hydrolysed feeds where samples with the lower viscosity were expected to have
higher fluxes due to the expected increase in shear rate based on Equation 5.12.
However, a close inspection of the calculated shear rates shows that this is not the case.
The calculated shear rates during microfiltration of the homogenised feeds were very
similar. The calculated Reynolds number also indicate laminar flow regime for all the
process feeds used while the actual measured pressure drops along the membrane path
length were also similar for the feedstocks used (Paxial ~ 10 kPa). Paxial indicates fluid
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velocity within the channels in the microscale CFF device and similar Paxial meant
similar fluid velocities of the samples. These flow indicators (shear rate, Reynolds
numbers, Paxial) establish that similar hydrodynamic conditions were achieved during
the crossflow microfiltration of the different homogenised E. coli samples and could
explain the similarity of the permeate fluxes which were achieved during microscale
CFF. The results confirm the reported limitations of flat sheet membrane systems in
manipulating permeate fluxes in terms of fluid hydrodynamics (Cheryan, 1998). As
mentioned in Section 5.4.5 these types of membrane system generally operate in the
laminar region where increased fluid velocity do not represent a corresponding increase
in permeate flux, particularly at higher cell concentrations.
In their study, Lee et al. (2004) have reported the improved microfiltration (with buffer
exchange) efficiency of inclusion body (IB) extracts with the addition of Benzonase®.
The crossflow microfiltration device used was a ceramic monotube, with pulsed
backwashing employed throughout the diafiltration process. However, in their study,
the hydrolysis was achieved after 12-14 h of incubation in Benzonase® which resulted
in DNA fragments sizes of ~ 500 bp only (compared to the 2 h incubation used here,
with DNA fragments < 2000 bp in the presence of intact chromosomal DNAs, Figure
6.3). Thus, the flux improvement in the work of Lee and co-workers (2004) cannot be
attributed alone to the use of Benzonase®.
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6.3.5.2 Impact of transmembrane pressure on flux
The transmembrane pressure (PTM) maintained during the crossflow microfiltration
experiments in Section 6.3.5.1 was 22 kPa. When the PTM was increased to 70 kPa, the
permeate fluxes of each of the homogenised samples did not significantly change from
the fluxes obtained at the lower PTM. This is similar to the behaviour of a high cell
density Baker’s yeast suspension illustrated in Chapter 5 which was explained as due to
the high concentrations used (30 gDCW L-1 and 90 gDCW L-1, respectively for Baker’s
yeast used in Chapter 5 and E. coli suspensions used in this chapter). At high
concentrations, operating conditions such as PTM and velocity do not significantly
affect the steady state flux (Cheryan, 1998). The same was also shown in the seminal
study by Patel (1987) in which the pressure-independence behaviour was attributed to
concentration polarization effects as well as the low turbulence achieved by the
filtration module.
Equation 6.1 shows a hydrodynamic model developed by Schulz and Ripperger (1989)
which relates the back-transport behaviour with equation of cake filtration theory in
Equation 1.11. One basis of the model is the mass balance of the retained material
(cake) on the membrane. The model assumes the hydraulic resistances of most cakes
are larger than the membrane resistance thus making Rm negligible, and that the rate of
back-transport from the membrane to the bulk stream is proportional to the velocity
gradient on the membrane and also to the layer thickness. It was shown in Section 3.3.6
that the hydraulic resistance of biological filter cakes, including filter cakes of E. coli
Fab’, are significantly larger than published membrane resistances, thus the model is
applicable in this case.
 
BHP
BcTM
ss cD
vcP
J




ΔK l
(6.1)
~ 203 ~
Equation 6.1 is specifically applied to the steady state case and laminar flow. In this
equation, Jss is the steady state flux, K1 is the constant of proportionality for laminar
flow, PTM is the transmembrane pressure, c is the density of the cake layer, cB is the
concentration in the bulk stream, v is the crossflow velocity, P is the viscosity of the
permeate,  is the specific cake resistance, DH is the hydraulic diameter. As shown in
Equation 6.1, Jss is not proportional to PTM or v but rather it is proportional to PTM0.5
and v0.5.
From Equation 6.1 it can be illustrated that for a 2-fold increase in permeate flux, at
least a 4-fold increase in transmembrane pressure is required. Considering that E. coli
cells are compressible, including E. coli homogenates as shown in Section 4.3.3.2., it is
expected that will correspondingly increase with PTM. Given the opposing effects of
PTM and , it is therefore not expected to significantly increase with PTM.
Analysis of the transient flux data (e.g. that of the SNase sample in Appendix 3.4 and
also Figure 5.5 for Baker’s yeast) show how the fluxes of these relatively high cell
density feeds immediately deviate from the expected water flux behaviour at the
beginning of the filtration run. These could mean that membrane adsorption (surface or
pore) takes place quickly since the start of the filtration process and resulted in an
immediate drop in permeation fluxes compared to the expected clean membrane water
flux. The same filtration behaviour can be observed with data from the microscale
device (e.g. SNase sample in Appendix 3.5 and Baker’s yeast in Figure 5.6) where it
can be observed, even by visual observation of the slope of the line, that the rate at
which the permeate passed through the membrane rapidly reached a constant value
which is away from the water flux line (dashed lines). The results, together with the
observed pressure-independent behaviour, suggest that when using complex feedstocks
such as the ones used in this work, surface or pore adsorption as well as concentration
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polarisation may be dominating the microfiltration process. This is not an unreasonable
deduction given that the concentration of macromolecules and of colloidal particles in
these complex process feeds could be high enough to result in this phenomenon. It is
important to note that the experiments conducted do not provide information on
irreversible fouling, which, if present, would further corroborate the observed pressure-
independent behaviour of the permeate flux.
6.3.6 Microscale CFF study of E. coli homogenates: Fab’ recovery
Aside from permeate flux, another key microfiltration performance criteria is the
recovery of the desired product in the process stream of interest. In this case, the key
process stream is the permeate and the key performance indicator is the Fab’
transmission which is related to Fab’ recovery.
6.3.6.1 Impact of DNA hydrolysis on Fab’ transmission
Figure 6.9 illustrates the behaviour of Fab’ transmission as a function of Benzonase®
content or presence of Staphylococcal nuclease in the homogenised E. coli cell
suspensions. Statistical analysis indicates that the DNA hydrolysis, either by
Benzonase® treatment or co-expression of Staphylococcal nuclease, has a significant
effect on Fab’ transmission (p < 0.05). In the case of the SNase, Figure 6.9 shows that
SNase has better Fab’ transmission than the Control. On the other hand, the BNase
feeds have demonstrated lower Fab’ transmission. The differences in transmission
behaviour of the feedstocks with and without Benzonase® could be due to the
Benzonase® treatment further enhancing the Fab’-cell debris interaction.
As shown in Figure 6.9, the transmission of Fab’ using the control sample is around
70%. As a soluble product, it was expected that Fab’ will not be rejected during
microfiltration and should be mostly, if not fully, recovered in the permeate. Since this
is not the case, one explanation would be that Fab’ fragments interact with the cell
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debris. This was already observed in the results shown in Section 4 during
microfiltration and was implied in Section 6.3.3.2 when freeze-thawed cells of the same
concentration showed a higher measured Fab’ concentration than freshly harvested
cells. During CFF, some of the Fab’ fragments, which were otherwise in solution, could
have adsorbed onto the cell debris particles which formed a cake during the crossflow
microfiltration process. It appears that this could have happened when using the Control
as shown by the low Fab’ transmission (~70%). The addition of Benzonase® seems to
have exacerbated this Fab’-cell debris interaction as indicated by the decreased Fab’
transmission (< 70%) compared to the Control.
On the other hand, the SNase feedstocks appears to have none of this interaction since
Fab’ transmission was almost 100%. Note that the SNase feedstocks have relative lower
Fab’ content than the control feedstocks (as shown in Section 6.3.3). If there was Fab’-
cell debris interaction, the loss of (transmitted) Fab’ in the permeate will be more
pronounced. However, this was not observed. It is therefore assumed that even if the
Fab’ content has been optimised to match the Fab’ content of the control samples, the
transmission of Fab’ in the SNase will still be better than Control.
6.3.6.2 Impact of transmembrane pressure on Fab’ transmission
Increasing the transmembrane pressure (PTM) from 22 kPa to 75 kPa did not
significantly change the Fab’ transmission in the different feedstocks (p > 0.05). This
confirms the deductions made on the observed permeate flux and on Fab’ transmission.
Given that concentration polarization of particulate debris was recognised as a reason
for the pressure-independent flux behaviour demonstrated in Section 6.3.5, and that
Fab’-cell debris interaction was the cause of transmission performance illustrated in
Section 6.3.6.1, it follows that Fab’ transmission is also pressure-independent.
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6.3.7 Microscale CFF study of E. coli homogenates: total protein recovery
The total protein recovery in the permeate stream is another important microfiltration
performance indicator. Taken together with Fab’ transmission, total protein recovery
indicates the selectivity of the crossflow microfiltration process. Figure 6.10 presents
the total soluble protein transmission for all feed samples for the two PTM conditions
used. Analysis of the data in this figure demonstrates a small positive correlation of
protein transmission with Benzonase® treatment under the two PTM conditions.
However, the SNase feedstock demonstrated a different CFF behaviour in terms of
protein recovery. At the lower PTM, a higher protein transmission is observed; while at
the higher PTM, the protein transmission of the Control is not significantly different
than the protein transmission of the SNase feed (p > 0.05).
It is clear from Figure 6.10 that, notwithstanding the impact of DNA hydrolysis, an
increase in PTM results in a decrease in total protein transmission. The importance of a
low recovery of total soluble protein has already been described in Chapter 4.
Specifically, the removal of host cell proteins (HCP) in the overall Fab’ recovery is
essential since these proteins could precipitate under the conditions used in
chromatographic separation and purification of the Fab’ fragments (Spitalli, 2009). In
protein A chromatography, HCP were found to cause precipitation, with the precipitates
being a risk to the in-process sterile filters or reduce resin lifetime (Vunuum et al.,
2009). Therefore, the removal of HCP during the early primary recovery steps is
valuable for the whole bioprocess sequence.
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6.3.8 Microscale CFF study of E. coli homogenates: DNA removal
It is important for biopharmaceutical products to have chromosomal DNA levels at a
minimum. The US FDA has set the residual DNA levels to less than 100 picogram per
dose (Cooke et al., 2003). Since chromosomal DNA is negatively charged, it is
routinely separated from the Fab’ product by anion exchange chromatography after
Fab’ capture (Spitali, 2009). Figure 6.11 shows the transmission levels of
chromosomal DNA during crossflow microfiltration of the homogenised E. coli
homogenates. The figure illustrates an interaction between key effects of DNA
hydrolysis by Benzonase® treatment and the operating transmembrane pressure during
crossflow microfiltration. On the other hand, the homogenate feed with co-expressed
nuclease (SNase) has lower DNA transmission than the Control. The differences
between the samples are significant (p < 0.05) and with a larger observed difference at
the lower PTM (22 kPa).
Figure 6.12 shows the agarose gel of the CFF samples. This clearly indicates a
reduction in DNA content in the permeates compared to the feeds as illustrated by the
reduced intensity of the smear in the DNA gel. It is important to point out that even
without DNA hydrolysis, the Control demonstrates a considerable reduction in DNA
levels in the permeate as illustrated in Figure 6.11 and 6.12. Furthermore, in Figure
6.12, the lane corresponding to the permeate of the Control evidently shows a decrease
in the larger (intact) DNA fragments which were thought to be left inside the wells of
the lanes in the DNA gel. This suggests that the crossflow microfiltration process
facilitated the retention of the larger DNA fragments.
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The transmission of DNA at the lower PTM follows a similar pattern, although at
smaller levels, to that of the Fab’ transmission. It is possible that there was some Fab’-
DNA interaction during the CFF process due to their opposing charges. At the
operating pH (pH 7.0), Fab’ has a slightly positive charge since the isoelectric point of
Fab’ is pI 8.0 (Humphreys et al., 2004; Spitali, 2009). In addition to this, DNA-cell
debris interaction is also possible because DNA transmission levels were lower than
Fab’ transmission levels. In general, the very low transmission of DNA (< 50%) from
the different feedstocks is advantageous for the next chromatographic operations for
reasons previously described.
The DNA transmission data completes the crossflow microfiltration criteria for
assessing overall performance. Taken as a whole, the results on permeate flux, Fab’
transmission, total soluble protein transmission and DNA transmission indicate that the
best crossflow microfiltration conditions would be at the higher PTM (in this case, 75
kPa). At this condition, permeate flux and Fab’ levels are at best while DNA and total
soluble protein contents in the permeate are at their lowest. In the last section, the
results of a large scale CFF operation based on this best condition will be shown in
tandem with pilot scale centrifugation data.
6.3.9 Comparison of clarification methods for E. coli Fab’ homogenates
The results described in the previous sections were obtained by using the novel
microscale CFF device developed in this work (shown in Chapter 5). The experiments
were performed to gain an understanding of the crossflow microfiltration behaviour of
the different homogenised E. coli Fab’ samples with or without DNA hydrolysis. Based
on the information from the preceding section, large scale crossflow microfiltration and
pilot-scale centrifugation experiments were performed for both Control and SNase
feedstocks.
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Table 6.3 shows the component profile of the clarified Fab’ solution from the permeate
of the large scale CFF process. In the same table, the component profile of clarified
Fab’ solution from a pilot scale centrifuge is also shown. From visual inspection of the
two solutions, it was noticed that the Fab’ solution from CFF is clear and transparent
while the Fab’ solution from the centrifugation process is turbid. The turbidity of the
Fab’ solution from centrifugation is expected. It is commonly known that centrifugation
is usually followed by depth filtration as a secondary clarification step to obtain
particle-free solutions in the harvest of therapeutic monoclonal antibodies and related
proteins (See Figure 1.5). It is evident from Table 6.3 that the centrifugation process
recovered most Fab’ than crossflow microfiltration. However, it could also be observed
that the Fab’ solution from the crossflow microfiltration process has lower levels of
contaminating protein and chromosomal DNA.
Table 6.3 Comparison of clarified E. coli Fab’ profiles from large scale experiments of
crossflow microfiltration and centrifugation.
Clarification
method
Control SNase
Fab’
(g mL-1)
DNA
(g mL-1)
Total
protein
(mg mL-1)
Fab’
(g mL-1)
DNA
(g mL-1)
Total
protein
(mg mL-1)
Crossflow
microfiltration1 679 476 13 58 160 10
Centrifugation2 1074 4183 39 83 1251 28
1 According to section 2.6.2 using Pellicon 2-Mini, PTM is 100 kPa, crossflow rate of 80 L h-1, 0.22 m
PVDF
2 According to section 2.2.4 using Carr Powerfuge, feed flow rate of 30 L h-1
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The operating condition for CFF was based on information from the results of
microscale experiments in Sections 6.3.6 – 6.3.8. although the actual PTM is higher
(100 kPa in the large scale experiment compared to the 75 kPa in microscale). Despite
this, the flux obtained and transmission levels achieved were similar to the microscale
data indicating that the pressure-independent behaviour extends up to 100 kPa in this
case. On the other hand, the operating condition for the pilot scale centrifugation
process was already under optimal conditions (Balasundaram et al., 2009b). The feed
flowrate, currently at 30 L h-1, is at the low end of applicable feed rates. Processing
larger volumes of feed will therefore require a considerable length of processing time.
Increasing the flowrate, however, has its own disadvantage since it is widely known
that increasing feed rates in centrifugation will result in a decrease in the clarification
efficiency.
6.4 Conclusions
The aim of this chapter was to demonstrate the utility of a novel microscale CFF device
in obtaining bioprocessing information by predicting the performance of larger scale
crossflow microfiltration module. Specifically, the impact of DNA hydrolysis on
crossflow microfiltration processes was investigated.
Initially, the impact of DNA hydrolysis on the physical properties of the different E.
coli homogenate feedstocks was investigated (Table 6.1). It was shown (Section 6.3.1)
that the addition of Benzonase® nuclease or the co-release of Staphylococcal nuclease
from cell engineered E. coli Fab’ digested DNA molecules into smaller fragments
(Figure 6.3). The DNA hydrolysis facilitated the decrease in viscosity (Figure 6.4) of
the different homogenate feedstocks (Table 6.1). DNA hydrolysis using Benzonase®
nuclease did not affect the degree of release of the Fab’ fragments (Section 6.3.3). It
was demonstrated (Sections 6.3.1-6.3.3) that freeze-thawing resulted in a decrease in
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viscosity of the Control and BNase samples (low concentration), an increase in Fab’
content, and a decrease in total protein content. However, freeze-thawed SNase
homogenates have been demonstrated to have similar rheological properties as fresh
SNase (Figure 6.4) and so have been used in the further study of primary recovery of
Fab’ fragments.
A good prediction of the larger-scale crossflow microfiltration module was
demonstrated (Figure 6.7) by the novel microscale CFF design using the E. coli Fab’
homogenates (Control and SNase) and so the microscale CFF device was used in the
detailed analysis of the impact of DNA hydrolysis on crossflow microfiltration
processes (Sections 6.3.5-6.3.8).
Crossflow microfiltration of the different E. coli Fab’ homogenates showed that DNA
hydrolysis does not significantly affect the permeate flux (Figure 6.8). However, DNA
hydrolysis significantly impacts on the levels of Fab’ transmission (Figure 6.9) and
total soluble protein transmission (Figure 6.10). The SNase feedstocks had the highest
levels of Fab’ transmission and total soluble protein transmission at the lower PTM
investigated. Both the permeate flux and the Fab’ transmissions of the homogenates
were independent of pressure but the total protein transmission decreased with an
increase in PTM. The transmission of DNA was found to be affected by both the extent
of DNA hydrolysis and PTM (Figure 6.11 and Figure 6.12).
Lastly, based on the results of the microscale evaluation of the crossflow microfiltration
behaviour of E. coli Fab’ homogenates, the best operating condition was identified.
This information was used to operate a large-scale crossflow microfiltration experiment
and compared with pilot-scale centrifugation (Table 6.3).
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As a whole, this chapter demonstrated the application of the microscale crossflow
microfiltration device in investigating the CFF behaviour of industrially relevant,
complex feedstocks. The use of the microscale approach in crossflow microfiltration
has clearly facilitated the acquisition of bioprocess information that enabled the process
comparison of larger-scale unit operations. The microscale approach also aided in
recognizing the mechanisms of the crossflow microfiltration performance of the
different homogenates, with or without DNA hydrolysis (e.g. Fab’-cell debris and Fab’-
DNA interactions could have influenced transmission levels). However, the nature
and mechanism of how these interactions occur during microfiltration is not well
understood and the current study was not designed to cover such investigation. The
microscale devices developed in this work can be used in future research to study these
interactions.
In conclusion, DNA hydrolysis improved the crossflow microfiltration performance of
E. coli Fab’ homogenates. Centrifugation has shown a higher recovery of Fab’
fragments however, it has also recovered most contaminating proteins and DNA. Both
Fab’ content and the levels of contaminating components should be considered in
deciding which process route to proceed. In the whole bioprocess approach described in
Section 1.2, a wider view of the impact of certain process stream profiles will enable to
choose the process option that is best not only for a specific process step but for the
overall bioprocess sequence. The microscale CFF device used in this work has provided
extensive data on crossflow microfiltration which will allow the broad and exhaustive
evaluation necessary for a whole bioprocess approach.
_____________________
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7. Conclusions and Future Work
7.1 Summary and overall conclusions
The overall aim of this thesis was to establish a microscale bioprocessing platform for
the investigation of both dead-end and cross flow filtration (CFF) operations and the
impact of upstream operations on filtration performance (Section 1.6). A key
consideration in this work is the compatibility of these microscale filtration platforms
with laboratory automation, specifically the Tecan™ laboratory robotic platform
(Figure 2.1). The establishment of a microscale filtration platform contributes to the
whole bioprocess development approach (Section 1.1.) within the context of
biopharmaceutical product development. The goal of the whole bioprocess is to
understand each unit operation or step within a bioprocess sequence (in this case:
membrane filtration) and to determine the impact of each of these steps in subsequent
unit operations. The combination of microscale bioprocessing with laboratory
automation allows the rapid evaluation of the unit operations within a bioprocess
sequence (Micheletti et al., 2006). Microscale bioprocessing enables the study of wider
design space, specifically facilitated by its high-throughput and low-volume features.
The time- and cost-effectiveness of the high throughput process development approach
to obtain process and product understanding is increasingly being recognised (Bhambure
et al., 2011).
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The primary recovery of humanised antibody Fab’ fragments was used as a case study
for the evaluation of the microfiltration methodologies established in this work. Fab’
fragments have only been recently approved for therapeutic applications; therefore a
defined production process has yet to become widely established (Shukla and Thömmes,
2010). There is thus an opportunity to contribute to the understanding and development
of different processes and unit operations for antibody Fab’ fragments currently in the
development pipeline.
The membrane filtration processes investigated in this work were dead-end
microfiltration and cross flow microfiltration processes for the primary recovery of
antibody Fab’ fragments. The first two results chapters (Chapter 3 and 4) have focused
on dead-end microfiltration process. The last two results chapters (Chapter 5 and 6) have
focused on the crossflow filtration process.
A series of objectives were outlined (Section 1.6) in order to achieve the overall aim of
establishing a microscale platform for the investigation of these processes for the
primary recovery of antibody Fab’ fragments. The organization of these objectives
followed these general steps:
1. the determination of scale down criteria;
2. the design and creation of the microscale filtration device based on (1);
3. the design of associated microscale filtration methodology that is compatible
with laboratory automation;
4. the evaluation of the device and methodology in studying filtration processes;
and
5. the application of the device and methodology.
The microscale dead-end filtration device has previously been created and investigated
by Jackson et al. (2006). In this thesis, the methodology associated with the microscale
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dead-end filtration device has been further developed. Thus, for the dead-end filtration
process, steps 3 to 5 above were re-established. Chapter 3 has demonstrated a single-
plate/two-step methodology in determining the specific cake resistance () of antibody
Fab’ fragments during dead-end microfiltration (Section 3.3.3). The method has
reduced the sample volume to half of that used by Jackson et al. (2006). A single-
plate/single-step methodology was also demonstrated that could facilitate the reduction
of sequences for automation thus simplifying the experimental determination of
pressure-dependence of  (Section 3.3.5). Chapter 4 established the application of the
new microscale methodology for dead-end filtration in assessing a linked bioprocess
sequence comprising of the Fab’ release step followed by recovery by dead-end
microfiltration. The impact of cell disruption techniques, and specific operating
conditions to release the Fab’ fragments from E. coli cells on the specific cake
resistances were illustrated (Section 4.3).
Establishment of the crossflow filtration option required the creation of a completely
novel device which is automation compatible. Therefore, in the case of the microscale
CFF option, steps 1 to 5 of the generic steps earlier described were performed. In
Chapter 5, the scale down basis was identified (Section 5.2), and the design process and
the characteristics of the novel device were presented (Section 5.4.1). A microscale
crossflow methodology was developed (Section 5.4.3 - 5.4.4) and the preliminary
evaluation of the device plus methodology was demonstrated using a model feed
(Section 5.4.5). It was shown that the microscale CFF device has comparable
performance in terms of steady state permeate flux of the model feed system within ±
10% difference (Figure 5.7). This was achieved with a ten-fold reduction in volume and
a 100-fold reduction in membrane area.
Chapter 6 has illustrated: (1) the scale comparison of the microscale CFF device with
the larger scale CFF module using the industrially relevant E. coli Fab’ feedstocks
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(Section 6.3.4); (2) the application of the microscale CFF device in studying the effect
of DNA hydrolysis on crossflow microfiltration (Section 6.3.5 – 6.3.8); and (3) the
utility of the microscale CFF device in the rapid identification of key process
information (e.g. operating conditions such as PTM) (Section 6.3.9). The identification
of key scale up condition (e.g. PTM) enabled the analysis of process stream profiles of
different options of larger-scale unit operations for primary Fab’ recovery (Section
6.3.9).
The above results demonstrate the accomplishment of the overall aim of the thesis to
establish a microscale bioprocessing platform for membrane filtration processes. In the
following section the implications of using the microscale filtration platform and the
wider application of the devices are illustrated.
7.2 Broader implications and applications
There are several implications which could be derived from the course of developing
and evaluating the microscale bioprocessing platform for membrane filtration presented
in this thesis. Two key implications are related to the whole bioprocess approach in
analysing bioprocesses and the re-evaluation of existing theories and models for
membrane microfiltration, specifically those applied to crossflow microfiltration.
7.2.1 Enabling whole bioprocess analysis
The application of the microscale devices and methodologies in the study of dead-end
filtration and crossflow filtration processes has manifested the importance of a “whole
bioprocess” approach in the bioprocess development. In Chapter 4, an essential finding
is the divergent effects of the Fab’ release step and the dead-end microfiltration step on
overall recovery of antibody Fab’ fragments (Section 4.3.1). This finding highlighted the
need for an extensive evaluation of bioprocess sequences in product recovery
optimisation and not to only focus on a single unit operation. With the aid of the
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microscale dead-end filtration device it was demonstrated that the key issues affecting
the linked process sequence could be identified. In Chapter 6, the microscale crossflow
microfiltration study on the effect of DNA hydrolysis demonstrated the divergent effects
of different crossflow microfiltration conditions as well as the conditions (nuclease
source, concentration) for DNA hydrolysis on the profile of the process streams. The
data obtained (Section 6.3.5 - 6.3.8) revealed the necessary trade-offs to consider, such
as the level of product recovery and the contaminant profile, in selecting bioprocess
routes as well as in deciding to improve producer strains through cell engineering.
The usefulness of the microscale membrane devices presented here has so far been
mostly applied to the study of the effect of upstream unit operations, such as
fermentation and cell disruption, on membrane filtration processes. This kind of
investigation can be extended further downstream of primary recovery, that is on the
capture and purification of the process streams to get the desired therapeutic protein.
For example, the microscale membrane filtration devices can be applied in combination
with studies using automated microscale chromatographic purification which has
already been shown as a strategy for process development (Wenger et al., 2007;
Coffman et al., 2008; Kramarczyk et al., 2008). Since the parameters for scale
translation and the required automation for these two unit operations have already been
established, together with known microscale fermentation strategies, a rapid evaluation
of the “whole bioprocess” sequence (Figure 1.2) is now possible. As the development
of the microscale devices for each unit operations are refined, greater confidence in the
“whole bioprocess” approach is also expected to develop.
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7.2.2 Enabling deeper understanding of microfiltration processes
The relatively small-volume feed requirement, the parallel and automation-compatible
experimentation of the microscale filtration devices mean that a wider scope of
experimental design space can be investigated using industrially-relevant, complex
biological feedstocks. The amount of data which could be generated from microscale
bioprocessing studies would enable the re-evaluation of available theories and models
on membrane filtration processes specially those concerning complex biological
feedstocks. As demonstrated in Section 3.3.6, there is a large difference in the dead-end
microfiltration of non-biological and biological feeds. Biological feedstocks could also
differ, depending on the complexity of the soluble components (macromolecules,
colloids, etc.) and the interaction of these components with the cellular debris. Cake
filtration analysis may now be performed in view of the interacting effects of surface
adsorption of soluble material in suspension (which in turn may affect Rm) and the cell
debris-protein interaction on the measured specific cake resistance () of specific
feedstocks, instead of using model feeds to characterise and predict dead-end
microfiltration behaviour.
The observed pressure-independence of the permeate fluxes of the yeast (Section 5.4.5)
and E. coli Fab’ suspensions (Section 6.3.5) were unusual, but plausible. The current
available experimental data as well as crossflow filtration theories were limited in their
application to the current data because of the complexity of the feed characteristics and
therefore, in explaining the crossflow microfiltration behaviour. Note that most of the
deterministic models only apply to narrow definitions of the feed suspensions which do
not capture the complexity of most biological feeds.
Current crossflow filtration models are mostly derived for application to ultrafiltration
processes with only a few fundamental studies dedicated to the understanding of
crossflow microfiltration processes. However, the microfiltration behaviour of crossflow
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processes has the added dimensions of the debris-debris, debris-protein, protein-
membrane and debris-membrane interactions which are more than the usual solute-
solute-membrane interaction that dominate ultrafiltration processes. The use of the
microscale CFF device will facilitate the better understanding of the mechanism of the
crossflow microfiltration processes of complex feeds.
Given the constraints in resources during process development, it is best to determine a
property of a bioprocess feedstock that reflects the collective impact of the different
physical properties of the components in a feed suspension for microfiltration. As shown
in Section 4.3.2, the specific cake resistance, reflects even the slightest changes in the
solution components of E. coli Fab’ extracts as a result of slight change in extraction
condition (e.g. pH). Therefore, can be a better predictor of the filtration behaviour of
feed suspensions.
From dead-end filtration experiments, insights on the dependence of the specific cake
resistance on solution properties could be obtained. Combined with CFF microfiltration
experiments, an exhaustive view of the microfiltration behaviour is obtained and
therefore, better information can lead to better process design.
Finally, it would be interesting to see how a certain feed’s dead-end microfiltration
performance can actually predict the crossflow microfiltration behaviour. The amount of
feed volume necessary for microscale dead-end filtration is very small (~40x smaller)
compared to the required volume for microscale crossflow filtration thus there is a
complementary benefit in understanding a certain feedstock’s microfiltration
performance using the dead-end and crossflow filtration modes of operation.
The context of this work was within biopharmaceutical product development but it is
envisioned that the microscale membrane filtration methodologies could be applied to
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any membrane filtration processes using complex biological feeds (e.g. other
biotechnological processes such as separation of extracellular enzymes from cells,
fractionation of complex molecules based on size, etc). Although, some slight
modification of microscale methodologies maybe required. Further work such as these
are presented in the next section.
7.3 Recommendations for future research
After highlighting the outcome of the work performed in this thesis (Section 7.1) and
demonstrating the broader implications and applications of the microscale membrane
filtration devices (Section 7.2), this section will present the necessary work in the short
term in order to get a complete characterisation of the microscale microfiltration systems
developed in this work.
 The microscale dead-end microfiltration methodology which was developed and
evaluated in Chapter 3 can be further assessed by applying it in the study of dead-
end microfiltration behaviour of other complex biological feeds, perhaps using
different industrially relevant expression systems (e.g. mammalian cells, Pichia
pastoris), which would cover a broad range of filtration characteristics. These can
provide insights whether, for example, there is a need to replenish easily filterable
(high flux) feeds in the feed/retentate wells or if the length of filtration time to get
over the “initial phase of filtration” is the same for the different materials. The
former requires a strategy for feeding without disturbing the cake formation, and
the latter is important specifically for the two-step/single plate methodology
(Section 3.3.3) where it necessary to determine after how long should the first-step
filtration period to run.
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 Further experiments can be made, in relation to the above, to assess different
membrane types and membrane pore sizes. Again, with particular focus initially on
the applicability of the microscale methodology for initial process selection.
 Further experiments can be made in relation to Section 4.3.1, specifically using the
linked sequence at microscale of thermo-chemical extraction and dead-end
filtration, in order to understand the release mechanism of Fab’ and HCP. A
detailed study on the impact of the different component profiles on microfiltration
performance can be performed. The aim is to enhance understanding of the
extraction processes and the impact on succeeding microfiltration operation.
 Further studies similar to those described in Section 4.3.2.2 should be performed to
determine the impact of combining heat with sonication or homogenisation on the
specific cake resistance and compare the dead-end microfiltration performance with
heat extracted E. coli Fab’. A broad range of temperatures can be studied,
including the heat extraction method, so that a complete picture of the impact of
cell disruption method can be achieved. This is to enable the analysis of the
different process trade-offs which may emerge.
 Additionally, the heating profile at microscale should be studied to determine if this
also mimics the heating profile at larger scale. The focus should not only be on the
temperature profiles but also on the component analysis (e.g. Fab’, total soluble
protein, DNA).
 The microscale crossflow microfiltration device (Figure 5.2) was designed without
turbulence promoters or screens. These screens are present in the larger-scale
module (Figure 5.1). In order to understand how the promoters affect the
microfiltration performance of complex feeds, studies should be performed to
evaluate the effect of the turbulence promoters, in their current design, inside the
larger scale device. A hydrodynamic description, as well as a description relating to
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mass transfer may be determined so that this can be related to the conditions
achieved at microscale which do not have turbulence promoter.
 Further studies to optimise the crossflow method to further reduce the required feed
volume should be performed. It is important to determine whether this minimum
volume is feed-specific.
 In relation to the above, crossflow microfiltration experiments should be performed
using other expression systems such as those described for dead-end microfiltration
(e.g. mammalian cells, Pichia pastoris). These experiments will provide insights on
the robustness of the microscale CFF methodology.
 Investigate if the CFF performance of the cell engineered E. coli co-expressing
Staphylococcal nuclease changes when Fab’ expression of this strain has been
optimised.
 Based on the results in Section 4.3 and 6.3, there is a need to increase the Fab’ yield
from microfiltration. It is thought that Fab’ interact with the cell debris and are
therefore adsorbed on or trapped within the cake being formed during CFF/dead-
end microfiltration. Thus, it is necessary to investigate how to reduce Fab’-cell
debris interaction during dead-end or crossflow microfiltration by studying the
impact of pH, ionic strength, freeze-thawing, heating etc.
 In order to enhance the dead-end and crossflow microfiltration device design and to
improve its compatibility with automation the following work is required:
- To explore ways of pumping fluid which is representative of large scale
operation and determine how this can be integrated within the laboratory robotic
platform (Tecan™);
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- To re-design the crossflow microfiltration device to reduce the channel heights
to further increase possible range of shear rates. A second prototype has been
designed and Fabricated with slightly different dimension in feed/retentate
channel height (smaller) and permeate channel height (smaller, not inclined
downwards). However, this has not yet been evaluated.
- To re-design the dead-end and crossflow microfiltration devices to improve
permeate collection. In particular, the collectors could be made of materials that
are conductive like that of the Tecan™ tips. The conductivity of the material
can be used to detect liquid volume electronically. Together with the
quantification of the permeate for the product or total protein, the measured
conductivity could also be used as an indicator of a change in soluble contents
or concentration in the permeate.
 Given the large amount of data generated by using the microscale dead-end and
crossflow filtration devices (e.g. time, pressures, permeate volumes, contaminant
and product profiles, etc.) it would be helpful to have a data processing tool which
allows the capture of raw data from the laboratory robotic platform and will convert
the data to useful process attributes (e.g. flux, volume versus time, flux versus
pressure relationships, etc.). This data processing/data analysis tool will enable the
rapid navigation within the experimental design space and will readily provide the
information to decide on process adjustments and evaluate specifications.
 Lastly, in order to have a broad range of crossflow microfiltration operation
conditions, a microscale mimic of other crossflow modules will be valuable. For
example, modules which operate under turbulent regime will provide a comparison
on the crossflow characteristics and performance of the E. coli Fab’’ feedstock used
here. The crossflow microfiltration module mimicked in this work operates under
laminar-flow with flat-sheet membranes. The limitations ascribed to the crossflow
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processes described here only reflect the limitations of the module itself, not
necessarily of the crossflow operation as a whole. Thus, having microscale mimics
of different modules with different hydrodynamic characteristics will enable to
gather information that will provide a better understanding of the crossflow
microfiltration processes of feedstocks derived from biological materials.
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E.coli. Filled circles are biomass. Squares are concentrations of Fab’ inside the cell
(filled) and Fab’ fragments excreted in the medium.
Fermentation profile during production of antibody Fab’ fragments from
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Appendix 1.2
vacuum separator (Te
Sample Tecan Gemini™ program for the automated operation of the
-VacS) on the
~
deck of the Tecan.
238 ~
Appendix 1.3
() concentrations.
Optical density measurements corresponding to dry cell (
Appendix 1.4
~
Typical total protein calibration curve.
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) and wet cell
Appendix 1.5
to Tustian (2008); (B) blank sample composed of the binding buffer 20 mM sodium
phosphate at pH 7.4 ; and (C) Fab’ lysate from thermo
Typical chromatograms of: (A) Fab’ standard prepared by and according
~
Fab’
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-chemical extraction.
(A)
(B)
(C)
Appendix 1.7
(r2>0.95) which depicts Newtonian fluid behaviour. Samples are from freeze
cells with concentrations of 15% (
Appendix 1.6
Typical shear stress
Typical calibration c
~
-shear rate curve showing a linear relationship
) and 30% (
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urve of the Fab’ standard.
) wet cell weight (w/w).
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Appendix 2
This section has the cited Appendices from Chapter 5.
Appendix 2.1 Estimation of Pellicon-2™ dimensions
Parameter Pellicon-2™Mini (V-screen)
Total membrane area (cm2) 1000
Nominal width (cm) 5.6
Channels per device 5*
Membranes per device 10*
Active membrane length (cm) 16.5
Total active membrane width (cm) 60*
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Appendix 2.2 Momentum balance to derive Equation 5.13
For flow through channels (rectangular ducts) where flow is against gravity, the
Bernoulli equation appears as:
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which is the equation shown in Equation 5.13.
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DNAs in freeze
; [2, 3] freeze
BNase; [9] 15X BNase; [10] 30X BNase. Homogenisation performed according to
Section 2.3.2. DNA hydrolysis according to Section 6.3.1. DN
according to Section 2.9.6. Agarose gel performed according to Section 2.9.7. BP
pairs.
Appendix 3.2
DNAs in freeze
; [2] freeze
BNase; [7] 15X BNase; [8]
Section 2.3.2. DNA hydrolysis according to Section 6.3.1. DNA sample preparation
according to Section 2.9.6. Agarose gel performed according to Section 2.9.7. BP
pairs.
Agarose gel showing the hydrolysis by Benzonase® of chromosomal
-thawed homogenised (30% w/w)
-thawed Control; [4,5] 3X BNase; [6] 6X BNase; [7] 9X BNase; [8] 12X
Agarose gel showing the hydrolysis by Benzonase® of chromosomal
-thawed homogenised (15% w/w)
-thawed Control; [3] 3X BNase; [4] 6X BNase; [5] 9X BNase; [6] 12X
BP
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30X BNase. Homogenisation performed according to
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E. Coli
E. Coli
[5] [6] [7] [8]
[6] [7] [8] [9]
cells: Lanes: [1]
A sample preparation
cells: Lanes: [1]
[10]
– MW marker
– MW marker
– base
– base
Appendix 3.3
absolute viscosities in Figure 6.4. Sample is fresh Control, homogenised according to
Section 2.3.3. Rheological properties were measured according to Section 2.10.2
Appendix 3.4
experiments withSNase.
0.22m PVDF membrane. Experiments were performed as described in Section 2.7.2.
Data points were calculated using Equation 2.3.
An example of a
Typical permeate
Crossflow rate = 80 L h
~
shear stress
flowrate data from lab
246 ~
-strain plot used as basis for determining
-1, P
-scale crossflow microfiltration
TM = 22 kPa, Am = 0.1 m2 using
Appendix 3.5
experiments with SNase (Channel 2). Crossflow rate = 14 L h
0.001 m
Cumulative permeate data from microscale crossflow microfiltration
2 using 0.22m PVDF membrane.
~
Dashed line (near Y
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-1, P
-axis) is water flux line.
TM.ave = 22 kPa, Am =
